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Abstract 
Tailoring vessel morphology in vivo 
By 
Daniel J Gould 
Tissue engineering is a rapidly growing field which seeks to provide 
alternatives to organ transplantation in order to address the increasing need for 
transplantable tissues. One huge hurdle in this effort is the provision of thick tissues; 
this hurdle exists because currently there is no way to provide prevascularized or 
rapidly vascularizable scaffolds. To design thick, vascularized tissues, scaffolds are 
needed that can induce vessels which are similar to the microvasculature found in 
normal tissues. Angiogenic biomaterials are being developed to provide useful 
scaffolds to address this problem. 
In this thesis angiogenic and cell signaling and adhesion factors were 
incorporated into a biomimetic poly( ethylene glycol) (PEG) hydrogel system. The 
composition of these hydrogels was precisely tuned to induce the formation of 
differing vessel morphology. To sensitively measure induced microvascular 
morphology and to compare it to native microvessels in several tissues, this thesis 
developed an image-based tool for quantification of scale invariant and classical 
measures of vessel morphology. The tool displayed great utility in the comparison of 
native vessels and remodeling vessels in normal tissues. To utilize this tool to tune 
the vessel response in vivo, Flkl::myr-mCherry fluorescently labeled mice were 
implanted with Platelet Derived Growth Factor-BB (PDGF-BB) and basic Fibroblast 
Growth Factor (FGF-2) containing PEG-based hydrogels in a modified mouse corneal 
angiogenesis assay. Resulting vessels were imaged with confocal microscopy, 
analyzed with the image based tool created in this thesis to compare morphological 
differences between treatment groups, and used to create a linear relationship between 
space filling parameters and dose of growth factor release. Morphological parameters 
of native mouse tissue vessels were then compared to the linear fit to calculate the 
dose of growth factors needed to induce vessels similar in morphology to native 
vessels. Resulting induced vessels did match in morphology to the target vessels. 
Several other covalently bound signals were then analyzed in the assay and resulting 
morphology of vessels was compared in several studies which further highlighted the 
utility of the micropocket assay in conjunction with the image based tool for vessel 
morphological quantification. Finally, an alternative method to provide rapid 
vasculature to the constructs, which relied on pre-seeded hydrogels encapsulated 
endothelial cells was also developed and shown to allow anastamosis between 
induced host vessels and the implanted construct within 48 hours. 
These results indicate great promise in the rational design of synthetic, 
bioactive hydrogels, which can be used as a platform to study microvascular 
induction for regenerative medicine and angiogenesis research. Future applications of 
this research may help to develop therapeutic strategies to ameliorate human disease 
by replacing organs or correcting vessel morphology in the case of ischemic diseases 
and cancer. 
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1. Background and Significance 
The focus of this thesis is the rational design of angiogenic tissue engineering 
scaffolds which can induce the formation of a microvascular host response. This 
contribution is critical to the field because recently developed tissue engineering 
products for use in humans lack microvascularization. These successfully 
engineered thin tissue components include cartilage, bladder and cornea. The lack of 
microvascularization limits the types of tissue replacements that can be engineered. 
In order to better understand the need for microvascularization, a basic discussion on 
the demand for tissue engineering, an overview of current strategies employed by 
tissue engineering and some successes and challenges within the field must first be 
presented. 
1.1 Motivation: The Increasing Need for and Cost of Transplantation 
Fuels Demand for Tissue Engineering 
Many disease processes in the United States involve the destruction or damage 
of organs and tissues. The cause of destruction of these tissues can originate from 
ischemic insult triggered by cardiovascular disease, infection, auto-immune attack, 
cancerous invasion, genetic conditions or toxic exposure. 
Hundreds of conditions can 
contribute to the destruction of 
host organs and ultimately 
necessitate either assistance of 
organ function or complete organ 
transplantation in the host. The 
most common diseases requiring 
organ transplant include Polycystic 
Kidney Disease, Diabetes 
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Figure 1-1: Waiting list for transplantation. Current 
statistics for total number of people on the waiting 
list for an organ transplant are broken down by 
organ type (United Network of Organ Sharing, May 
2010). 
Mellitus, Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis, 
Hypertension, Coronary Heart Disease, Cardiomyopathy, Short Gut Syndrome, 
Cirrhosis and Hepatitis (Graham 2010). In the US, there are currently over 100,000 
people awaiting organ transplantation (figure 1-1). Those awaiting organ 
transplantation mostly need kidney transplantation or liver transplantation these 
represent approximately 90% of the people on organ waiting lists. Both liver and 
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kidney tissues are extremely well vascularized, with complex microvascular networks 
to allow for the diffusion and excretion of waste products and the reabsorption of 
nutrients and metabolites. There are countless other conditions involving many 
tissues for which there are no current transplantable methods to alleviate their disease, 
or to allow recovery of function. 
One important consideration of transplantation is the cost associated with this 
dramatic surgical procedure and the maintenance of the graft for many years 
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following surgery. Of those awaiting transplantation, around 20% will receive their 
organ per year, and the cost for organ transplantation in the ftrst year alone will range 
between $275,000 for a pancreas and $1.1 million for a heart-lung or intestine 
transplant (Graham 2010). Roughly $200,000 of the total cost for organ transplant 
comes from procurement and immunosuppressants in the ftrst year, however, over 
time immunosuppression can contribute an additional $200,000 to the total cost of 
transplantation (Graham 2010). Furthermore, the process of immunosuppression, 
though vital to the success of the transplant, can leave the host at risk for numerous 
infections and the drugs themselves often cause unwanted side effects. One proposed 
alternative to tissue transplantation is the development of new tissues and organs 
derived from cells extracted from the host using technology developed in the fteld of 
tissue engineering. The argument for this technology is that it will decrease monetary 
and human costs by eliminating post transplant immunosuppression and the 
transportation and surgical costs for procurement of donor organs. Also tissue 
engineering could provide new options for previously untreatable diseases. 
Tissue engineering is a relatively new fteld of research, which may have roots 
in ancient practices but was best presented in the landmark paper of Langer and 
Vacanti in 1993 (Langer and Vacanti 1993). Tissue engineering involves the use of 
three critical ingredients, cells, scaffolding, and cytokines to fabricate tissues as a 
therapeutic (Langer and Vacanti 1993; Mikos 2006). The goal of this fteld is to 
replace damaged tissues and organs, in order to provide a greater pool of resources for 
those awaiting transplantation, as well as to reduce the costs of organ replacement, by 
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reducing immunosuppression required (using host cells) and reducing procurement 
costs. Furthermore, tissue engineering serves to provide new therapeutic solutions for 
conditions of tissue loss where transplantation is not currently possible. In many 
disease conditions this new field will help to better the available treatments by 
contributing vascularized tissue constructs for implantation; this is particularly 
relevant to many diseases involving a compromised vascular system. 
1.2. Limitations of Tissue Engineering: Current Approaches 
Tissue engineering has yet to address the issue of solid, thick tissues, requiring 
nutrient delivery over more than 150 microns, which is the transport limit of diffusion 
for most metabolic substrates 01 acanti; Vacanti, Vacanti et al. 2007). The focus of 
many labs is to develop microvascularized tissue engineered constructs, in order to 
provide a solution to the diffusion problem, and to ultimately design and develop 
thick tissues or whole organs to replace damaged tissues (Hoganson, Pryor et al. 
2008). This represents a major hurdle to tissue engineering and the fabrication of a 
microvascularized or rapidly perfused tissue construct is a highly sought after goal 
01 acanti, Vacanti et al. 2007). One strategy towards this goal is to develop 
prevascularized constructs for implantation (Hoganson, Pryor et al. 2008), while other 
strategies focus on rapid vascular invasion and perfusion (Atala 2006). The main 
focus of this thesis is to develop rapidly vascularized scaffolds that recreate vascular 
space-filling properties similar to those found in normal, functional tissues, to provide 
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adequate perfusion of implanted constructs. In addition to this approach, the 
prevascularization of implants in vitro and then the development of a specialized 
implantation scheme to stimulate anastomosis with induced host vessels in vivo is also 
achieved, in order to provide proof of principle for an alternative method to overcome 
the thick tissue hurdle in tissue engineering. 
Previous attempts have been made to 
provide prevascularized tissue engineering 
scaffolds. These attempts have included the 
use of mesenchymal stem cells in 
conjunction with Human Umbilical Vein 
derived Endothelial Cells (HUVECs- a 
common source of endothelial cells) to form 
vessel beds in the cranial window of scid 
mice (Au, Tam et al. 2008). Also similar 
attempts have been made with the use of 
human embryonic stem cells which were 
differentiated into endothelial cells, then 
implanted into the scid mouse through a 
cranial window and likewise showed 
vascular integration (see figure 1-2) (Wang, 
-~·\ I 
Jt \ '-. • . 
-..- -
~ I ( ' ' ' 
i -- l ; d 1 1 \I 
\I-' 
-· 
.. , _.,.· 
' I_ , 
-~ 
- .... 
u:/.' ' - • )4 ()J'/ -
/ /, /·· w ' 
J> ., \.. ' 
[)J,r;!.2 t' .... \... l ..-. , 
Figure 1-2 : Incorporated Endothelial 
Constructs. Adapted from Wang et al 
and Au et al. In the top panels, 
endothelial cells are labeled with GFP 
and co-cultured and implanted with 
bone marrow derived mesenchymal 
cells. They form robust vascular 
networks in the scid mouse cranial 
window, which persist for 140 days. In 
the five panels below, endothelial cells 
derived from human embryonic stem 
cells are labeled green with GFP and 
are similarly implanted and shown to be 
perfused at day 11 . 
Au et al. 2007). Although both of these methods were successful at demonstrating 
vessel integration in the brain, neither used brain derived endothelial cells, and both 
L 
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created functional vessels in this system, but the monitoring of the mice using a 
cranial window is complex and requires many precautions and considerations, as the 
mice have compromised immune systems. A better model would allow for facile 
monitoring in non-immune compromised mice to determine if vascular networks for 
tissue engineering applications could stand the test of implantation. In this thesis I 
have helped develop a model that allows for the in vivo study of vascularization in 
non-immune compromised, fluorescently labeled mice. In order to effectively induce 
microvascularization of engineered constructs in our laboratory model, a basic 
understanding of vessel biology is instrumental and will be described in the next 
section. 
1.3. Blood Vessels 
1.3.1 Vascular development and basic structure 
Most blood vessels consist of tubes of endothelium, surrounded by a muscular 
layer and an adventitial layer, tube diameters vary based on the distance of vessels 
from the heart and the function of those vessels. 
Smaller vessels 
contain an intimal 
endothelial layer, though the 
medial smooth muscle layer 
may be attenuated to as few 
as three smooth muscle 
cells, or may be replaced 
entirely by single pericytes 
(figure 1-3, adapted from 
(Kovacic 2009)). 
The Structure of blood vessels. from: "Heart Development", 
Harvey, R.P. and Rosenthal, N. 1999. Academic Press, San Diego, p. 240. 
Arutrlole Lumen 
c 
Figure 1-3: The structure of blood vessels , adapted from 
Kovacic et al , 2009. 
Capillaries form immediately from adjacent arterioles in most tissues with the only 
cell remaining between the capillary and the perfused tissue being the pericyte. 
Pericytes spread across the capillary to help regulate permeability either through 
contractile force or direct signaling and help maintain the basement membrane in 
these regions (Bohnsack 2003; Carmeliet 2005). In several tissues where diffusion is 
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the main function, there are capillaries without high levels of resident pericytes. In all 
tissues, the pericyte is critical to the stability and function ofvessels. One factor 
known to be responsible for the recruitment of the pericyte is Platelet Derived Growth 
Factor-BB (PDGF-BB) (Carmeliet 2005), and a schematic ofthe process of mural cell 
recruitment is shown in figure 1-4. Vessels require this supportive element and thus, 
any attempt at formation of a microvasculature in vivo should be demonstrated to 
recruit similar type cells. 
PDGF-b se-
creted by tip 
cells 
ECM bound PDGF-b 
Ang 1 activated Tie2 mediates 
endothelial cell survival and 
mural cell attachment 
Recruited pericyte, expressing 
PDGF-b receptor 
Ang 1 is ex-
pressed by peri-
vascular cells 
Ang 2 (endothelial de-
rived) mediates ne2 
inhibition and causes 
endothelial cell death 
and defective mural 
cell attachment. 
Figure 1-4: Angiogenesis and mural cell recruitment. Adapted from (Gaengel, Genove et al. 
2009). Ang 1, Ang 2 and PDGF-88 provide critical stimulus for angiogenesis. 
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Early in development, vessel formation is dictated by the local development of 
endothelial cell progenitors into a primitive vessel network. After development of the 
primitive vessel network, pericytes and other mural cells may be recruited to the 
vasculature, via signaling through PDGF-BB to aid in the formation of mature 
microvessels (Carmeliet 2005). 
For the purposes of this thesis, special focus will be centered on the 
microvasculature of tissues. Within developing tissues, molecules like Vascular 
Endothelial Growth Factor -A (VEGF-A) and Semaphorins dictate the areas of vessel 
invasion and formation. Some supporting cells secrete diffusible factors like VEGF-
A to help recruit endothelial cells, while the endothelial cells secrete diffusible 
PDGF-BB to help recruit pericytes, which in turn stabilize the vessel networks 
(Bautch 2009). This process is likely in flux during angiogenesis in tissues. The 
process of angiogenesis has been widely studied to help treat ischemic diseases 
through direct administration of angiogenic agents and angioproliferative diseases 
through the use of angiostatic agents (Carmeliet 2005; Beenken and Mohammadi 
2009). A greater understanding of the process of angiogenesis is helpful in the design 
of vascularized tissue engineering scaffolds. 
1.3.2 Angiogenesis 
Angiogenesis is directed through the initiation of a response from nearby 
vessels to some diffusible cytokine, often VEGF-A (Carmeliet 2005; Bautch 2009). 
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The vessel endothelial cell reacts to the signal and an angiogenic tip cell buds from 
the vessel. This tip cell migrates towards the chemotactic signal and additional 
endothelial cells migrate and proliferate to extend towards the signal concentration 
gradient (Carmeliet 2005). A tubule is formed behind the tip cell from fusing cell 
vesicles. The tip cell secretes PDGF-BB, which becomes bound to the matrix 
proteoglycans and diffuses to recruit pericytes, which migrate towards the new vessel 
tubes (Gaengel, Genove et 
al. 2009). At the site of 
the new vessels, 
endothelial cells secrete 
Angiopoietin 2 (Ang2) 
which is a soluble ligand 
for the tyrosine kinase 
receptor Tie2 and 
perivascular cells release 
Angl which activates Tie2 
(Gaengel, Genove et al. 
2009). Tie-2 mediates 
hPC Bo 
marrow 
Figure 1-5: Neovascularization adapted from (Isner and 
Asahara 1999). 
endothelial cell survival and mural cell attachment, and thus the recruitment of 
pericytes is critical to the stability of new vessel beds (Gaengel, Genove et al. 2009). 
Later, mural cells communicate with endothelial cells through gap junctions to 
stabilize vessels. Also, other signals from the EGDl-Rac pathway regulate N-
Cadherin trafficking and thus mural cell adhesion. Therapeutic neovascularization 
involves angiogenesis, not only inducing sprouting from existing vessels, but also 
recruiting endothelial progenitor cells (EPCs) for in situ differentiation and 
proliferation (Isner and Asahara 1999) (figure 1-5). 
1.3.3 Growth Factors for Angiogenesis 
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Two key factors involved in angiogenesis are basic fibroblast growth factor 
(FGF2) and platelet derived growth factor-BB (PDGF-BB). FGF2 signals through 
FGF receptors (FGFRs) and regulates many events in development, including 
mesoderm patterning and organ development (Kimelman and Kirschner 1987; Welm 
2002). FGF2 also regulates key physiological functions involved in angiogenesis 
and wound repair (Turner and Grose). FGFs are glycoproteins, which bind matrix 
components and heparin sulphate proteoglycans (HPSGs) from the cell surface (Ori, 
Wilkinson et al. 2008). They are released from matrix by proteases and heparinases 
to bind the cell surface HSPGs, which stabilize their interactions with their receptors. 
FGF acts through four conserved tyrosine kinase receptors and one non tyrosine 
kinase receptor, which may down regulate signaling (figure 1-6) (Wiedemann and 
Trueb 2000). 
FGF s1gnalltng pathways 
• Negative feedback. For example, through 
SPRY, SEF. MAPKP3 and MKPl 
• Downstream transcnption factors. 
For example. FOS. )UN and_PEA~3 ___ __, 
Nature Reviews I Cancer 
Figure 1-6: FGF signalling. Adapted from (Wiedemann and Trueb 2000). Fgf signaling is 
involved in many processes in the cell, and can be transduced through the PIP-IP3 
cascade, as well as through STATS and through AKT and MAPK pathways. 
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The receptors exhibit ligand driven dimerization and signaling (Welm 2002), through 
tyrosine kinase dependent auto phosphorylation of the FGFR intracellular tail, which 
then serves as a docking site for many adaptor proteins and other signaling proteins 
which may trigger RAS, RAF, MAPK PI3K and AKT pathways (Wiedemann and 
Trueb 2000). FGF-2 binds FGFR2 isoform Illc to initiate vessel formation by 
stimulating endothelial cell proliferation and vessel stabilization (Werner and Grose 
2003) by inducing migration and proliferation of smooth muscle cells (Parsons-
Wingerter, Elliott et al. 2000). 
This process is selective for small vessels in the arterial tree (Parsons-
Wingerter, Elliott et al. 2000). Furthermore, FGF-2 induces production of matrix 
metalloproteinases (MMPs ), secreted by ECs to allow migrating blood vessels to 
penetrate extracellular matrix (ECM) (Bikfalvi, Klein et al. 1997; Davis 2008). 
Hypoxia induced FGF-2 production in macrophages regulates expression ofkey 
angiogenic molecules, such as collagenases, B 1 integrins, and urokinase type 
plasminogen activator (Werner and Grose 2003). Platelet Derived Growth Factor 
(PDGF) is chemotactic for wound healing cells in the body. It stimulates fibroblast 
production of ECM and myofibroblast growth and contraction (Werner and Grose 
2003). There are four different monomers ofPDGF (A,B,C and D), and the 
homodimer PDGF-BB signals through the tyrosine kinase receptor PDGFRB with the 
highest affinity to recruit supporting pericytes and stabilize new vessel formation 
(Heldin and Westermark 1999). Hypoxia, shear stress, and growth factors induce 
endothelial cells at the sprouting tip of capillaries to release PDGF-BB (Cao 2003). 
--------------------------------------
PDGF-BB aids in vessel stabilization by stimulating production of extracellular 
matrix proteins that compose the basement membrane, including fibronectin, 
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collagen, and proteoglycans. PDGF-BB also stimulates secretion of collagenases, key 
for cell migration (Cao 2003). These factors can be used for therapeutic 
vascularization. Notably, PDGF-BB has been FDA approved in a recombinant form 
for the treatment of diabetic and pressure ulcers, and is the only drug FDA approved 
for chronic wound care (Stephan, Olivera et al. 2008). Furthermore, gene delivery of 
PDGF-BB with adenovirus has been found effective and is in FDA trials (Margolis, 
Crombleholme et al. 2000). 
Cao et al. demonstrated that PDGF-BB and FGF-2 have a synergistic effect 
when used in a 4:1 concentration on blood vessel growth and stability (Cao 2004) as 
compared to the use of each growth factor alone through the use of a corneal 
micropocket assay in vivo. Vessels generated by VEGF-A are more fenestrated and 
appear less stable and less well organized compared to those generated by FGF-2 
(Cao 2003). Although VEGF can induce vascularization of the cornea, new vessels 
do not persist longer than 70 days (Cao 2003). A more stable network can be formed 
with the use ofPDGF-BB and FGF-2 (Cao 2003) which persists at least 210 days 
(figure 1-7). Therefore, PDGF-BB and FGF-2 induce more stable vessels by 
recruiting pericytes to promote formation of vascular networks which persist after the 
withdrawal of the factors for over a year (Cao 2003). These factors will provide 
necessary signaling to nearby vessels to trigger stable vessel invasion and perfusion of 
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Figure 1-7: Growth Factors for Angiogenesis in the Cornea. Adapted from (Cao 2003). In these 
experiments, Combinations of PDGF and FGF were shown to generate longer lasting stable 
vessels than the use of either factor alone in a corneal angiogenesis assay. 
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implanted tissue constructs. Beyond signaling molecules for angiogenesis, the basic 
scaffolding material for the tissue scaffolds also needs to carefully be selected. 
1.4. Engineering Microvascular Constructs 
1.4.1 Poly (ethylene-glycol) (PEG) hydrogels as a model scaffold 
Many scaffolds exist for the process of tissue engineering. One category 
includes natural materials, like collagen, fibrin, alginate and agarose, while another 
category includes synthetic materials, like poly( dimethyl siloxane) (PDMS), 
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poly( ethylene glycol) (PEG) and poly( ethylene terephthalate )(PET), also known as 
Dacron (Liu, Xia et al. 2007). Natural materials are desirable because they are known 
to be biologically compatible, they contain many biological substrates, and they are 
easily derived and they are generally less expensive to render than synthetics. Some 
of the limitations of natural materials include the presence of biological infectious 
agents, chemical pathogens from their decellularization, generalized inconsistency 
with their composition, immunogenicity in hosts and the inability to tightly control all 
properties of the scaffold (Liu, Xia et al. 2007). In contrast, synthetic materials are 
less likely to be biologically contaminated, they are less immunogenic and their 
composition is more tightly controlled, offering a truly blank slate for scaffold design 
(Liu, Xia et al. 2007). 
In particular, PEG is a useful synthetic material because it is hydrophilic and 
may be rendered cross-linkable through addition of acrylate chains or other linking 
agents (Zisch, Lutolf et al.). The hydrophilic nature of PEG hydrogels allows them to 
resist protein adsorption, rendering them mostly bioinert. This makes them more 
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biocompatible because they typically do not form granulomatous or highly fibrous 
capsules when implanted. They are mechanically tunable by varying the molecular 
weight and the gel weight percentage, so that they can mimic natural stiffnesses 
within the cellular environment. 
The functionalization and cross linking of PEG may be achieved through 
reaction ofPEG with acryloyl chloride to form PEGDA (figure 1-8). PEGDA then 
may be reacted with cysteine-bound peptides via a Michaelis addition to generate cell 
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Figure 1-8: PEG functionalization and cross-linking. Adapted from (Miller, Shen et al.). 
adhesive (with RGDS), growth stimulating (with PDGF-BB), or MMP-sensitive 
PEG-acrylate chains. Alternatively, PEG-Succinimidyl Carboxymethyl (PEG-SMC) 
may be readily conjugated to pre-synthesized cell adhesive peptides (figure 1-9) 
which may also be commercially purchased (RGDS). Biodegradable hydrogels may 
be prepared by reacting dissolved GGGPQGIWGQGK (abbreviated PQ), peptide 
with acryloyl-PEG-SMC to incorporate PQ into the polymer backbone (Lutolf, Lauer-
Fields et al. 2003). Ultimately, the resultant chains which have PEG-PQ-PEG can be 
crosslinked in the presence ofthe photoinititator 2,2-dimethoxy-2-
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phenylacetophenone (acetophenone) dissolved in N-vinylpyrrolidone (NVP) (300 
mg/mL), in order to generate a free-radical driven photopolymerization. This step 
allows for the formation ofhydrogels in relatively gentle conditions so that 
crosslinking can be done in the presence of sensitive growth factors and even with 
cells, to form virtually any shape hydrogel for implantation. 
Biomimetic (PEG) hydrogel scaffolds have demonstrated tremendous utility in 
the design of tissue engineered constructs (Cosgriff-Hernandez, Hahn et al.; 
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Gonzalez, Gobin et al. 2004; DeLong, Gobin et al. 2005). Modified hydrogels allow 
for biological activity, through the incorporation of cell adhesion peptides (Zisch, 
Lutolfet al. 2003) and growth factors (West and Hubbell1998; Mann, Gobin et al. 
2001; Moon, Saik et al. 2010), as well as through incorporation of degradable 
peptides within the backbone of the polymer (West and Hubbell1998). Hydrogels 
sensitive to degradation by MMPs were developed by West and Hubbel in 1998 by 
synthesis of block co-polymers of PEG and degradable peptides, flanked with acrylate 
chains which are photopolymerizable (West 2006). Other cell-adhesion molecules 
which have been functionalized to PEG include YIGSR and IKA VAV, derived from 
laminin and REDV and KQAGDV from fibronectin (Gonzalez, Gobin et al. 2004). 
The laminin derivatives may provide promise as they have been shown to stimulate 
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human mesenchymal stem cell survival and neuronal differentiation in vitro 
(Delcroix, Schiller et al.). Many more cell adhesive signals will likely be developed, 
based on integrin domains, and will provide greater functionality of the PEG hydrogel 
system. For this project, degradable PEG-PQ-PEG based hydrogels will be utilized as 
a scaffold for engineering a niche and studying induced vasculature in vivo in a 
modified mouse corneal micropocket assay. 
1.4.2 The Modified Corneal Micropocket Assay: The mouse cornea as an in 
vivo transplantation site 
Kenyon et al. pioneered the use of a mouse corneal micropocket assay to show 
the angiogenic potential of growth factors (Kenyon 1996). The mouse corneal 
micropocket angiogenic assay is a well- studied model for assaying the activity of 
pro- or anti-angiogenic factors in vivo for several reasons. Importantly, the cornea is 
avascular in the native state, allowing for the optical clarity needed for vision to take 
place. The avascular nature of the cornea allows for facile differentiation of 
angiogenic responses and vascular patterns (Ambati and Sakurai 2006). All vessels 
present in the cornea after implantation of growth factors can thus be attributed to the 
growth factors. 
To allow for the adequate transmission of light, the cornea must remain 
avascular, and thus transparent. The undisturbed cornea maintains its avascular 
nature with several factors, including the soluble inhibitor ofVEGF sflt1 (Chang, 
Gabison et al. 2001; Ambati and Sakurai 2006), pigment epithelium derived factor, 
20 
and many tethered anti-matrix metalloproteinases within the corneal stroma (Chang, 
Gabison et al. 2001). This balance is relatively robust, and in humans, few disease 
states lead to vascularization of the cornea, including hypoxic conditions (from 
extended contact lens use) and massive inflammatory conditions, in which a 
predominant leukocytic response is initiated (Ellenberg, Azar et al.). Anti-angiogenic 
factors may be overcome with the addition of soluble growth factors, including VEGF 
and this has been shown by many groups (Kenyon 1996; Rogers 2007). The cornea 
has proven an acceptable location to study angiogenesis, and has been used in many 
studies of cancer therapeutics (Streilein 2003) . 
Besides being angiogenically privileged, the cornea is also immune privileged 
(Cursiefen 2007), thus it provides an acceptable niche for implantation of foreign 
materials and cells (Cursiefen 2007) which might typically trigger an immune 
response in other implant locations within the host. Previously, cancer cells have 
been shown to survive and be angiogenic when implanted into the cornea (Kim, Li et 
al. 1993 ). This serves as support for the idea that cells may be encapsulated within a 
scaffold containing diffusible growth factors, then implanted within the cornea and 
studied without triggering a large immune response. The immune privileged state is 
actively maintained by the reduced expression of major histocompatability complex 
(MHC) class I and reduced numbers of immune cells expressing MHC class II 
(Ellenberg, Azar et al.). Furthermore, an immunosuppressive environment is 
maintained by the presence of soluble factors such as a-melanocyte-stimulating 
hormone and vasoactive intestinal polypeptide (Chang, Gabison et al. 2001; Cursiefen 
21 
2007). The immune privileged state of the cornea, along with the angiogenic 
privilege it exhibits provides an environment for in vivo studies of tissue constructs, to 
allow for optimization of angiogenesis and implanted cell survival and differentiation. 
Several other in vivo methods have been developed for implantation of tissue 
constructs, including the dorsal skin fold apparatus, and intra-abdominal omental 
implantation, both of which are problematic when assessing neovascularization, 
because they both contain background vessels. 
Previous work performed in the laboratories of both Dickinson and West has 
served to modify the cornea micropocket assay using PEG hydrogels as a delivery 
vehicle in an effort to generate tissue constructs (figure 1-1 0) (Moon, Saik et al. 
PEGDA+ VEGF +PEG-VEGF +RGDS-488 (7d post-implantation) 
Depth Cod1ng 
Figure 1-10: This figure demonstrates several implanted hydrogels containing (PQ) 
degradable sequences in the backbone allow for MMP-mediated degradation by invading 
vessels(E-L). From Moon et al 2010. 
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2010). Hydrogels have been rendered degradable by the host in vivo through 
incorporation of matrix metalloproteinase (MMP) sensitive cleavable cross links into 
the polymer backbone (PEG-GGGPQGIWGQGK-PEG) (West and Hubbell1998), 
(Soo-Hong, Jordan et al. 2005; Moon, Saik et al. 2010). Matrix metalloproteinases 
(MMPs) 2 and 9 are secreted by invading host vessels and degrade the PQ peptide 
sequence within the backbone of the polymer. MMPs 2 and 9 are particularly 
important because they are known to be important in the host angiogenic response 
and they are found to be secreted by endothelial cells, in response to FGF-2 making 
degradation into the gel relatively specific (Haas 2005). The typical host response of 
the cornea to implanted hydrogels lacking growth factors involves a thickening of 
perilimbic vessels proximal to the implant site (Moon, Saik et al. 201 0; Poche, Saik et 
al. 2010). However, this represents a relatively weak reaction in comparison to the 
vascularization seen with the inclusion of diffusible angiogenic factors. The 
vascularization is particularly easy to assess and image, because the mouse used in 
these studies contains and endothelial bound fluorophore, mCherry, which is 
expressed via the FLKl marker with a myristoylation sequence which binds the 
fluorophore to endothelial cell membranes. This allows for excellent vascular 
labeling and imaging. 
The in vivo micropocket assay allows for the study of vascularization of 
fabricated tissue constructs, and the next step is to define the parameters for the 
optimization of angiogenesis within this environment. 
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1.5 Cell Based Methods for Prevascularization 
One method to create vascularized constructs involves pre-vascularization of 
either the recipient site or the construct containing the encapsulated cells with 
endothelial cells, to ensure rapid anastomosis and perfusion. This has previously been 
demonstrated in vivo using human umbilical vein endothelial cells (HUVECS) with 
fibroblasts in co-culture, where in vitro culture required 7 days and in vivo time to 
perfusion was 5 days (Chen, Aledia et al. 2008). Another suitable line for this 
application is the brain derived endothelial line (b.end3 or bend cells) (Montesano, 
Pepper et al. 1990; Omidi, Campbell et al. 2003). These cells are appealing because 
they are thought to induce a barrier similar to that seen in the blood-brain barrier. 
This means they can induce a unique vascular bed that will allow for the diffusion of 
those nutrients needed for survival of neural cells, and they may inhibit the passage of 
metabolites and other blood soluble factors into the new neural tissue which may be 
damaging. Bend cells have been studied in vitro, and remain viable and proliferate 
after encapsulation. They also form tubules in vitro (Montesano, Pepper et al. 1990) 
and when encapsulated in PEG-PQ-PEG hydrogels and then grown in culture (Saik 
and Gould in submission). Although many other cell types have been attempted for 
implantation to aid vascularization, this project will focus on bend cells for the 
purpose of developing a rapidly vascularizable construct or scaffold for the delivery 
of neural stem cells and other cell types. 
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1.6. Measurement of Vessel Morphology 
In this thesis, I induce vessel growth using soluble and tethered growth factors 
in order to tune the vascular response in vivo, providing a robust system for control of 
angiogenesis for biomaterials and tissue engineering applications. In order to tune the 
microvasculature, I have developed a quantification method of the vessel response in 
this thesis. Vessels can be characterized in many ways, and have been in order to 
study vascular disease, cancer progression and basic physiological properties (Less, 
Skalak et al. 1991). Vessels induced by growth factors as described above can be 
categorized similar to the manner proposed by Rogers et al. (Rogers 2007) where they 
applied a subjective grading system to the types ofvessels grown into the gel, as well 
as a slit-lamp measurement of vessel area, calculated by estimating length ofvessels 
and clock hours (radial length). This method is only relevant to characterizing the 
intensity of vascular response in the cornea. More inclusive and descriptive 
measurements ofvessels for the purposes of mimicking their structure are necessary. 
There is vast literature concerning the quantification ofvessel morphology, 
from initial studies of vessel length and diameter to more complex physiological, 
molecular and higher level structural or super structural analysis (Jain, Schlenger et 
al. 1997). These include vascular length, surface area, volume, number of vessels in 
the network, fractal dimensions of the network (Masters 2004 ), and basement 
membrane formation ( col4 deposition) (McKay, Gedeon et al. 2008; Gould, 
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Vadakkan et al. 2010; Yang, Yu et al. 2010; Gould Submitted- In preparation). The 
classical measures are not scale invariant, and they may change as the focus region or 
the region of interest of vessels decreases, they do not account for the change in scale 
seen. Ideally, scale invariant measures of vessel morphology should be determined in 
order to allow for scale up in design to engineer methods for angiogenesis. Also, any 
characterization of quantification scheme should incorporate an automated approach, 
in order to allow for the processing of tremendous numbers of images of the vessels 
in question. This thesis provides an automated method to examine the scale-invariant 
space filling parameters of vessels. 
1. 6.1 Automated methods to measure vessel morphology 
Algorithms have been developed in the past to aid segmentation with pattern 
recognition (W. E. Higgins 1989), model based approaches, tracking approaches, 
artificial intelligence approaches, neural network based approaches and miscellaneous 
tube-like object detection (Kirbas C 2004). These methods help to define vascular 
morphology, but in the case of new biological tools, including membrane-based labels 
of vessels, the classical measures which require extraction using automated methods 
fail for several reasons (Kirbas C 2004). The labels are not homogenous which may 
be due to biological phenomena, and vessel closing algorithms are required to 
artificially fill in vessel segments and to ignore this information (Gould, Vadakkan et 
al. 201 0). Given the modified micropocket assay is conducted in membrane labeled 
Flkl-myr::mCherry mice, classification should take into account the distribution of 
the fluorophore when characterizing morphology. 
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One automated program developed to analyze images of vasculature is 
VESGEN 2D (Mary, Patricia et al. 2009), which determines local vessel diameter, 
tortuosity, and avascular spacing. It correlates these measures with hierarchical 
branch organizations. The creators ofVESGEN suggest that specific growth factors 
induce "signature fingerprints" within the morphology of generated vessels, which are 
hierarchically dependent (McKay, Gedeon et al. 2008). Though generalities can be 
made about the vessel structures using classical measurements of vessel morphology, 
including average vessel diameter and branch distance, a more comprehensive 
measure of global vessel morphology based on space filling properties may be 
helpful in demonstrating subtle differences between tissues. This is particularly 
relevant in the case of membrane labeled vessels, in which subtle variations in signal 
may indicate biologically relevant information. Furthermore, this algorithm 
(VESGEN) and classical methods fail to characterize differences seen in engineered 
vessels, as the vessel structures are not hierarchically ordered and they grow not in 
developmental context, but in response to inducing growth factors. 
1.6.2 Space-filling measures: Vessel Density, Fractal Dimension, Generalized 
Fractal Dimensions and Lacunarity 
The density of vessels occupying a tissue has implications for the exchange of 
oxygen and nutrients, and this concept is not difficult to relate to many tissues, in 
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terms of function. Vessel density has been measured in the past, using algorithms 
which count occupied pixels and divide these by the total number of pixels for a given 
image size, performing a density calculation (Penn and Gay 1992). This by itself 
provides information on the amount of space filled by vessels, but the measure is not 
scale invariant, and therefore it fails to be a good tool for comparison across different 
tissue beds. In contrast, fractal analysis, which is a scale-invariant measure of how 
vessels fill space (Masters 2004), in conjunction with lacunarity analysis, which is a 
scale-invariant measure of the distribution of empty space around vessels, provides 
for comparison across different vessels in tissue beds (Lopes and Betrouni 2009). In 
the 1960's the adjective 'fractal' was first used by mathematical Benoit Mandelbrot to 
describe objects with complex geometry which can only be described by a non-
integer dimension using non-euclidean geometry (Mandelbrot 1963; Mandelbrot 
1982; Lopes and Betrouni 2009). This means these objects look similar at different 
scales. In Euclidean geometry, a line is represented as having a dimension of 1, and a 
box has a dimension of 2, (existing in x and y coordinates), but branching and 
complex structures exist somewhere in between, with a fractional dimension, hence 
the term, "fractal". Perfectly formed snowflakes and leaves are fractals, as are 
patterns created by diffusion limited processes; also regularly branching structures 
exhibit measurable fractal properties. The underlying process which forms these 
objects can be determined by the fractal dimension, as is the case in diffusion limited 
processes (Lopes and Betrouni 2009). In reality, no snowflakes, leaves, or human 
vessels are truly completely described with a single fractal dimension alone. Subtle 
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variations in growth or fluctuations during formation affect the morphology of these 
objects. To better characterize these objects, multifractal analysis which measures 
generalized fractal dimensions can be applied to determine if an object is a simple 
mono fractal or if there are fluctuations in the underlying self similarity (Lopes and 
Betrouni 2009). Multifractal analysis can detect these fluctuations and can provide 
more information about the space an object fills, and might provide insight into the 
underlying processes which affected the formation or the remodeling of that structure. 
Lacunarity is a complementary measure of the empty space surrounding objects, and 
it quantifies the distribution of the empty space surrounding complex objects. Fractal 
dimension and lacunarity analysis are ideal for quantifying complexity and space-
filling in vascular mesh-like or distributary networks. These properties help to 
robustly differentiate patterns with differing levels of branching and heterogeneity. 
Tools in image analysis have recently been developed to help create global 
characterization schemes for biological systems (Baish and Jain 2000) and include 
fractal dimension (Mandelbrot 1982), lacunarity analysis (Tolle, McJunkin et al. 
2008) and multifractal analysis (Posadas, Gimenez et al. 2001; Gould, Vadakkan et al. 
2011). These methods have demonstrated great promise in biological applications, 
including in the diagnosis oflung cancer (Al-Kadi and Watson 2008), osteoporosis 
(Zaia, Eleonori et al. 2006) and melanoma (Gilmore, Hofmann-Wellenhof et al. 
2009). And more recently they have been applied to segregate pathological retinal 
angiogenesis (Avakian, Kalina et al. 2002) from normal retinal vasculature (Stosic, 
Tatijana et al. 2006). 
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These tools help to assess the space-filling nature ofvessels. In images of 
vessels labeled with dextran, the lumens ofthese vessels are completely filled and are 
easy to trace using classical hierarchical methods. The tracing methods break down 
when applied to membrane-labeled vessels which are now available in biology (either 
through genetic conjugation of a fluorophore or immunohistochemistry) because of 
uneven distribution of labels on the vessels. More information can be extracted from 
the distribution of these labels using space filling methods, instead of hierarchical 
tracing algorithms. Since the non-homogeneous distribution of labels on vessels may 
be biologically relevant, space-filling measures may provide more information than 
classical morphological measures. In this project, these new methods are applied in 
the automated study of vessels generated within tissue scaffolds providing a new 
classification tool for vessels. These methods have helped aid design of 
microvascularized constructs for tissue engineering strategies in this thesis. This 
contribution could be critical to the design of vascularized scaffolds for use in 
transplantation. 
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1. 7 Thesis Overview 
In Conclusion, tissue engineering is a rapidly developing field which promises 
to create new tissues from stem cells, scaffolds, and biological factors to repair 
diseased or damaged organs. In order to best repair tissues after damage, replacement 
angiogenic scaffolds could be best optimized by mimicking normal vascular 
morphology. The focus of my thesis has been to determine new ways to quantify the 
microvasculature in vivo, and in angiogenic engineered constructs. I applied this 
method to vessels induced in the modified corneal micropocket assay and found that 
the vessel response is tunable and that it is possible to induce vessels which are 
similar to those found in native tissues. Finally I have implanted brain derived 
endothelial cells in a two-step adaptation of the mouse corneal micropocket assay to 
provide a tool for rapid anastomosis with induced host vessels. 
In the following chapters, I describe the primary results of this thesis project. 
First, I discuss the development of a new image-based tool for the study of scale 
invariant parameters of vessel morphology. This tool provided critical information 
about vessels and their response in vivo to growth factors, and information which may 
be utilized in future design, given the scalable nature of the morphology data. 
Second, I describe the use of this tool in the design of induced vascular beds. Host 
vessels were induced in vivo in a mouse corneal micropocket assay to recapitulate 
vessels in native host tissues. Third, I used other covalently bound factors to tune 
vessel induction in vivo. Finally I describe a novel implantation scheme to allow for 
31 
anastomosis between encapsulated endothelial cells and the host induced vascular 
response in a corneal micropocket. This thesis serves to provide a platform for the 
study of anastomosis and perfusion of implanted tissue engineered constructs in vivo 
by providing a protocol for future optimization of angiogenic scaffolds and cell-based 
therapeutics. This in vivo platform may be applied in future studies of native and 
diseased vessel morphology, angiogenic biomaterials, and implanted cell constructs. 
Ultimately, this project has contributed to the field ofbioengineering by furthering 
knowledge in these areas, moving towards the goal of implantable tissue engineered 
constructs. 
Chapter 2: Multifractal and Lacunarity Analysis of Microvascular 
Morphology and Remodeling 
This chapter is adapted from the article titled "Multifractal and Lacunarity 
Analysis of Microvascular Morphology and Remodeling" (Gould, Vadakkan et al. 
2010) published in the journal Microcirculation, available online Feb 6th 2011. 
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This chapter outlines the adaptation of space filling measures used previously 
to study vessels along with classical methods to quantify vessel morphology and to 
characterize microvessels. Furthermore, it adapts the use of a new technique, 
multifractal analysis, previously used to examine multiscale systems and retinal 
vessel morphology. The technique is applied to stable vessel beds in skin and muscle, 
remodeling vasculature and vessels in the neural stem cell niche, the sub ependymal 
zone (SEZ) in the brain to identify fractal dimension, lacunarity and density of vessels 
to aid in their future design. 
Classical measures of vessel morphology, including diameter and density, 
have been employed by other research groups to study microvasculature in 
endothelial membrane labeled mice. These measurements prove sufficient to 
differentiate vascular beds for some studies; however, they are less well suited for 
quantifying changes in microcirculatory networks lacking hierarchical structure, like 
those occurring in the microvasculature in many organs. This study demonstrates that 
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automated multifractal analysis and lacunarity may be implemented with classical 
methods like density, vessel diameter and branching to quantify microvascular 
morphology. Using multifractal analysis and lacunarity, an automated extraction tool 
with a processing pipeline to characterize 2D representations of 3D microvasculature 
is presented by this work. The application of this analysis is in images taken from four 
tissue types and the hyaloid vasculature during remodeling. This study demonstrates 
that individual vessel networks possess specific multifractal spectra, which serve as 
'fingerprints' in that they are each individual and distinguishable. The networks 
analyzed are shown to be multifractal by this work. Also, when compared, kidney 
microvasculature has the largest fractal dimension and the lowest lacunarity versus 
microvasculature networks in the cortex, skin, and thigh muscle. During hyaloid 
remodeling, there were differences in multifractal spectra reflecting the functional 
developmental transition from a space filling vasculature which nurtures the lens to a 
less dense vasculature as it regresses, to permit unobstructed vision. This work shows 
that multifractal analysis and lacunarity are valuable additions to classical measures 
of vascular morphology and will have utility in future studies of normal, developing, 
engineered and pathological tissues. 
2.1 Introduction 
Vessel morphology in any tissue depends on genetic control during 
development, remodeling related to hemodynamics and metabolic demand, and 
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pathological events. Thus, significant changes occur in vessel architecture during 
vessel remodeling in normal development (Lucitti, Jones et al. 2007; Poche 2009), in 
response to physiological changes, such as increased oxygenation demands (Bergman 
and Ullberg 1998), and as a result of pathology as in the case of vessels in tumors 
(Dajnowiec and Langille 2007). Quantitative analysis of changes in vessel 
architecture provides a powerful means to assess functional changes (West, Brown et 
al. 1997; Murray (1926); Kurz (1997)) and to establish prognosis in the case of 
pathological conditions (Sabo, Boltenko et al. 2001; Lin 2008). Moreover, for tissue 
engineering applications, it is important to use quantitative methods to describe vessel 
structures in order to develop truly biomimetic vascularized scaffolds (Hoganson, 
Pryor et al. 2008; Grayson, Martens et al. 2009). Thus, there has been a great 
emphasis on defining and developing methods to quantify these important changes in 
vessel morphology. 
Previously developed methods to quantify vessel morphology include the 
mean diameter of vessels, mean length of vessel segments, branch angle, vessel area 
density (the fraction of image area occupied by the vessels), and vessel length density 
(the fraction of image area occupied by the skeleton of the vessels). Moreover, 
hierarchically branched vessels have been further characterized by more elaborate 
methods, such as by allocating the branching order to the measures described above 
(McKay, Gedeon et al. 2008; Yang, Yu et al. 2010). However, such methods are 
generally applied to vessel trees with clear parent to daughter branch architectures 
(Stosic, Tatijana et al. 2006). While these measurements are adequate for many 
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studies, including those of larger vessel segments like the branches of the great 
arteries and pulmonary vasculature (Horsfield 1978), they are less well suited for 
quantifying changes in microcirculatory networks that lack hierarchical structure and 
have a more homogeneous distribution of vessel diameters. Thus, to more aptly 
describe these networks, more advanced methods that determine the space filling 
properties of these networks have been implemented. 
One measurement of the space filled by an object if density, and vessel density 
is the simplest expression of how vessels fill a space (Fontanini G 1995; Claudio, 
Anna et al. 1999; Uzzan, Nicolas et al. 2004) and can be measured from images of 
vessels by counting the number pixels that contain part of the vessel image and 
dividing these by the total number of pixels for a given image (Penn and Gay 1992). 
This value by itself provides information on the amount of space filled by vessels, but 
the density is not scale invariant, and therefore it fails to be a good tool for 
comparison across different tissue beds. More recently, fractal analysis has been used 
to describe the space filling properties of vessels (Masters 2004) and offers an 
improvement over density, as it is a scale-invariant measure of the space filled by an 
object. The term 'fractal' was first used by Mandelbrot to describe objects with 
complex geometry which occupy non-integer dimensions (Mandelbrot 1963; 
Mandelbrot 1982; Lopes and Betrouni 2009). Fractal objects look similar at different 
length scales, and in the late 1980s, fractal analysis was used to describe patterns of 
retinal vessels (Masters 1989). The fractal dimension, D0 also known as the 
Hausdorff-Besicovitch dimension is used to describe the fractal properties of a 
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structure (Mandelbrot 1982) and is most commonly determined with the box counting 
algorithm (see figure 2.1). For the box counting algorithm, a binary image of an 
object (where pixels either have a value of 1 or 0) is partitioned into several boxes 
each ofwidth E. Then, the number of boxes N(E) that contain at least one signal pixel 
(a pixel with a value equal to 1) is enumerated. The procedure is repeated for different 
values of E. The fractal dimension is determined by plotting log(N(E)) versus log( E) 
and determining the slope of the linear region of the plot (Baish and Jain 2000). Thus, 
the fractal dimension is a single value that reflects the minimum dimension of the 
space required to embed the object. Numerous studies have applied this analysis to 
quantify changes in the vasculature (Masters 1989; Parsons-Wingerter, Elliott et al. 
2000; Sabo, Boltenko et al. 2001; Stosic, Tatijana et al. 2006; Grayson, Martens et al. 
2009; Doubal, MacGillivray et al. 2010). 
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Figure 2.1: Determination of the fractal dimension of an object. A schematic of the box counting 
algorithm is shown here. Note, the grid has box widths, and ass decreases, the total number of 
boxes N(s) increases (figure A). In the case of a fractal N(s) is related to s by the relation N(s)- s-
00. D0 is defined as the box counting fractal dimension. Figure B shows the plot of N(t) vs. E. The 
log-log plot is shown in figure C along with the linear fits to the plot. Two equations are shown in the 
upper right hand corner of figure C. The first one corresponds to the linear fit to all points; the 
second one corresponds to the linear fit to the data excluding the lowest and highest s values. The 
lowest s value corresponds to the width of the pixel in the image; the largest s value corresponds to 
the bounding size of the image. Therefore, it is reasonable to define the linear region of the log-log 
plot as between the limiting values. The R2 values in both cases are close to 1. The standard errors 
of the slopes of the lines based on linear regression are 0.10 and 0.09 respectively. The slopes of 
the lines are not significantly different. Hence, for this project, all points will be used to calculate the 
slope of the linear region (fractal dimension). 
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Although vessels can be considered as fractal structures, two problems arise 
from using the fractal dimension alone. First, although the fractal dimension describes 
how much space is filled, this value does not indicate the distribution of that object 
within the space filled by the object. To address this limitation, Mandelbrot 
introduced lacunarity to further characterize fractal objects (29). Lacunarity is a 
parameter that describes the distribution of the sizes of gaps or lacunae surrounding 
the object within the image. Greater lacunarity reflects a greater size distribution of 
the lacunae, or said in another way, a higher degree of"gappiness". Lacunarity can be 
used to distinguish objects with similar fractal dimensions because some objects with 
the same or similar fractal dimension will fill the space differently (Mandelbrot 
1982), but lacunarity can also be used independently as a general tool for describing 
spatial patterns (Plotnick, Gardner et al. 1996). Lacunarity is routinely measured 
using a gliding box algorithm (Masters 2004; Tolle, McJunkin et al. 2008). The 
algorithm is described briefly as follows: an E x E box with width E is placed at the top 
left comer of an image. The number of signal pixels in the box is counted. The box is 
then glided one pixel to the right and the number of pixels in the E x E box is counted. 
The process is repeated until the box reaches the bottom right comer of the image. If t 
is the size ofthe image, the number ofboxes ofwidth E is N(E) = (t -E+li. The width 
E of the box is chosen such that its numerical value is equal to 2,4,8, .. , t. For each box 
width E, the following two quantities are measured: the sum of the number of signal 
pixels in each box Q 1 = Lip( i,E) and the sum of the square of the number of signal 
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pixels in each box Q2 = LiP(i,Ef Lacunarity L(E) at a box size E is defined as (N(E) x 
Q2) I Qt The value p(i,E) is the number of signal pixels in the ith box and i E [ f, 
N (E)]. In the gliding box algorithm, the box of size E is placed over each pixel in the 
image and p(i,E) is calculated for each box centered on the ithpixel. Thus, lacunarity 
measurement adds significantly to the description of an object with a known fractal 
dimension because it describes the empty space around the object, and thus it relates 
how the object fills space. 
The second limitation of simple fractal analysis is that it assumes that vessels 
can be described by a single fractal dimension alone, when in reality, complex 
structures exist with subsets of regions having different scaling properties. In fact, 
very few examples exist of structures with perfect mono fractal geometries. For 
example, although theoretical structures with monofractal behavior can be generated, 
such as Koch's snowflake, numerical models of naturally occurring snowflakes in fact 
exhibit multifractal behavior (Wolf 1996) because subtle variations in growth or 
fluctuations during formation affect the geometry ofthese objects. Also although 
simple fractal processes were initially proposed to adequately describe the formation 
of Diffusion Limited Aggregates (DLAs) (Matsushita, Sano et al. 1984; Meakin, 
Stanley et al. 1985); recently these processes have been shown to be better described 
using generalized fractal dimensions in a multifractal approach (Lee and Stanley 
1988; Block, von Bloh et al. 1990; Vicsek and et al. 1990; Chaudhari, Sanders Y an et 
al. 2002). Thus, in many cases, multifractal analysis provides more information about 
the space-filling properties than the fractal dimension (D0) alone (Lopes and Betrouni 
2009). One recent example of the application of multifractal analysis to vessel 
structures has been in the vessels of the retina. These vessels were first assumed to 
follow a simple fractal pattern (Masters 1989) but have more recently been shown to 
be multifractal in nature (Stosic, Tatijana et al. 2006). 
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One can measure the generalized fractal dimensions in order to construct the 
multifractal spectra by modifying the box-counting algorithm. The simple box-
counting fractal dimension method only quantifies the number ofboxes that contain 
signal pixels, ignoring the density of signal pixels (representing intensity fluctuation) 
in each box at all box widths (s). For multifractal analysis, one must consider the 
density of signal pixels in each box (Chhabra 1989) as shown by Posadas et al. 2003 
(Posadas, Gimenez et al. 2003). A detailed description of this analysis is in the 
Materials and Methods section. The benefit of this multi fractal technique was first 
recognized in its application in geography and polymer chemistry (Milne 1991; Lam 
1993; Kats and Kutarov 1996), but very recently it has demonstrated utility in its 
application to vasculature (Stosic, Tatijana et al. 2006; Douba1, MacGillivray et al. 
2010; Grauslund, Green et al. 2010; Sng, Sabanayagam et al. 2010). 
Here three new methods are described: fractal analysis, multifractal analysis 
and lacunarity analysis to characterize microvessels of a transgenic mouse in which a 
fluorescent protein (mCherry) fused to a myristoylation tag is expressed in endothelial 
cells under the control ofFlk1 promoter elements (Larina 2009). Using an image 
processing pipeline and automated statistical methods, traditional measures of vessel 
morphology (diameter, area density) are combined with fractal dimension and 
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lacunarity as well as with multi fractal analysis using images of microcirculatory 
networks in several different tissues and in the regressing hyaloid vasculature. In this 
study it was found that indeed all of the vessel networks analyzed have multifractal 
geometries. Moreover, classical measures alone were found to be insufficient to 
distinguish differences in microvascular structures from images of different tissues; 
however, such differences could be detected from comparisons of multifractal spectra 
and the lacunarity parameter. Finally, multifractal and lacunarity analysis was shown 
to provide the most sensitive measure of changes in vessel morphology associated 
with hyaloid vessel regression. 
2.2 Materials and Methods 
2.2.1 Image Acquisition 
Images ofFlk1-myr::mCherry labeled vessels were acquired from fixed, 
sectioned tissues obtained from euthanized Flk1-myr::mCherry transgenic animals in 
accordance with an IACUC approved animal protocol at Baylor College of Medicine. 
Confocal images were obtained using an LSM 510 META (Carl Zeiss) confocal 
microscope and a C-Apochromat 40x/1.2 water immersion lens. A 543 nm laser was 
used to excite the mCherry fluorophore, and z-stacks of vessels labeled by mCherry 
were collected. Z-stacks of 17.5 urn thick sections of the tissues were collected such 
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that the step size between two successive images in the z-stacks was 2.5 urn. Each 8-
bit image in the z-stack consisted of 512 x 512 pixels. 
2.2.2. Image Processing 
Images of the vascular beds were processed by first converting Zeiss LSM z-
stacks to maximum intensity projections using ImageJ software (Rasband 2010). A 
significant variation in signal intensity was not detected from the top to the bottom of 
the stack; therefore, no correction was applied along the z-stack before taking the 
maximum intensity projection. The custom contrast enhancement methods used to 
threshold the images were chosen such that the weakest signal in the projected image 
was captured in the thresholded image. Next, projected images were exported to 
Adobe Photoshop CS2 and the unsharp mask filter with a radius of 12 pixels was 
applied to improve image quality by intensifying the vascular patterns while 
decreasing background noise in nearby regions. The unsharp mask is a high-pass filter 
that removes the low frequency noise component of the image and enhances the high 
frequency signal component. Finally, images were further processed using a series of 
MATLAB programs that are freely available from the MATLAB central exchange to 
threshold and binarize the images so they would be suitable for the designed 
algorithms (see references). First, 8 bit images were binarized by applying an 
intensity threshold of 10 (Bemis 2005), and the raw images were overlapped with the 
thresholded images (Gould 2010). The intensity value that gave the best overlap, such 
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that the original vessel structures were preserved while the background noise was 
diminished, was chosen as the threshold; uniformly this value was 10 in the case of 
the images in this study. Figure 2.2 summarizes the image processing steps. 
Therefore, after the threshold was applied, the image was binarized such that all 
pixels with a value above 10 were designated as a value of one (referred to as signal 
pixels) and all those below were designated as zero (referred to as empty pixels). 
Several other MATLAB programs were then used to determine the vessel density, 
lacunarity, fractal dimension and multifractal spectrum of the binary images ofblood 
vessels (Moisy 2006; Vadakkan 2009; Vadakkan 2009). Figure 2.2 A is the projection 
image of a 17.5 micron thick stack of images from a section of the cerebral cortex 
vasculature of a Flk 1-myr: :mCherry mouse expressing the fluorescent protein 
mCherry in the vasculature. The pre-processing steps consisted of applying an 
unsharp mask filter to improve image quality (figure 2.2 C) and then applying an 
intensity threshold to binarize the grayscale image. Note that the binarized image 
(figure 2.2 D) has gaps (black pixels) within the vessel surface (white pixels). These 
gaps in the surface markers represent an example of intensity variation inherent in any 
membrane based label. Morphological closing algorithms (Eddins 2007) may serve to 
fill the gaps; however, because this intensity variation is likely to be biologically 
relevant as little manipulation as possible of these images provides the clearest picture 
of true vessel morphology. The finalized processed image was overlapped with the 
original image to demonstrate preservation of vessel diameters (2.2E). Furthermore, 
the vessel diameters were measured in the two images and histograms were compared 
to identify the distribution of vessel diameters and to compare the original and 
processed image, in order to demonstrate that the processing step did not change the 
vessel diameters significantly (2.2F, 2.20). 
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Figure 2.2: A flow chart of image contrast enhancement Figure A is the maximum intensity 
projection image of a 17.5 um thick confocal z-stack of cortex vasculature at post natal day 6 (P6). 
The vessels are tagged by the fluorescent marker mCherry. Figure B is the grayscale image 
obtained by maximum intensity projection of the z-stack used in figure A. Figure C was obtained 
from figure B by applying an unsharp mask filter (radius 12). Figure D is the binary image obtained 
from figure C by applying an intensity threshold of 10 using a MATLAB program (Bemis 2005). The 
original image in figure A is then overlapped with the image in figure D to check whether the 
thresholded image is a good representation of the original image. Regions in yellow show the 
overlap between the two images (figures A and D) in figure E. Importantly the vessel diameters from 
the original and the processed images do not differ significantly thus the processing steps preserve 
critical information about the original vessel beds for analysis and comparison. The similarities in 
the histograms of the vessels (figure F) and the similarities of the average vessel diameters with in 
each bin (figure G) support this observation. Note the gaps on the vessel surface due to 
thresholding. Vessel density, box counting dimension, and lacunarity obtained by applying the set of 
operations mentioned above are listed in table 2.1. Scale bar = 50 micrometers. 
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2.2.3. Vessel Morphology Analysis 
After processing the images to ensure retention of key biological features, the 
binary images were then subjected to several algorithms to determine the fractal 
dimension, lacunarity and multifractal spectra. These methods are briefly described 
below. 
2.2.4. Box Counting Fractal Dimension (D0) 
The fractal dimension was measured by overlaying a binary image of a 
vascular system with a grid ofboxes and counting the number ofboxes, N(8), that 
contain at least one signal pixel (Baish and Jain 2000). The fractal dimension (D0) 
was determined from the slope ofthe linear region in the log-log plot ofN(8) versus 8 
and is sometimes referred to as the capacity dimension. The number of boxes at 
given box width 8 was assumed to scale with the box width as N(8)- 8-no. The 
numerical values of the widths of the boxes used are 1, 2, 4, 8, ... , 512 (maximum 
number ofpixels) (see Figure 2.1). Although these box widths were chosen so that all 
length scales are represented, data points corresponding to a box width of a single 
pixel and the maximum width of pixels were eliminated in a second calculation to 
exclude an effect from noise or finite size effect (Figure 2.1, dashed box) and showed 
no significant difference. In fact the fractal dimension for the middle range of values 
only (4, 8, ... and 64 pixels) was also determined and was found to be no different 
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from the data presented in Figure 2.1 (data not shown). The similar values for the 
slope were expected because vessel diameters ranged from 4 to 16 urn, corresponding 
to box width sizes of8-32 pixels, and the middle region represented that range ofbox 
sizes. For the experimental images all length scales are included since some 
continuous vessel segments span nearly the width of the field of view. However, it 
was confirmed that the data were not influenced by noise or finite size effect for each 
data set by comparing the slope over the entire range with the slope obtained from the 
middle set of values ( 4-64 pixels). 
Fractal analysis required binarized images and considered boxes as positive 
(containing at least one signal pixel) or negative (containing no signal pixels). In 
images of membrane labeled vessels because the number of signal pixels is different 
from one box to another for any given box width (figure 2.1) simple box counting 
analysis is insufficient to fully characterize these complex vessel structures. In order 
to address this issue a multifractal method was developed and employed and will be 
described in a later section. It is important to note that the use of erosion or 
skeletonization methods was avoided in order to maintain intensity variations which 
could likely be biologically relevant. In this study the measurement of the box 
counting fractal dimension D0 is performed using a MATLAB program available free 
online through the MATLAB central database (Moisy 2006). 
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2.2.5. Lacunarity 
The fractal analysis allows for the determination of the dimension of the 
images, but in order to determine an independent measure of how the vessels in these 
images are distributed in space, lacunarity analysis provides the best parameter. 
Lacunarity was measured using a custom MATLAB program (Vadakkan 2009) based 
on the gliding box algorithm (Tolle, McJunkin et al. 2008). The lacunarity at a box 
sizes was defined as L(s) = (N(s) x Q2) I Q12• Q1 = LiP(i,s) and the sum ofthe square 
of the number of signal pixels in each box Q2 = Li p(i,s )2• In the vascular patterns 
analyzed, the lacunarity function L( s) resembled a hyperbola; therefore, the lacunarity 
function was fitted with the hyperbolic function, L( s) = b I sa + c (Zaia, Eleonori et al. 
2006) in which b (referred to as the lacunarity parameter) is related to the concavity 
of the hyperbola. A low b value defines a hyperbola with wide concavity (high 
lacunarity); meaning that a low b value describes an object with a high distribution of 
empty gaps throughout, or a high level of"gappiness". For fractal patterns, the 
lacunarity plot is a straight line on a log-log graph. Taking the logarithm of the 
hyperbolic function L(s) = blsa + c the out put is ln(L(s)-c) = ln(b)- a ln(s), which is 
the equation of a straight line. The linear relationship justifies the choice of the 
hyperbolic function. The use ofthe hyperbolic function is further supported by the R2 
values obtained from the fitting of the function to the data points. 
49 
2.2.6. Generalized Fractal Dimensions and Multifractal Analysis 
Lacunarity in conjunction with fractal dimension can provide information on 
how much space is filled by an object and how it is distributed within space, but they 
only provide discrete parameters that are not continuous over a range of dimensions. 
Multifractal analysis provides information on how an object fills space, but also 
provides information about how the entropy within an image changes as a function of 
the scale used to investigate it, as well as how the scale affects similarity or 
correlation within the image. Furthermore, Multifractal analysis yields a continuous 
spectrum representing the amount of space filled by the object, as well as the 
distribution of that object within space and allows for greater comparison of like 
objects, by providing useful shape features of the curve of the spectra, including 
symmetry and heterogeneity features which can be used to distinguish similar objects. 
Here, we seek to determine the generalized fractal dimensions of the vascular 
structures in order to determine if they are, indeed, multi fractal. Multifractal analysis 
takes intensity variations like those seen in membrane labeled vessels (figure 2.2) into 
account by measuring pixel density within a box (Posadas, Gimenez et al. 2003). 
Pixel Density 
Pixel density in any given box is defined as the number of signal pixels in that 
box divided by the number of signal pixels in the entire image. A signal pixel in a 
binary image is defined as a pixel whose intensity is 1 after thresholding to form a 
binary image. In a binary image, the number of signal pixels I (the number of signal 
pixels+ empty pixels (total Pixels)) is defined as the pixel density. 
Generalized Fractal Dimensions 
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The generalized fractal dimensions are defined through the scaling relation Li 
[Pi{c)] q ~ E t(q)' where -r(q) = (q-1) Dq, q E (-00, +co), and i E [1, N(E)] (Posadas, 
Gimenez et al. 2003). The numerical values ofDq corresponding to different values of 
q are the generalized fractal dimensions of a structure. For a simple fractal (also 
called a monofractal structure), Dq is independent of the value of q. D0, D1, and D2, 
are called respectively, the box counting dimension (also capacity dimension), the 
entropy dimension, and the correlation dimension. D0, D1, and D2 are related by the 
inequality D0 ~ D1 ~ D2 in the case of a multifractal. Conversely, the equality holds 
in the case of a simple fractal. A vascular structure is considered a multifractal 
structure only ifthere is a statistically significant difference between D0, D1, and D2. 
A description of the generalized fractal dimensions in a manner similar to the 
box counting dimension is made by changing the variables from (q, -r) to (ex, f) such 
that ex= 8-r I 8q and f (ex)= exq- -r. This transformation, called a Legendre 
transformation (Frisch and Vergas sola, 1991, (Meneveau and Sreenivasan 1991) has 
been used before to relate the D(q) spectrum to the f(ex) spectrum (Stosic, Tatijana et 
al. 2006). 
The number ofboxes N(a) for which the probability Pi( E) has exponents 
between lX and lX + da scales as E -f(a). Thus, f(a) is the fractal dimension of the set of 
boxes for which the exponent is lX. The plot off( a} against a(q) is referred to as the 
multifractal spectrum in this and other papers (Posadas, Gimenez et al. 2003; Stosic, 
Tatijana et al. 2006). The comparison of these spectra in a multifractal analysis as 
defined by Chhabra and Jensen (Chhabra 1989) is described later in this work. 
Measuring Generalized Dimensions and Generating a Multifractal Spectrum 
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To measure the generalized fractal dimensions of a binary image, the binary 
image is overlaid with N(E) boxes each ofwidth E. Associated with each box of index 
i is a measure Pi( E), which is defined as the number of signal pixels in the ith box of 
width E divided by the total number of signal pixels in the image (pixel density). 
Determining q with respect to Pi( E) is given by the equation given below. 
(1) 
1-l/q,E) E [0,1] for each value of q. In this case, we used q ranges from -2 to +2 
in steps ofO.l. Also, Li [Pi(E)] q ~ E 1:(q). Importantly, the value of't'(q) is determined 
by taking the slope oflog(Ii [Pi(E)] q) versus log (E). 
f( q) and a( q) are determined using the following two equations: 
f(q) =lim (E~O) [ { Li 1-li(q,E) log( 1-l/q,E)) } I logE] (2) 
a(q) =lim (E~O) [ { Li 1-l/q,E) log(Pi(E)) } I logE] (3) 
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The functions f(q) and a(q) (equations 2 and 3) represent the moments of the 
distribution Pi. The values of these functions for each of the values of q allow us to 
construct the multifractal spectrum. Equations 2 and 3 can thus be used to determine 
f(a) for each a(q) (Posadas, Gimenez et al. 2003). The multifractal spectrum is the f 
(a)- a curve defined by the equation given below. 
f(a) = aq- 't(q). 
A flowchart depicting the construction of the multi fractal spectra is included in 
figure 2.3. A program written for this project in MATLAB was used to calculate the 
functions f(q) and a(q) using the equations above (available online, see references). 
Figure 2.3 demonstrates this analysis on one ofthe images of the retinal vessels 
depicted later, in 2.6 D. The image of retinal vessels is first overlaid with a grid and q 
is determined as described above. Then, 't( q) is measured for each value of q, given 
that 't(q) is the slope oflog(Li [PiCE)] q) versus log (E). For each E, equations 1, 2, and 
3 are calculated for all values of q. 't(q) is then plotted versus q for each value of q 
(figure 2.3 A). The equation used to estimate 't(q) is shown in the text within the box. 
Two lines have been drawn upon the figure A to illustrate the change in slope in the 
't( q) spectrum (arrowheads). This change in slope is a characteristic of a multi fractal. 
Figure B shows the plots off( q) and a( q). f( q) is the slope of the line obtained by 
plotting (Li /-li(q,E) log(/-li(q,E))) against log E. a(q) is the slope of the line obtained by 
plotting (Li /-li(q,E) log(Pi(E))) against log E. The equations used to calculate f(q) and 
a(q) are shown in the Figure B. 
Finally the multifractal spectrum is 
determined an plotted as the 
multi fractal spectrum is the f (a) - a 
curve defined by the equation f (a)= aq 
- T( q). Figure C is the multifractal 
spectrum ofthe image ofvessels in 
figure 2.6 D. 
By construction, lllq,£) E [0,1] 
for each value of q. In this set of 
experiments, for each value of q, linear 
fits to the plots of numerators versus 
denominators in the above equations 
were used to calculate f(q) and a(q). 
All q values in the range from -2 to +2 
were used to calculate f( q) and a( q) . 
The q values were increased in steps of 
0.1 (Posadas, Gimenez et al. 2003 ; 
Stosic, Tatijana et al. 2006). The 
linearity of fits was assessed using R2 
values. The multi fractal spectra of the 
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Figure 2.3: Work flow in the multifractal analysis. The 
image of the retinal vessel in figure 2.6 0 is used to 
demonstrate the multifractal analysis step by step. 
First, r(q) is measured for each value of q. For each ~: , 
equations 1, 2, and 3 are calculated for all values of q. 
r(q) is the slope of log(L; [P;(t: )] q) versus log ( ~: ). Figure 
A shows the plot of r(q) versus q. The equation used 
to estimate r(q) is shown in the text within the box. 
Two lines have been drawn upon the figure A to 
illustrate the change in slope in the r(q) spectrum 
(arrowheads). Such a change in slope is a 
characteristic of a multifractal. Figure B shows the 
plots of f(q) and a(q). f(q) is the slope of the line 
obtained by plotting (L; !J;(q ,~: ) log(J..t; (q ,~: ))) against log c. 
ex(q) is the slope of the line obtained by plotting (L; 
J..l ; (q ,~: ) log(P;(t: ))) against log ~:. The equations used to 
calculate f(q) and a(q) are shown in the Figure B. 
Figure C is the multifractal spectrum of the image in 
figure 2.6 D. The multifractal spectrum is the f (ex) - ex 
curve defined by the equation f (ex) = exq - r(q). 
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binary images were obtained by plotting f(a) against a(q); only a(q) values with an R2 
value above 0.95 were considered for plotting and comparison. 
In conducting the multi fractal analysis, and in all of the measurements, 2D 
projections from 3D z-stacks were used. To understand ifthe process of projection 
changed our measurements, the analysis on each slice from the z stack was conducted 
and then compared the average values for each parameter to the projection image 
values (figure 2.4). There were slight, but insignificant, differences between the slice 
averages and the projection values for vessel density, fractal dimension and lacunarity 
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Figure 2.4: Comparison of slice-by-slice means versus projection means. The vessel density, 
fractal dimension and lacunarity were measured as described in the manuscript for each image 
in the z-stack (figure A). Next the average values and the standard deviations of vessel 
density, fractal dimension and lacunarity were calculated. The mean values obtained from 
slice-by-slice analysis of the z-stack are plotted alongside the mean values obtained from 
projection images of vessels (figures A-C). Similar trends in the morphological parameters are 
seen between the two groups. Thus for the vessel images used in this manuscript, projection 
analysis is similar to the slice by slice analysis in detecting trends between the vessel images. 
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for each tissue type. Importantly, the trends were preserved between tissue types, and 
the values increased as predicted in the projection cases. 
The multifractal analysis was compared in similar fashion (figure 2.5). The 
overlap between the spectra of each slice and the projected spectra again showed that 
the trends between tissue types were preserved as well. 
The methods described above were demonstrated to be robust in analysis of 
images of vessels from different tissues. The results of the application of these tools 
to images of vessel beds are described below. 
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Figure 2.5: Validation of the use of two dimensional projections via comparison of multifractal 
analysis applied to projection images and to slice by slice analysis . Here, the individual images 
comprising the z-stacks for all of the tissue beds were each individually subjected to multifractal 
analysis. This figure summarizes the raw data for each of the seven images comprising the stacks 
in the column labeled E-H . 1-L shows the average value of the points on the various multifractal 
spectra derived from each individual slice. Because the raw data appeared relatively similar, this 
average was plotted with error bars representing the standard deviation at each value of f(a) for a. 
In the final column labeled M-P, the multifractal spectra for the projected images are shown for 
comparison to the average values. The trends between 1-L and between M-P are similar and both 
reflect changing generalized fractal dimensions between vessel beds. In the vascular beds 
discussed in this paper, the thickness of the z-stacks of the tissue was 17.5 micrometers. If the z-
stacks were much thicker, then the projected image of the vessels could overlap and would be 
measured as occupying more space (due to a contribution from vessel elements in other planes). In 
fact, it is possible to fully fill the projected image space with vessel elements by increasing the 
number of slices in the z-stack and consequently increasing the tissue thickness sampled . In this 
case, a fractal dimension of 2 will be measured as the upper limit of the projection images. Our 
analysis demonstrates that the projection images of the vessels are sufficient to demonstrate 
differences between vessels from different tissues, and that the projection process itself does not 
significantly alter the dataset. Scale bar= 100 micrometers. 
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Data Analysis 
Vessel density, lacunarity, fractal dimension and multifractal spectra were 
measured from images of vessels from the, cortex, kidney, skin, and thigh muscle of 
mice at postnatal day 6 (P6), and hyaloid vasculature from PO-PlO (Moisy 2006; 
Vadakkan 2009; Vadakkan 2009). Vessel diameters were measured manually by 
using the length measurement tool in the overlay menu in the Zeiss LSM image 
browser. Statistical significance of the differences between diameters, densities, 
fractal dimensions, lacunarity parameters, and generalized fractal dimensions among 
different tissue types and remodeling vascular patterns was tested with ANOV A 
analysis and post hoc- Tukey's Test. The error estimates of the box counting 
dimension and generalized fractal dimensions are based on linear regression analysis 
of the linear fitting of the log/log plot of the curves associated with each of the 
moments using MS Excel. Error estimates of the lacunarity parameters were based on 
the jackknife method (Efron 1979; Harris 1998) (described below). The hyperbolic 
function is non-linear, and thus the jackknife method was used to calculate error 
estimates of the least squares parameters. In comparing fractal dimension, 
generalized dimensions, and lacunarity, the statistical significance between a pair of 
data sets was tested by checking whether the mean values of the pair overlap with 
each other after adding or subtracting the error estimates to their respective mean 
values. 
Below is a description that proves that Dq = D0 regardless of the value of q. 
For a monofractal, Pi( e)- E Do (fractal dimension is same in each box i). 
Li [Pi( E)]= 1 (normalization condition) 
LI-E -Do (substituting for Pi( e)) 
Li [Pi(e)] q = EqDo LI= e<q-I)Do- e<q-I)Dq 
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Therefore, Dq = D0 regardless of the value of q. For a given spatial structure 
such as a vascular bed, fractal dimension need not be same in each box. Typically Dq 
is a monotonically decreasing function of q. So the inequality D0 > D1 > D2 holds. A 
test vascular tree and the corresponding Dq versus q plot are shown to illustrate the 
above arguments below in figure 2.6. 
Jackknife method: 
The hyperbolic function is non-linear. To estimate the errors in the least 
squares parameters when a non-linear fit is performed, the jackknife method has been 
shown to be reliable (Efron 1979). Briefly, the jackknife can be described as follows. 
Consider a data set ofN measurements. In the first iteration using the jackknife 
method, the first measurement of the data set is removed and the least squares values 
of the parameters are estimated from all remaining measurements. In the second 
iteration, the second value is removed (but the first value is included) and the least 
squares values are again estimated. In the third iteration, the third value is removed 
and so on. The procedure is repeated by sequentially removing each measurement in 
the data set so that N-1 values are considered in each iteration. 
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2.3 Results and Discussion 
The methods have now been described in great detail for the application of 
quantifying microvessel morphology. The purpose of this study was to develop and 
to test these automated methods to distinguish the complexity between different 
vessel beds. To compare measurements of space filling properties (fractal dimension, 
multifractal spectra and lacunarity parameter) with more traditional measures of 
vessel diameter and density, new analytical tools have been developed and validated 
in this project. A simple box counting method was used to measure fractal dimension 
(figure 2.1) and then modified to allow for measurements of the generalized box 
counting dimensions (multifractal analysis). These methods were used in conjunction 
with a gliding box algorithm as described in the methods section to quantify the 
lacunarity of images of the vessel structures. In addition to these measurements, the 
pre-processing pipeline was developed to allow for image cleanup and conversion to 
binary format to preserve vessel morphology and space-filling characteristics of the 
fluorescent vessel label (figure 2.2). 
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To validate the MATLAB program created in this study (Vadakkan 2009), five 
validation steps were employed. First, a multi fractal analysis of three mono fractal 
structures, a straight line (figure 2.6 A), a checkerboard (2.6 B), and a Sierpinski 
carpet (2.6 C), and then similar analysis of an image of the retinal vasculature (2.6 D), 
which has a known multifractal organization was conducted. Figure 2.6 E-H represent 
the generalized dimensions obtained from images A-D, respectively. As expected, in 
the case of the straight line, all values of q (the generalized dimensions) were equal to 
1 and the multifractal spectrum condensed to a point (figure 2.6 A, E). Similarly, for 
the checkerboard, the output from the program matched the known generalized 
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Figure 2.6: Multifractal analysis of a straight line (A), checkerboard (B), Sierpinski carpet (C) and 
retinal vasculature (D). The generalized dimensions of the line in A were all equal to 1 (E). The 
generalized dimensions of the checkerboard (B) were all equal to 2 (F). C is a monofractal 
called a Sierpinski carpet with a fractal dimension of 1.79. The generalized dimensions of the 
carpet were equal to 1.79 (G). Dis the image of retinal vessels taken from the database for 
retinal images called STARE (Giodbaum 2010). The vasculature is different from the three 
patterns discussed above in that the space filling property of the vasculature cannot be 
described by a single dimension as in the previous cases. A set of generalized dimensions is 
required to characterize the retinal vascular pattern (H). The retinal vasculature is an example of 
a multifractal found in nature. In fact, in nature most objects are quasi fractal and must be 
measured with generalized dimensions to fully capture their behavior. All monofractals 
represent a special case of multifractal behavior in which all generalized dimensions are equal. 
Scale bar= 200 micrometers. 
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dimensions as all values were equal to 2 (figure 2.6 B, F). Third, the fractal dimension 
of a modified Sierpinski carpet (a self similar fractal) with a known fractal dimension 
of 1. 79 was measured. The generalized fractal dimensions (D0, Db D2) that was 
measured using the program created in this project all matched this value as expected 
for a monofractal (figure 2.6 C,G). Next, an image ofblood vessels from the retina, 
obtained from the retinal vascular database, STARE was analyzed (Glodbaum 2010) 
(figure 2.6 D, H). Retinal vessels have been shown to have a multifractal organization 
(Stosic, Tatijana et al. 2006). Here it was similarly found that D0, Db D2 had different 
values, demonstrating the multifractal nature of this vessel bed. Finally, the program 
was tested by acquiring two images of the same field of view by scanning one image 
(figure 2.7 A) and then rotating the scan field by 5° (figure 2.7 B). Xu et al., have 
previously demonstrated that the generalized fractal dimensions are rotationally 
invariant (Xu, Ji et al. 2009), and as expected, no difference was found between these 
values for the rotated images analyzed here (figure 2.7 C,D). Also, for all the data 
mentioned above, it was confirmed that the box counting dimension D0 measured 
from the multifractal program created here (Vadakkan 2009) was indistinguishable 
from the box counting dimension measured using another program written by a 
different author (Moisy 2006). These tests indicated that this study's program 
generated data consistent with expected outcomes given control images. These 
validation steps have shown that the multifractal method written for this study can be 
applied to images of vessels to extract a value for the simple fractal dimension which 
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is similar to the values calculated by other, simpler, algorithms available online which 
determine only the discrete fractal dimension. 
~;~:< 
1.75 
1.7 
1.5 
Skin 
1.5 
Rotated Image 
1.6 
Do 
1.73 ± 0.08 
1.73 ± 0.08 
1.7 
a(q) 
1.8 
01 
1.63 ± 0.02 
1.62 ± 0.02 
1.9 2 
02 
1.58 ± 0.03 
1.57 ± 0.03 
Figure 2. 7: Rotational invariance of the fractal dimension. This figure shows images of vessels 
from the skin of Flk1-m)'r··mCherry mice, (figures A and B). Figures A and Bare taken in the 
same location, but figure B is rotated 5 degrees counterclockwise. Figure C depicts the 
overlap of the multifractal spectra of images A and B. The generalized fractal dimensions 
measured from the spectra show no difference between the original image and the rotated 
image. Our findings are similar to the findings of Xu et al., and demonstrate that these 
measures are invariant under rotation (Xu, Ji et al. 2009). Scale bar= 50 micrometers. 
To compare traditional measures of diameter and density with more complex 
measures of fractal dimension, multifractal spectra and lacunarity parameter, images 
ofFlkl-myr::mCherry labeled microvessels from multiple tissue types were used. 
Figure 2.8 shows thresholded confocal images ofFlkl-myr::mCherry labeled vessels 
in mice taken from the cortex, kidney, skin and thigh muscle at postnatal day 6 (P6). 
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From these images, the mean vessel diameter, vessel density, fractal dimension (D0), 
the generalized fractal dimensions (D0, D1, D2) and the lacunarity parameter (b) were 
determined as described in the methods section. These measurements are summarized 
in table 2.1, where measurements from the control images shown in figure 2.6 are 
also included to provide a comparison of mono fractal and multifractal images. 
Cortex 
Figure 2.8: Thresholded confocal images of microvessels in four different tissues taken 
from postnatal day 6 (P6) of Flk1-myr::mCherry mice. Figure A is the thresholded image 
of the vasculature in the cortex, 8 is kidney, Cis skin and Dis muscle (vastus medialus). 
Scale bar = 50 micrometers. 
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Upon determination of the classical measures, a statistically significant 
difference was found in the diameters between the images from cortex and muscle 
(p<O.Ol), as well as images from kidney and skin (P<0.05), and images from kidney 
and muscle microvasculature (p<O.Ol). Comparisons between other groups showed 
no significant difference in diameters. The vessel density measurements from images 
of vessels were indistinguishable between the image of skin and the image of cortex, 
but both of these differed significantly from the kidney and muscle images. Density 
measurements from the kidney and muscle images also differed statistically from 
each other. Next the fractal dimension, generalized dimensions and lacunarity of 
vessel structures were analyzed in images of the four tissues (table 2.1 ). 
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b 
Veuel Vassel Fracbll (LacunMily 
dilln .... (lm) density elm ensiGn 0. D, Dz , ..... .., 
line 1.00:1:0.00 1.00:i: 0.00 1.00:1:0.00 0.00 
Checker 2.00:i:O.OO 2.00:i:O.OO 2.00:1:0.00 0.00 
Sierpin:ski calpet 1.79:1:0.02 1.79:i: 0.02 1.79:i: 0.02 0.40:1:0.01 
Retinal vessels 1.75:1:0.06 1.72 * 0.04 1.69:i: 0.03 0.49:i: 0.01 
Kidney 8.55:t: 1.93 0.36:1:0.01 1.89:i: 0.02 1.88:1:0.03 1.84:1:0.02 1.82:1:0.02 1.92 * 0.(8 
Skin '1.27 * 1.63 Q24 :i:0.01 1.80:i: 0.03 1.78:1:0.04 1.74 * 0.03 1.'13 * 0.02 1.03 * 0.03 
Cona 8.45:1:2.20 Q24 :i:0.01 1.75:i: 0.03 1.77:i: 0.04 1.73 * 0.03 1.71 * 0.03 o.97:i:O.m 
Musde 6.51 * 1.41 Q17 :i:0.01 1.'10:1: 0.05 1.74:1:0.06 1.68:i: 0.04 1.66:i: 0.03 0.'13 :1:0.03 
Table 2.1: Microvascular Morphology Quantification. The set of vessel morphological measurements 
corresponding to the binary images in figure 2.8, and the generalized dimensions and lacunarity from 
the four test cases from figure 2.6 are summarized. Generalized fractal dimensions obtained from 
multifractal spectra correspond to q = 0, 1 and 2, respectively. The lacunarity parameter b was 
estimated based from the hyperbolic fit. Taken together, the data in the table suggest that generalized 
dimensions 0 0, 0 1, and 0 2 as well as the parameter b can be used to characterize the difference in the 
morphology of the beds even when differences between mean diameters of the vessels are less 
pronounced. The test cases of the sierpinski carpet and the retinal vessels contrast monofractal and 
multi fractal behavior. Error estimates of vessel diameters are the standard deviations of the measured 
vessel diameter segments in each image. Error estimates of vessel area density were calculated by 
partitioning the images into boxes of different widths and then averaging over the vessel densities 
obtained using boxes of different widths. Regression of these values provided an R2 of at least 0.98 in 
all cases. The error estimates of box counting dimension and generalized fractal dimensions are 
standard errors estimated using a regression analysis in MS excel. The error values of lacunarity are 
standard deviations measured using the jackknife method (Efron 1979; Harris 1998). In all cases, R2 
values of the fits were greater than or equal to 0.98 for lacunarity, fractal dimension and generalized 
dimension regression analysis. 
The fractal dimension analysis clearly showed that there are differences in the 
space filling properties in all of these images. Although vessel density and fractal 
dimension are both measures of how vessels occupy space, they do not always 
correlate because variations in vessel diameter can alter density but may not alter 
fractal dimension. However, for these images, where vessel diameters were 
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comparable, there was a significant correlation between vessel density and fractal 
dimension measured using the box counting algorithm (R2 = 0.99, table 2.1). These 
data suggest that complexity increases with added vessel elements in these cases. 
To determine whether the vessel structures in these images had a multifractal 
or monofractal character the control cases from figure 2.6 were used as a baseline for 
comparison of mono fractal to multi fractal behavior of the different tissues. What was 
found were distinct values for D0, D1. D2 from images of all four tissues, indicating 
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Figure 2.9: A graph of lacunarity values L(e:) versus the box widths (e:) for various tissues. The 
lacunarity plots overlap in the case of skin and cortex, while the plots in the case of kidney and 
muscle tissues are well separated from each other and also from the plots of cortex and skin. 
that, indeed, these vessel structures have a multifractal organization. The gaps or 
lacunae in the vascular patterns were quantified by measuring the lacunarity 
parameter b in each case. Figure 2.9 shows the lacunarity values measured from the 
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confocal images of various tissues. In all cases the data for box widths were able to be 
fitted in the range from 8 to 512 with the hyperbolic function listed above (L(E) = b I 
Ea +c) with R2 > 0.98. The hyperbolic function corresponding to the kidney had the 
largest lacunarity parameter b (meaning it has the lowest lacunarity) while that of the 
muscle had the smallest lacunarity parameter b. The difference in lacunarity 
parameters was representative of the fact that the image of the muscle vessels had a 
wide range of gap sizes compared to the kidney, and thus, muscle vessels had the 
highest lacunarity. The b values for the various images of vessels in the tissues are 
summarized in table 2.1. The lacunarity analysis complemented the fractal dimension 
by adding information about how the vessels filled the space, reflected in the 
distribution of lacunae. It was observed in these data sets that as the fractal dimension 
went up, the lacunarity parameter b increased meaning the lacunarity decreased (see 
table 2.1 ). This is as one might expect, since when vessel branches are more dense, 
there is less available space between vessels, limiting the size distribution of the 
lacunae. However, this is not to say that the relationship between lacunarity and 
fractal dimension is fixed. It is important to consider that large vessels that may 
occupy the same amount of space in tissue as smaller, more highly branched vessels 
(same vessel density), but may not impose the same limits to the size oflacunae or 
have the same fractal dimension. Thus, considering both of these independent 
measures provides more information about how the vessels fill the tissue space. 
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In addition to considering the generalized fractal dimensions (D0, Db D2), the 
multi fractal spectrum can be plotted to visualize the distribution of the space occupied 
by vascular structures. Figure 2.10 shows the multifractal spectra corresponding to 
vasculature in different tissues. The peak value of the multi fractal spectra corresponds 
to D0. The f(a) values to the left and right ofD0 correspond to positive and negative 
values of q, respectively. Since a( q) values are estimated from the linear fits to the 
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Figure 2.10: The multifractal spectra of the images of vascular patterns presented in figure 
2.8. The spectra corresponding to patterns with larger lacunarity are shifted to the lower a 
range and have lower maxima in comparison to patterns with smaller lacunarity. Dashed 
lines indicate values of a beyond which the R2 values associated with the linear fits in the 
evaluation of a fall below 0.95. f(a) values with a values whose R2 above 0.95 lie to the 
left of the dashed lines. 
equations described earlier, values of q > 0 and q < 0 for which R2 > 0.95 were used 
(Posadas, Gimenez et al. 2003). The cut off values for q < 0 with R2 < 0.95 are 
represented by dashed lines on the spectra. The shift in the peaks of the spectra from 
top to bottom (figure 2.10) is due to differences in the values ofD0 (table 2.1), 
corresponding to the apex of the spectrum. 
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For example, the kidney vessels occupy more space than the muscle vessels, 
and hence their D0 values were significantly higher. The images from cortex and skin 
are difficult to compare, and this analysis allowed us to show that they have similar 
morphology based on their space filling properties. The spectra derived from vessel 
images from the four tissues were also shifted with respect to the x -axis, the value for 
a( q). It was found that multifractal spectra corresponding to smaller fractal dimension 
(D0) and larger lacunarity (smaller lacunarity parameter b) were shifted to smaller 
values of the f(a)- a space. While the lacunarity parameter is not necessarily related 
to the multifractal spectra, others have also observed a correlation between the 
lacunarity and the shift of the spectra in the f(a)- a space (Posadas, Gimenez et al. 
2003; Stosic, Tatijana et al. 2006). 
From the 
multifractal spectra, two 
other observations could 
be made (figure 2.11). 
First, figure 2.11 A shows 
the plot of a(O) versus D0 
for the various tissues 
discussed above. The 
magnitude of the 
difference in the values of 
a(O) and D0 is a measure 
of heterogeneity of the 
vascular pattern, which is 
defined as the range of 
scaling exponents required 
to characterize the pattern. 
Second, a key feature of 
multifractal behavior is 
heterogeneity in scaling 
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Figure 2.11: Assessment of multifractal behavior and curve 
symmetry. The homogeneity of a structure can be 
determined by the proximity of its data point to the 1 : 1 line 
on the a(O)- 0 0 plot, and the symmetry of a multifractal 
spectrum can be assessed by the proximity of its widths to 
the 1:1 line on the a(O)- a(qi,+) versus a(qi,-)- a(O) plot. A 
shows that the patterns in figure 4 are heterogeneous and 
thus cannot be described by box counting dimension alone. 
B shows the asymmetry of the multifractal spectra of images 
from different tissue types. The spectra of cortex, skin, and 
muscle are more symmetric than the spectrum of kidney. 
behavior of different regions of the pattern. Thus, the multi fractal behavior can also 
be directly assessed from a(O) and D0 , in addition to comparing the values obtained 
from the generalized fractal dimensions (D0, D~. D2) (table 2.1 ). If the data points lie 
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on the 1: 1 line, the pattern is homogeneous and can be characterized by Do alone. The 
data points from the images of the tissue vasculature do not lie on the 1: 1 line; in fact, 
they all deviate from this line (figure 2.11 A). Deviation from the 1: 1line indicates 
that the microvascular patterns discussed above are heterogeneous and are more 
appropriately described by the multifractal spectra rather than by their box counting 
dimensions alone. This process is similar to the heterogeneity analysis described in 
Posadas et al. (Posadas, Gimenez et al. 2003). The symmetry of the multifractal 
spectrum offers further information about the distribution of fractal dimensions of the 
vessel pattern (i.e., the space that is occupied by the vessels in the images). The 
symmetry of the multifractal spectrum can be assessed by measuring the widths (a( qi,-
)- a(O)) and (a(O)- a(qi,+)) (Posadas, Gimenez et al. 2003). The values ofqi,- andqi,+ 
correspond to negative and positive values of q taken from the range of q values over 
which the multi fractal scaling was observed. The spectrum is symmetric if the two 
widths are equal. In the context of soil structures, massive structures with low 
porosity have been shown to have asymmetric spectra (Posadas, Gimenez et al. 2003). 
In the present context, vascular beds with high density and low lacunarity 
should have relatively asymmetric spectra. For the images of kidney, cortex, skin, and 
muscle vessels, the widths of the spectra are shown in figure 2.11 B. The data points 
for cortex, skin, and muscle were closer to the 1: 1 line than the data point for kidney 
vessels. Thus the multifractal spectra of cortex, skin, and muscle vessels were more 
symmetric compared to the spectrum of kidney vessels. Asymmetry in the 
multi fractal spectra of the kidney may be related to the fact that the vascular network 
is characterized by high vessel density, high fractal dimension, and low lacunarity, 
which may all contribute to relative asymmetry of the multi fractal spectra compared 
to other vascular beds. 
72 
The studies above indicate that multifractal analysis is valuable in identifying 
significant differences between vessels in different tissues. Next it was tested whether 
these methods could be used to describe changes during vessel remodeling within the 
same tissue. Vessel regression was studied by analyzing images from the hyaloid 
vasculature in the eyes of neonatal mouse pups. The hyaloid vessels make up a 
transient vessel network that nurtures the lens during embryonic development. These 
vessels regress just before birth in humans and postnatally in rodents by macrophage-
mediated vessel pruning to eliminate vessels that would otherwise obstruct vision 
(Lang and Bishop 1993; Zhu, Madigan et al. 2000; Poche 2009). Figure 2.12 A-D are 
grayscale confocal microscope images of the hyaloid vasculature ofFlk1-
myr::mCherry mice from ages postnatal day 0 (PO) to P10, which demonstrate this 
regression. Again, vessel diameter, vessel density, fractal dimension, generalized 
fractal dimensions and the lacunarity parameter were measured and are shown in table 
2.2. 
Figure 2.12: Hyaloid regression in the postnatal mouse. Figures A-D are grayscale 
confocal microscope images of hyaloid vasculature in the retina of a Flk1 -
myr::mCherry mouse taken from PO to P1 0. P refers to the postnatal stage of the 
mouse imaged, as in postnatal day 0 through day 10. Figures E-H are images of the 
regions in figures A-C first cropped and dilated to occupy 512 x 512 pixels, then 
modified with an unsharp mask in Adobe CS2 with radius set to 12. Figures 1-L are 
binary images obtained from 0 -F after applying an intensity threshold. Scale bar = 
50 micrometers. 
73 
74 
The only significant differences between mean vessel diameters were between the PO, 
P3 and P7 vessel diameters in comparison to the PlO stage (P=O.Ol). There was no 
significant difference in vessel diameter between PO, P3 and P7 vessels in the hyaloid 
vasculature (P>0.05) (table 2; figure 2.13 A) as determined by ANOV A and post hoc 
Tukey's tests. During the vessel regression process, it was clear that vessel density 
decreased from PO to PlO (table 2.2). Reduction in vessel density corresponds with 
the functional vascular transition from nurturing the lens at PO to clearing the visual 
path at PlO. When the fractal dimension and generalized fractal dimensions were 
examined at successive postnatal stages, differences were found between D0, Dt. D2, 
again indicating that the hyaloid vasculature exhibited multifractal behavior. 
Furthermore, the generalized fractal dimensions decreased from PO to P 10, while 
lacunarity increased (parameter b decreased) (table 2.2) as the regressing vessels 
occupied less space. In fact, fractal dimension and vessel density at all stages of 
remodeling were linearly correlated (figure 2.13 B, R2=0.99). This was an interesting 
observation but the complete meaning of this observation remains to be understood. 
The singular discrete values of the parameters are reported below, however the 
multifractal spectra are valuable for reasons stated above, and they are demonstrated 
below. 
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Vessel Vessel Fractal Geft...aaed fractal dimensions bf,.acun•ay 
Age dillmetler {1ft!) density dimensJan 0, o, 0. ~
PO 12.98± 2.63 0.26± 0.01 1.76:1:0.03 1.78 :f: 0.04 1.75 :f: 0.03 1.73 :f: 0.03 1.67 :f: 0.12 
P3 11.83 ± 3A5 0.22 :f: 0.01 1.72 :f: 0.03 1.73,. 0.04 1.70 :f: 0.03 1.69 :f: 0.03 1.08:1:0.06 
P7 12.43 :f: 2.65 0.19± 0.01 1.69± 0.03 1.69 :f: 0.04 1.66± 0.03 1.66± 0.03 0.85±0.03 
P10 9.60± 331 0.07 :f: 0.01 1.49 :f: 0.06 1.52 :f: 0.08 1.47 :f: 0.03 1.46 :f: 0.04 0.19 :f: 0.01 
Table 2.2: Morphological Remodeling of the Mouse Hyaloid Vasculature. The various quantities 
that may be used to quantify the time evolution of the hyaloid vasculature in the images 2.12 1-L 
are tabulated here. Collectively, the data strongly support the claim that 0 0 , D1, 0 2 , and b can be 
used to capture changes in vessel morphology even when the differences in mean vessel 
diameters at various developmental stages are less pronounced. Errors were estimated as in 
table 2.1. In all cases, the R2 values from regression analysis were equal to or greater than 0.98. 
The multifractal spectra of the remodeling stages during hyaloid regression are 
shown in figure 2.13 C. As in the previous data set, an inverse correlation was 
observed between D0 and lacunarity. The spectrum on the top right corresponds to PO, 
which has the largest D0 and also the smallest lacunarity, and the spectrum on the 
bottom left corresponds to P10, with the smallest D0 and largest lacunarity. It was 
noted that the deviation between D0, D1, D2 was smaller for the hyaloid vasculature 
than for the deviations seen for the same values in images from other vessel beds 
(table 2.2 vs. table 2.1 ). This prompted further analysis of the heterogeneity from the 
multifractal spectra. 
Figure 2.13 D shows that while the images of the vessels all exhibited 
multi fractal behavior, the values were closer to the 1: 1 line than in figure 2.11, and 
thus were less heterogeneous than the images of vessels from the other tissues. Figure 
2.13 E demonstrates the symmetry ofthe curves, and it is clearly seen that P3 and P7 
vessels lie closer to the 1: 1 line than PO and P 1 0 vessels, meaning P3 and P7 possess 
more symmetric spectra than PO and P10. The higher asymmetry in the spectrum of 
76 
PO is partly due to the presence of more vessels and thus higher complexity in the 
image at PO. In PlO there was more empty space in the image of the vessels, and due 
to the relatively low contribution of the vessels to the image, the curve was 
asymmetric and the corresponding data point laid above the 1: 1 line (more empty 
space than vessels causes this shift). Thus, the pattern of regression was obvious from 
plotting the multifractal spectra, even when there are incremental differences that 
could not be readily distinguished visually, as between P3 and P7 hyaloid vessels 
(2.12 1 vs. K). Thus, these data provided a convenient and robust way to quantify 
changes associated with developing vessels, such as regressing vessel networks. 
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Figure 2.13: Multifractal analysis of the hyaloid vasculature during regression . Figure A shows the 
average diameters of the vessels in the images 2.12 1-L. The only significant differences between 
vessel diameters are between the PO, P3, P7 stage vessels and P1 0 stage vessels (P<0.01 ). There 
is no significant difference in vessel diameter between the PO, P3, and P7 images of vessels in the 
hyaloid. Here, there is significant correlation between vessel densities and box counting dimensions 
(8, R2=0.99). 
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Figure 2.13 continued: Figure C shows the multifractal spectra of binary images 2.12 1-L. The 
spectrum at the top right corresponds to the hyaloid vasculature at PO. The pattern has the 
largest box counting dimension Do and the smallest lacunarity. The pattern on day P10 has 
the smallest box counting dimension Do and the largest lacunarity and is at bottom left. D 
shows the heterogeneity analysis and compares PO-P1 0. Figure E is the symmetry 
comparison of the spectra of PO-P1 0 hyaloid vessels. 2.13D is the heterogeneity analysis of 
the spectra from the hyaloid vessels. The values for the hyaloid vessels are closer to the 1:1 
line than in figure 2.11, and thus are less heterogeneous than the images of vessels from the 
other tissues. In figure E the symmetry data points for P3 and P7 vessels lie closer to the 1:1 
line than PO and P10 vessels. This means P3 and P7 are more symmetric than PO and P10. 
The higher asymmetry in the spectrum of PO is partly due to the presence of more vessels 
and thus higher complexity in the image at PO. In P1 0 there is more empty space in the 
image of the vessels. Due to the relatively low contribution of the vessels to the image, the 
curve is asymmetric and the corresponding data point lies above the 1:1 line (more empty 
space than vessels causes this shift). 
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The final goal of this study was to image and analyze vessels from the stem cell niche 
in the sub ependymal zone of the mouse brain. Towards this effort, images of the 
native neural stem cell niche, the sub-ependymal zone (SEZ), were analyzed to 
identify the vessel density, fractal dimension and lacunarity. Figure 2.14 
demonstrates the projections of vessels that were measured from this tissue. In A -C 
projections of the 56 urn thick stacks taken medially from the ventricle wall were 
shown. Figures D-I show projections of 22um thick stacks extracted as a subset from 
the 56um thick image set. Measurements on both the subventricular zone and the 
nascent striatum were recorded and compared using a pair wise t test assuming 
unequal variance. The vessel density (0.12 vs. 0.19 p<O.Ol), fractal dimension (1.66 
vs. 1.78 p<O.Ol) and lacunarity (0.49 vs. 0.87 p<O.Ol) were significantly different in 
the SEZ, compared to the nearby striatum (J-L). The fractal dimension, lacunarity 
and vessel density have not previously been reported in this fashion. This information 
provides valuable insight into the scale invariant distribution of vessels within the 
specialized neuro vascular niche, and is yet another example of the application of this 
new method to quantify vessel morphology. 
Vesse 
J 0.25 
• sEZ 
0 .2 
• Striatum 
1.85 ,---------------------; K 
1.8 +-------------~1 
1.75 +--------r--·1-----, 
0 .8 +----------l 
0 .6 +-----:k-------1 
0 .4 
0 .2 
0 
Figure 2.14: Analysis of the sub-ependymal zone (SEZ). The native vessels are shown in 
A-C and the stacks which represent the overlying SEZ and underlying cortex extracted from 
these three dimensional image sets are shown to the right , as D, F, H and E, G, I 
respectively. In J-L the morphological parameters are measured from the images of the 
SEZ, represented by D, F, and H. Scale bar= 100 micrometers. 
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2.4 Conclusions 
Here, it was demonstrated that multifractal analysis and lacunarity can be used 
to compare and describe the morphology of microvasculature labeled with a 
fluorescent protein reporter from different tissues along with more common measures 
used for differentiating vasculature (like in the case of vessel diameter). It was found 
that even in scenarios where changes in mean vessel diameter were not robust at 
determining changes in vascular morphology, such as remodeling of the hyaloid 
vasculature, multifractal spectra and lacunarity parameters could be used to reveal 
significant changes in vessel structure. Such an automated analysis could link 
morphology with control and experimental parameters in vascular patterns within 
developing, pathological, or engineered tissues. This approach is likely to be 
particularly useful for evaluating subtle differences or pathologies where vessel 
diameters are fairly constant and is well suited for making comparisons over time, as 
shown here in the evaluation of the hyaloid vessels. 
Simple fractal analysis has proven useful in analyzing retinal vessels to 
differentiate patients with lacunar-type stroke from normal patients (Doubal, 
MacGillivray et al. 2010), to determine macro- and microvascular complications in 
type 1 diabetes ( Grauslund, Green et al. 201 0), and to follow progression of chronic 
kidney failure (Sng, Sabanayagam et al. 2010). Only recently has the multifractal 
approach been instituted, and it has proven effective in discerning pathological 
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vessels from normal vessels in the case of proliferative diabetic retinopathy (Stosic, 
Tatijana et al. 2006). Although these studies have been conducted in retinal vessels 
because they are easily imaged in vivo, we propose that multifractal analysis could be 
further applied to other tissues from mice with labeled vasculature in a variety of 
disease models. Furthermore, it could be used to examine biopsied human specimens 
to more completely characterize developmental and diseased states, as well as the 
processes of neovascularization and vessel remodeling. 
The findings of the Doubal, Sng and Grausland helped establish the value of 
the scale invariant fractal dimension in quantifying changes in complexity and how 
those may reflect disease states of the vasculature. Stosic took the use of the 
multifractal analysis and brought this technology to the retinal vasculature and retinal 
disease states. The method in this thesis expands upon the use of the multifractal 
analysis and highlights the spectral fingerprint that is given in each image to help first 
validate the natural geometries are multifractal, and then to summarize the 
morphological findings with a complex spectral curve. Today there are many more 
labs focusing on the use of these tools to best quantify morphological changes in 
vessels. 
Given the utility of this method in vessel analysis, the scale-invariant 
parameters should be used in the future to help to develop our understanding of vessel 
morphology and complexity. 
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Chapter 3: Tailoring Vascular Morphology 
In this chapter, I optimize angiogenic growth factor release from engineered 
hydrogels to induce and support the formation of stable microvasculature resembling 
vessels from stable, native tissues and niches. I start offwith a brief introduction of 
important techniques used in this chapter, and then I describe the findings used in 
tuning the vessel response to match skin and muscle (3 .1) as well as to match vessels 
found in the sub ventricular zone of the brain (3.2). Section 3.1 from this chapter is 
taken from the publication, "Tailoring vessel morphology" by Gould DJ, Saik JE, 
Vadakkan TJ, West JL, Dickinson ME., now in preparation for submission to Tissue 
Engineering. 
3.1 Introduction: 
Biomaterials can provide a local, controlled delivery system for release of 
angiogenic growth factors as potential treatments for ischemic disease or to improve 
blood supply to engineered tissues. Precise control over delivery of these growth factor 
concentrations is necessary to induce desired cellular responses (Tayalia and Mooney 
2009). Several polymer delivery strategies have emerged to control growth factor 
delivery (Tayalia and Mooney 2009). For instance, growth factors can be incorporated 
into a polymer precursor solution prior to polymerization to entangle factors within a 
scaffold following polymer crosslinking. Growth factors are then released from the 
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scaffold via diffusion, establishing a concentration gradient. Growth factor delivery for 
angiogenesis has been achieved using natural scaffolds (Cascone, Sim et al. 1995; 
Greisler 1996; Schroeder-Tefft, Bentz et al. 1997; Yao, Roderfeld et al. 2006; Nillesen, 
Geutjes et al. 2007) as well as synthetic polymers (Cascone, Sim et al. 1995; Nimni 1997; 
Mann, Gobin et al. 2001; Zisch, Lutolf et al. 2003; Biondi, Ungaro et al. 2008; Gobin 
(2002)). Scaffolds delivering vascular endothelial growth factor (VEGF) have been used 
to induce dose dependant, pro-angiogenic responses including increased vascularization, 
pericyte coverage, and vessel perfusion (Davies, Dohner et al. 2008). VEGF dose and 
temporal distribution was also found to govern endothelial cell phenotype in an in vitro 
model as well as regulating optimal angiogenic sprouting in vivo (Silva and Mooney). 
Although many growth factors have been shown to have angiogenic properties, 
the majority of work has focused on three growth factors: vascular endothelial growth 
factor (VEGF), platelet derived growth factor (PDGF-BB), and fibroblast growth factor 
(FGF-2). VEGF, released in response to hypoxia, stimulates endothelial cells to migrate, 
proliferate, and differentiate (Nomi, Miyake et al. 2006). VEGF has been widely used to 
induce angiogenesis, but VEGF-induced vessels have been shown to be unstable, leaky 
and hemorrhagic (Jain 2005; Jain, Au et al. 2005). Hypoxia can also stimulate 
macrophages to release FGF-2, which triggers endothelial cell proliferation and 
migration, and regulates the expression of key angiogenic molecules, such as 
collagenases and ~1 integrins (Bikfalvi, Klein et al. 1997). FGF-2 induces migration and 
proliferation of smooth muscle cells (Jackson and Reidy 1993) which may help stabilize 
new vessel beds. PDGF-BB is another factor important in angiogenesis, which is 
released by endothelial tip cells in response to hypoxic conditions. This growth factor is 
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involved in the stabilization of developing capillaries by recruiting pericytes and inducing 
them to produce the extracellular matrix proteins that constitute the basement membranes 
of functional blood vessels. In addition, PDGF-BB has been implicated as a key factor in 
anastamosis formation (Cao, Brakenhielm et al. 2003; Gaengel, Genove et al. 2009). 
Cao et al. demonstrated the utility ofPDGF-BB and FGF-2 in combination in 
comparison to VEGF alone, by using hydron pellets to deliver these factors to the mouse 
cornea to study the angiogenic response (Cao 2004). In their study, the use ofPDGF-BB 
or VEGF-A alone led to total vessel regression by 24 days and by 70 days for FGF-2-
induced vessels (Cao, Brakenhielm et al. 2003; Cao 2004). Notably, vessels formed in 
response to the combination ofFGF-2 and PDGF-BB were stable for over 210 days. 
Implantation of individual factors led to a transient vessel response, which was shown by 
removing pellets containing the factors from the eye 6 days after implantation. This 
caused total vessel regression within one week in all samples except those containing the 
combination ofPDGF-BB and FGF-2. VEGF-A-induced vessels which were highly 
leaky, where vessels formed in response to PDGF-BB and FGF-2 remodeled into well-
defined branching and organized structures that were not leaky when perfused with 
fluorescent dextran (Cao, Brakenhielm et al. 2003). As an indicator of vessel maturity 25 
days after implantation, 70% ofvessels formed in response to PDGF-BB and FGF-2 were 
desmin positive as compared to only 40% for FGF-2 induced vessels (at this point all 
PDGF-BB induced vessels had regressed). The addition ofVEGF antagonists confirmed 
the VEGF-independent vessel formation using PDGF-BB and FGF-2 (Cao, Brakenhielm 
et al. 2003). Findings were corroborated in the hind limb ischemia model, which showed 
that PDGF-BB and FGF-2 increased collateral vessel growth and paw blood perfusion, 
-------- ---------------
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and vessels were well-organized and stable for over 60 days. The synergistic response 
was later found to result from FGF-2 activation of transcription of the PDGF-BB receptor 
in endothelial cells. PDGF-BB in turn, induces a positive feedback signal by amplifying 
FGF-2 expression in vascular mural cells (Cao, Cao et al. 2008). 
In light of the data showing that the combination ofFGF-2 and PDGF-BB 
promote the formation of more stable vessel structures than VEGF, there is now growing 
interest in using these factors to promote tissue repair by inducing vessel growth into 
biomaterial scaffolds for tissue engineering. In this study, the goal was to determine the 
relationship between growth factor dose and the morphology of induced vessels. 
Furthermore, it was important to determine whether varying concentrations ofFGF-2 and 
PDGF-BB result in predictable alterations in vessel morphology and to test whether the 
morphological features of the induced vessels could be tailored to mimic vessel 
morphology found in natural, endogenous tissues. To assess the morphology of induced 
or natural vessel beds, traditional criteria such as vessel diameter and density were 
utilized along with scale-invariant measures of the space-filling properties of vessels such 
as the fractal dimension (Do) and lacunarity. Recently the utility of such advanced 
methods to characterize vessel morphology has been shown (Gould, Vadakkan et al. 
201 0) . To deliver varying concentrations of growth factors, poly( ethylene glycol) (PEG) 
diacrylate, a photocrosslinkable and biocompatible polymer was chosen to deliver 
angiogenic growth factors in a local, controlled manner. These hydrogels were modified 
with an immobilized RGD peptide (a sequence commonly found in fibronectin and other 
cell-adhesive proteins) (DeLong, Gobin et al. 2005; Moon 2008) and rendered 
proteolytically degradable in response to migrating cells by incorporating matrix 
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metalloproteinase (MMP) sensitive cleavable peptide sequences into the polymer 
backbone (West and Hubbell1999; Moon 2008; Moon, Saik et al. 2010). The 
photocrosslinking process enables inclusion of releasable growth factors prior to 
crosslinking for local, controlled delivery to induce host vessel invasion (Leslie-Barbick, 
Moon et al. 2009). For the in vivo analysis of induced vessels, hydrogels were implanted 
into the mouse cornea using a mouse corneal micropocket angiogenesis model in 
transgenic mice expressing Flkl-myr: :mCherry in a model that has been extensively 
developed (Moon, Saik et al. 2010; Poche, Saik et al. 2010). The external nature ofthe 
cornea allows for facile surgical implantation and high-throughput analysis, the induced 
vessels can be quantitatively examined microscopically using high resolution methods, 
and angiogenesis is induced into an otherwise avascular tissue, facilitating morphological 
analysis (Gaudric, N'Guyen et al. 1992; Auerbach, Lewis et al. 2003). 
This corneal implantation, when coupled with a quantitative method for studying 
vessels proved to be a valuable platform for inducing and quantifying vessel morphology 
in this study. The host vessel response was then probed for tunability and finally was 
optimized to allow for tailoring of the vessel response to match target vessel morphology. 
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3.2 Inducing Tunable Vessel Morphology 
Hypothesis: The space filling properties o[induced vessels have a dose 
dependent relationship to pro-angiogenic growth (actor concentration. which can be 
used to fine tune morphology to match parameters of vasculature in tissues. 
The specific goals of this study are to define whether varying concentrations of 
FGF-2 and PDGF-BB result in predictable alterations in vessel morphology and to 
test whether the morphological features of the induced vessels mimic morphologies 
found in natural, functional vessels in endogenous tissues. 
3.2.1 Materials and Methods 
The experimental design for this aim is described here. The hypothesis was 
tested with the use of the corneal micropocket angiogenesis assay to implant 
degradable hydrogels into the mouse cornea for in vivo monitoring of vascular 
formation (figure 3.1). Hydrogels were A 
loaded with Platelet Derived Growth 
Growth Factor 2 (FGF2), which induce 3.1 : Implantation of hydrogels into the 
cornea to define optimal vessel ingression 
stable vessel growth and mural cell and perfusion. PEG hydrogel discs are 
inserted into an incision made in the cornea 
recruitment (Bohnsack 2003; Cao 2003; (A-D). The cornea is monitored over time to 
determine the extent of the angiogenic 
Cao 2004). The release kinetics of these response (E).(Poche, Saik et al. 2010) 
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factors (FGF2 and PDGF-BB) had already been characterized in vitro by 
collaborators in the West lab (figure 3.2). Several doses ofthese growth factors were 
tested in vivo to generate a curve of the response of vessel formation, in order to 
determine the relationship between implanted growth factor concentrations and the 
amount of the construct that invading vessels ultimately occupy. 
One goal in the design of these 
Protein Release from PEG-PQ-PEG 
"C 70 -+-PDGF 
constructs was rapid host vascularization. Ql 1 ..... FGF ; 60 1 I .!! Till ~ 50 &fl Invading vessels must reach the target 
implant within a short period of time, to 
allow for the efficient delivery of 
metabolites and oxygen, and thus permit 
survival of implanted cells. As previously 
1 I 
:!l 40 ~ 
... 
:. 30 
0 50 100 150 
Time (hours) 
Figure 3.2: Growth factor release from 
degradable hydrogels in vitro. J Saik 
!personal communication. 
stated, 7-14 days was chosen to provide the ideal engraftment environment; in 
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addition, as little time as possible for vessel invasion could allow for rapid perfusion 
of the newly implanted grafts. Beyond efficient delivery of nutrients, function of the 
tissue vasculature should be the next most important consideration. The goal of tissue 
engineering is to recapitulate closely tissue; therefore the goal was the recreation of as 
many of the morphological characteristics of the natural tissue niche as are possible. 
A dose response curve was compared to known space filling values measured 
from vessel beds in other tissues, including skin, the thigh muscle, and the sub-
ependymal zone (SEZ) in order to interpolate the concentration ofPDGF-BB and 
FGF2 needed to recapitulate the vascular morphology. Rigorous morphometric 
analysis to compare the resulting induced vasculature to endogenous vessels was 
undertaken. 
3.2.1.1 Synthesis and Purification of Proteolytically Degradable and Cell 
Adhesive Polymer Derivatives 
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Proteolytically degradable hydrogels were prepared by incorporating a peptide 
sensitive to MMP2 and MMP9, GGGPQGIWGQGK (abbreviated PQ), into the PEG 
backbone to generate the enzyme-cleavable PEG-PQ-PEG (West and Hubbelll998). 
Fmoc chemistry was used to synthesize the PQ peptide on an APEX 396 solid phase 
peptide synthesizer (Aapptec ), and the resulting peptide was then characterized using 
Matrix Assisted Laser Desorption Ionization Time Of Flight Mass Spec. Dissolved 
PQ peptide was reacted with dry acryloyl-PEG-SCM (3,400 Da; Laysan, Arab, AL) at 
a 2.1: 1 PEG-SCM: PQ molar ratio and characterized using a gel permeation 
chromatography (GPC) system with a PLgel column (5j.!m, 500A, Polymer 
Laboratories, Amherst, MA) and an evaporative light scattering (ELS) detector 
(Polymer Laboratories). PEG-RGDS was prepared similarly by reacting acryloyl-
PEG-SCM with RGDS (American Peptide, Sunnyvale, CA) at a molar ratio of 1.1:1 
in the presence ofDMSO. Fluorescently tagged PEG-RGDS used to enable 
visualization of implanted gels was synthesized by reacting PEG-RGDS with Alexa 
Fluor® 488 carboxylic acid, succinimidyl ester (Invitrogen) at a 10: 1 molar ratio of 
dye: PEG-RGDS in dimethylformamide as previously described (Moon, Saik et al. 
2010). 
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3.2.1.2 Hydrogel Fabrication 
Hydro gels were prepared for cross linking using a stock solution of the 
photoinititator 2,2-dimethoxy-2-phenylacetophenone (acetophenone) dissolved inN-
vinylpyrrolidone (NVP) (300 mg/ml). The prepolymer solution was prepared to 
contain a 10% polymer weight percentage (100 mg/ml) ofPEG-PQ-PEG, 3.5 
f..tmol/ml PEG-RGDS, 10 f.ll/ml acetophenone stock solution, and angiogenic growth 
factors. Four different concentrations of proteins for the dose escalation were tested: 
(1) 10 ng FGF-2 and 40 ng PDGF-BB (low dose), (2) 40 ng FGF-2 and 160 ng 
PDGF-BB (medium dose), (3) 80 ng FGF-2 and 320 ng PDGF-BB, and (4) 160 ng 
FGF-2 and 640 ng PDGF-BB (high dose shown in figures 6 and 3). Hydrogels were 
prepared by injecting 0.12 f.ll ofthe pre-polymer solution in between two precleaned, 
sigmacoted (Sigmacote, Sigma Aldrich) glass slides spaced by a 0.005 inch thick 
poly(tetra fluoroethylene) spacer and secured with binder clips to make a 0.005 inch 
high, cylindrical implant with a radius roughly 300 microns. The gels were exposed 
to UV light (B-200SP UV lamp, UVP, 365 nm, 10 mW/cm2) for two minutes to allow 
crosslinking and immediately implanted into the cornea micropocket as described 
below. 
3.2.1.3 FLK1-myr::mCherry Mice 
Mice expressing the mCherry fluorophore via the Flkl promoter have 
previously been characterized (Larina 2009). Mice used in this study were from the 
colony established in the Dickinson lab at Baylor College of Medicine containing 
fluorescently labeled endothelial cells, and all experiments were in accordance with 
an IACUC and AALAS approved animal protocol at Baylor College of Medicine. 
These mice allowed for visualization and imaging of blood vessels for this study. 
3.2.1.4 The Corneal Micropocket Assay 
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An incision was made in the cornea with a micro knife at approximately 50 
microns depth. Next, a Von-Graefe cataract knife was used to separate the stromal 
layer, allowing the formation of a micropocket. This process is depicted in figure 3.3. 
PEG based hydrogel implants were placed in the corneal pocket with great 
reproducibility 500 microns away from the limbus and checked for goodness of fit. 
For each treatment group five animals were studied. The number of animals selected 
was based on a power calculation assuming cr = 0.30, which was based on pilot 
studies. Controls included opposite eye sham surgery, which showed no vascular 
response in the nearby limbic region, and implantation ofhydrogels not containing 
growth factors, which produced a similar response to the sham surgery. These 
controls are published in similar work from these authors (Poche 2009). 
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3.2.1.5 Analysis of Angiogenic Response 
Several different growth factor groups were implanted for analysis, including 
one group with FGF-2, one group with PDGF-BB and one group containing both 
factors in a 1:4 ratio, respectively (as previously described). At designated 
timepoints, eyes were excised from euthanized mice, and the cornea was dissected 
and flatmounted by cutting the cornea in four locations 90 degrees apart, creating a 
relatively flat corneal surface (figure 3.3). Imaging regions were chosen by selecting 
a region within the original implant site where vessels had grown. Three slightly 
overlapping regions covering the vascularized area were selected for each sample. 
Confocal images ofFlkl-myr::mCherry labeled vessels were acquired from 
flatmounted corneas containing the tissue constructs using an LSM 510 META (Carl 
Zeiss) confocal microscope and a C-Apochromat 40x/1.2NA water immersion lens. A 
543 nm laser was used to excite the mCherry fluorophore, and 22 micron thick z-
stacks of vessels labeled by mCherry directly on the scaffolds were collected such 
that the step size between two successive images in z-stacks was 1.1 microns. This 
thickness was chosen because previous studies of vasculature where similar 
parameters were measured used these dimensions for tissue imaging (Gould, 
Vadakkan et al. 201 0). Each 8-bit image in the z-stacks consists of 512 x 512 pixels. 
In the final step, each image was subjected to quantification, and the measured 
parameters were compared. The variation of all samples was less than 1 0% so each 
sample's measurements were averaged, to determine the measured fractal, vessel 
density or lacunarity value. Within the low dose treatment subset of the FGF -2 only 
group, examples of implants were found that had vessels growing near the implants 
but not upon the surface of the hydrogel. These cases accounted for around 40% of 
the implants attempted in this dose group, thus making it impossible to quantify and 
compare space-filling measures for all implants. Given that finding, in the 
implantations that were possible to compare, similar trends to the other low dose 
treatment groups were found. 
3.2.1. 6 Vessel Branch Points and Diameters 
Vessel branching was quantified using the LSM image browser to count the 
total number of branch points per three dimensional image fields in each image of 
vessels. Diameters were likewise quantified, and the results were compared using 
ANOVA with post hoc Tukey's test. 
3.2.1. 7 Image processing 
Images of the vascular beds were processed as described in figure 3.3. This 
method was designed to replicate the method described in previous studies used to 
quantify microvessel morphology (Gould, Vadakkan et al. 2010). Briefly, stacks of 
the vessels were projected then thresholded in order to create binary images for 
processing. Thresholds were kept constant between images of vessel beds to ensure 
comparison methods. Figure 3.3 (A-D) summarizes the employed image pre-
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processing pipeline. Images of vessels were first converted to projections using 
Image J and then converted to 8-bit grayscale. These projected images were opened 
in Adobe Photoshop and had an unsharp mask applied to them, which serves as a 
high-pass filter to remove haziness from around the vessels while preserving vessel 
Hydrogel 
~? • 7-14 days 
Forceps:: =:::;:S~ta&iiliiil ~ =~~=~ 
Incise Cornea Select Imaging Region 
LSM raw image (Projection) 
+ 
Maximum intensity projection (Image J) 
+ 
Unsharp mask (Adobe CS2) 
+ 
Intensity threshold (MATLAB) 
+ 
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Figure 3.3: Schematic of the implantation and imaging procedure. First, a Von Graefe knife is 
used to make a partial-thickness incision into the mouse cornea and a micropocket is formed by 
separating the layers of the cornea stroma. Next, a crosslinking hydrogel incorporating 
fluorescently-tagged RGDS is immediately implanted into the micropocket. 7 or 14 days after 
implantation, the cornea of a euthanized mouse is flatmounted. Vessels on the hydrogel are 
imaged using confocal microscopy. Raw LSM images in the form of z-stacks of 22 microns are 
formulated into a 30 projection. Next, lmageJ is used to form a maximum intensity project. An 
unsharp mask is applied in Adobe Photoshop, followed by thresholding in MATLAB. The final 
images are used for quantification of vessel parameters. 
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diameters. The finished grayscale image was opened in MATLAB, and a threshold of 
90 was applied, based on the ability to maintain vessel diameter with no significant 
erosion or dilation seen between the original images and the thresholded image. 
3.2.1. 8 Fractal Dimension, Lacunarity, and Multifractal Spectra 
Induced vessel morphology was assessed by imaging vessels and applying 
algorithms developed and described in Gould et al.(Gould, Vadakkan et al. 2010) to 
determine vessel density, diameter, fractal dimension, and lacunarity. Also, the 
programs used to extract these parameters are available online through the MATLAB 
central file exchange (Vadakkan 2009; Vadakkan 2009; Gould, Vadakkan et al. 
2010). 
3.2.1.9 Vessel Density Measurement 
Briefly, to calculate vessel density, a binary image was created. Subsequently, 
the total number of pixels containing signal (white pixels) were determined and 
divided by the total number of pixels in the image (512x512) to output vessel density. 
3.2.1. 10 Fractal Dimension 
The fractal dimension was calculated using a box counting algorithm (Moisy 
2006; Lopes and Betrouni 2009). Here, a grid was applied to the binarized image of 
the vessels. Within this grid the length ofthe boxes determined is c. Next, the 
number ofpositive boxes (containing at least one white pixel) was counted, called N 
(c). Finally epsilon vs. N (c) was plotted and shown to have a logarithmic function 
(figure 3.4 B). Finally, the log (c) vs. log (N (c)) was plotted, and the slope was 
determined from the plot (figure 3.4 C). The slope is D0, the fractal dimension. 
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Figure 3.4: Measurement of the Fractal Dimension Using a Box-counting Algorithm. Here, A 
demonstrates the application of a grid to the image of engineered vessels. After applying a 
grid, positive boxes (containing at least one white pixel) are counted. B shows the plot of 
positive box number versus box size. C shows the log (positive boxes) versus log (box size) 
plot. The slope of this line is the fractal dimension. 
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3.2.1. 11 Lacunarity 
The lacunarity parameter (b) was routinely measured using a gliding box 
algorithm (Masters 2004; Tolle, McJunkin et al. 2008). Briefly, an£ x £box with 
width£ was placed at the top left comer of an image. The number of white pixels in 
the box was counted. The box was then glided to the right (one pixel) and the number 
of pixels in the £ x £ box was counted. The process was repeated until the box reaches 
the bottom right comer ofthe image. If£ is the size of the image, the number ofboxes 
of width £ is N ( £) = ( t-£+ 1 )2• The width £ of the box is chosen such that its numerical 
value is equal to 2, 4, 8, .. ,£. For each box width£, both the sum of the number of 
signal pixels in each box Q1 = LiP(i,£) and the sum ofthe square ofthe number of 
signal pixels in each box Q2 = LiP(i,£)2 are measured. Lacunarity L(c) at a box size£ 
is defined as (N(c) x Q2) I Qt p(i,£) is the number of signal pixels in the i1h box and i 
E [ 1, N ( £)]. In the gliding box algorithm, the box of size £ is placed over each pixel in 
the image and p( i,£) is calculated for each box centered on the i1h pixel. Therefore the 
lacunarity measurement adds to the description of an object with a known fractal 
dimension, in describing the empty space around the object, thus relating how the 
object fills space. 
3.2.1.12 Multifractal Analysis 
The multi fractal method described in the methods section of chapter two was 
implemented in this study to examine the morphology of vessels induced with the 
combination ofPDGF and FGF from the 14 day time point. Symmetry and 
heterogeneity analysis of the curves was performed in order to examine the High, 
Medium and Low dose treatments, in order to provide information about each 
multifractal distribution. 
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All of these methods were used to analyze images of blood vessels induced in 
response to varying doses of growth factors, in order to better understand host vessel 
induction, and to better tune the hydrogel implants to induce vessels with a desired 
morphology. The results from this process are described below. 
3.2.2 Results: Vessel Induction 
3.2.2.1 Induction ofVessels and Morphological Analysis 
Three different concentrations (doses) ofPDGF-BB and/or FGF-2 were used 
to induce vessel formation on PEG-based hydrogels implanted into the mouse cornea 
micropocket. Growth factors were used individually to attempt to parse out 
individual effects and in combination to investigate synergistic effects. Resulting 
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vessels were imaged 7 and 14 days after implantation (figure 3.5 A, B), and the 
resultant vessel morphology varied based on dose. Space-filling morphological 
parameters including fractal dimension, vessel density, and lacunarity were used to 
quantify resulting vessel morphology. Clear trends in the values of the morphological 
parameters were present, where higher dose treatments yield higher vessel density, 
greater fractal dimension and a higher lacunarity parameter b, reflecting less lacunae 
or open space between vessels versus lower dose treatments (figure 3.5 C, D). These 
trends were confirmed using statistical tests (ANOVA and Tukey's post hoc analysis), 
which indicated a significant difference between high and low dose groups at 7 and 
14 days in all treatment groups, (p<0.05) when using the vessel density and fractal 
dimension analysis. 
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Figure 3.5: Growth Factor Dose Induces Differing Vessel Morphology. 7 days (A) and 14 days (B) 
after implantation, vessels were visible in response to PDGF-BB and/or FGF-2 at three different 
concentrations. Vessel density, fractal dimension, and lacunarity were measured to quantify the 
vascular response (C-H) . 7 Days after implantation, vessel density, fractal dimension and lacunarity 
parameter b were found to increase as growth factor dose increased (C, E, G). 14 days after 
implantation , similar trends in vessel density, fracta l dimension and lacunarity parameter were 
observed in response to the growth factors PDGF-BB and FGF-2 at similar dose concentrations (D, 
F, H). For this study high dose was 640:160ng PDGF-BB: FGF-2, medium was 160:40ng PDGF-
BB: FGF-2, low dose was 40:10ng PDGF-BB: FGF-2. 
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In order to compare the differences between the individual experimental groups, 
between growth factor types, across dose concentrations, and at seven and fourteen 
days, ANOVA with post-hoc Tukey's tests were performed on each measured 
morphological parameter dataset. All of the observations for vessel density, fractal 
dimension, lacunarity, branch points, and vessel diameters are included in tables in 
the appendix (Tables A1-A5). Importantly, for brevity the key differences and 
observations are highlighted in the rest of this section, which helped to determine the 
best concentrations and types of factors to use as well as the best timepoint for tuning 
the microvasculature to mimic vessels from normal tissues. 
Three key findings were present: first, there were significant differences in all 
cases between high and low dose groups, indicating a dynamic range of vessel 
morphology (p<O.Ol), second, the PDGF I FGF combination group at 14 days 
exhibited significant differences between high, medium and low dose groups using 
vessel density, fractal dimension, and lacunarity (p<0.05), and third, other groups 
lacked the same level of separation between dose groups. 
At the 7 day timepoints, lacunarity proved significantly different amongst dose 
groups. However, at 14 days the differences between high and low dose groups were 
not significant except in the PDGF I FGF combination group which showed 
differences between all three dose groups (p<0.01) at 7 and 14 days. In all treatment 
cases, the high dose groups were significantly higher in vessel density and fractal 
dimension, while in some, the medium dose groups were significantly different from 
either the low or the high dose groups, but not both. 
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The high dose in all treatment groups exhibited vessel densities of around 40% 
at 7 days and near 35% at 14 days. Although these trends suggest remodeling, no 
significant difference within groups and doses in the density from 7 to 14 days was 
observed. In comparison to the 7 day vessels, the 14 day vessels were visually 
observed to have lower diameters, and the branching was similarly observed to be 
slightly lower in some groups (figure 3.5 A,B). Within the PDGF I FGF combination 
group, the high, medium and low dose groups were significantly different in 
branching morphology (p<0.01) at 7 days, with high dose exhibiting the greatest 
branching (74±5.5) versus medium (56±3.8) and low (17±5.0) dose groups (figure 3.6 
A). At 14 days similar differences within this treatment group were seen (p<0.05). 
This level of separation between doses with branching was not seen in the FGF and 
PDGF alone groups. Similar trends were observed for vessel diameters, within dose 
groups at 7 days, in that there were differences between high, medium and low dose 
groups in the case ofFGF or PDGF I FGF (p<0.01). In the PDGF alone treatment, 
there was only a significant difference between medium and low dose groups 
(p<0.01) (figure 3.6 C). 
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Figure 3.6: Branch point and vessel diameter comparisons. Branching was quantified, by counting 
the number of branch points using the LSM image browser software in the three dimensional z stacks 
of the different vessel structures at 7 and 14 days (A, B). Diameters of vessels were measured in 
similar fashion at 7 and 14 days (C, D) and a histogram was plotted to elaborate on the differences 
between vessel diameters (E). Interestingly, there were not significant differences between branching 
from 7 to 14 days in all groups except the medium dose group in the combination PDGF-BB I FGF-2 
treatment group (p<0.05). In the case of the vessel diameters, there were significant changes in 
treatment groups between 7 and 14 days, however, the differences that were apparent within 
treatments, between doses at seven days (p<0.01) were not seen in the 14 day timepoint in the 
PDGF-BB I FGF-2 combination treatment group. This suggests the combination group induces 
vessels with relatively stable branching and relatively uniform vessel diameter distribution at 14 days, 
reflected by the histogram in (F) which shows an increased fraction of 6-8um diameter vessels. 
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One important change highlighted by diameter measurements was the 
difference within dose groups and within specific dose levels between 7 and 14 days. 
In each group, with the exception of the PDGF only high dose group, there was a 
significant decrease in the average vessel diameter between the time points at 7 and 
14 days (p<0.05). Also at 14 days, the only group which had no significant difference 
between high, medium and low dose groups was the PDGF I FGF containing group. 
In contrast, the PDGF alone and FGF alone groups showed significant 
differences between the high and low dose groups, and medium and high dose groups 
(p<0.05). These data indicated that at 14 days, the vessel branches were relatively 
stable and that the vessel diameters are more uniform particularly in the PDGF I FGF 
combination group. In summary, the key findings were that significant differences in 
the vessel density, fractal dimension, and lacunarity were supported by similar 
differences in branching; that the branching differences were only consistently 
different in the combination treatment, and that the only group with relatively equally 
distributed vessel diameters in all three treatment groups was the combination 
treatment group. Importantly, vessels induced in response to encapsulated growth 
factors exhibit a tunable morphological range, and the combination treatment with 
PDGF and FGF provides the best range for fine tuning and optimization. 
3.2.2.2. Multifractal Analysis of Induced Vessels 
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Multifractal Analysis was performed on the images of vessels induced with the 
combination of PDGF and FGF at the 14 day timepoint. This analysis provided for a 
spectral analysis of the three different treatment groups. 
low Dose 
DO 
D1 
D2 
Medium 
Dose 
DO 
D1 
D2 
Sample 1 Error Sample 2 Error Sample 3 Error 
1.658485 0.03 1.582185 0.03 1.696165 0.02 
1.581964 0.01 1.535058 0.01 1.624481 0.01 
1.559515 0.01 1.511986 0,01 1.598304 0.01 
Sample 1 Error Sample 2 Error Sample 3 Error 
1.835848 0.01 1. 767277 0.02 1.815202 0.02 
1. 79356 0.01 1.709314 0.01 1.737585 0.01 
1. 778735 0.01 1.682708 0.01 1. 703069 0.01 
Average Error(sum) 
1.64561195 0.04690416 
1.58050109 0.01732051 
1.55660168 0.01732051 
Average Error(sum) 
1.80610901 0.03 
1.74681961 0.01732051 
1.7215039 0.01732051 
High 
Dose Sample 1 Error Sample 2 Error Sample 3 Error Average Error(sum) 
DO 1.92452 0.02 1.907061 0.03 1.921928 0.03 1.91783617 0.04690416 
D1 1.891114 0.02 1.867499 0.02 1.882057 0.02 1.88022326 0.03464102 
D2 1.875454 0.02 1.849198 0.02 1.862768 0.02 1.86247342 0.03464102 
Table 3.1: Generalized Fractal Dimensions of the Dose Escalation Samples. Here the 
generalized fractal dimensions are provided for each of the measured samples. The 
Average values are also presented along with the additive error for each calculation. 
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First, in order to determine if the images of the objects were in fact 
multi fractal, all of the generalized dimensions were recorded from the algorithm and 
the three different values for each of the samples in each of the three groups were 
recorded. Next, the error estimates were determined using the same methods from 
chapter 2, whereby the linear regression analysis was performed on each log/log plot 
of the moments from each of the generalized dimensions. These values are reported 
in Table (3.1), where the average measured generalized dimensions are reported along 
with the error estimates. The generalized dimensions are distinctly different, as 
reflected by the error estimates for each moment in each sample, satisfying the 
requirement for the provision of a multifractal. The plot of the generalized 
dimensions is shown in figure 3. 7, with the separation between each generalized 
dimension, and the additive error associated with each moment is represented by the 
error bars plotted on the graph. This graph helps to summarize the finding that the 
induced vessels in each treatment dose at 14 days possess multifractal behavior, and 
that they possess relatively different morphological structure, including distinctly 
different generalized dimensions. It is important to stipulate that the determination of 
multifractal behavior of each object is based on the analysis of each image and the 
separation of the generalized dimensions as dictated in table 3 .1. Additive error bars 
in the graph from figure 3. 7 do overlap in the case of the low and medium dose 
groups and are not indicative of whether or not each image represents an object with 
multifractal behavior. 
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Figure 3.7 :Generalized Fractal Dimension Plots. This graph shows the moments calculated 
for D(q) at each value of alpha, and the X values 0, 1, and 2 represent the moments of the 
Generalized Dimensions, DO, D1 and D2. The error bars come from the measured error at 
each moment of the plot, based on the linear regression of each linear fit for each moment. 
Since error bars represent the additive error of each of the three groups, their overlap does 
not exclude multifractal behavior. The determination of multifractal behavior is based on 
each image and is determined based on the error between dimensions as reported in table 
3.1 . 
Finally, the spectral output from the algorithm was plotted and is shown in 
figure 3.8. This figure helps to summarize the finding that each group of doses, low, 
medium and high, induced vessels which were multifractal and morphologically 
different. The spectra reflect the finding that high dose treatment led to the induction 
of vessels with relatively high complexity and low distribution of avascular space, as 
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represented by the upward and rightward shift of the spectral peak. This is in 
comparison to the medium dose treatment and the low dose treatment. The 
relationship of the spectral peaks of each sample mimic the findings of the simple 
fractal analysis from the previous section, where with greater doses there is increasing 
complexity and decreasing distribution of avascular space. 
Multifractal Spectrum Dose Escalation 
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Figure 3.8: Multifractal Spectral Analysis of the Dose Escalation Combination PDGF/FGF Treatment at 
14 days. This spectral graph helps to summarize the morphological differences between low, medium 
and high dose treatments at 14 days, as reflected by the images of each treatment group, shown to the 
left. The spectra shift upward and to the right with increasing dose, indicating increasing complexity of 
vessel morphology along with decreasing distribution of avascular space. The dashed lines indicate the 
cutoff values for which the r2 values of the linear fit for the approximation for the corresponding alpha 
values fall below 0.95. 
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Spectral analysis was then subjected to heterogeneity and symmetry analysis, 
to confirm multifractal behavior, and to examine the differences in the shape of each 
ofthe spectral curves. This is depicted in figure 3.9. 
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Figure 3.9: Heterogeneity and Symmetry Analysis . The Multifractal spectra were subjected 
to a Heterogeneity and symmetry analysis, in the same method as described in chapter two. 
The heterogeneity analysis helps to confirm the multifractal behavior of each of the samples, 
as the plotted values are not on the 1:1 line. Symmetry analysis helps to show that the High 
dose vessels have much more contribution of the overall image coming from the complex 
vascular space, in comparison to the medium dose treatment and the low dose treatment. 
The lose dose treatment group falls below the 1:1 line, indicating the avascular space 
contributes more to the spectrum than the vascular space in the images. 
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Spectral analysis helped to provide more information about the nature of the induced 
vessels as well as the differences in the shape of their morphological spectra. 
Heterogeneity analysis confirmed that the spectra were heterogeneous and did 
represent objects with multifractal behavior, as represented by the fact that the values 
do not fall on the 1: 1 line. Symmetry analysis provided information about the 
differences in the shapes of the spectral output for each dose treatment group. In the 
symmetry analysis, high dose treatment was shown to induce vessels where the 
vascular portion of the image accounted for more of the complexity ofthe object, as 
reflected by the points which fall above the 1: 1 line. This was in comparison to the 
medium and low dose groups, where the points are closer to the 1 : 1 line, and in these 
images, the non vascular space contributes more to the spectral output. In the low 
dose treatment group, the non vascular space actually contributes more to the 
morphology of the object than the vascular space and this is why two values fall 
below the 1: 1 line. In total, heterogeneity and symmetry analysis help to further 
scrutinize the differences seen in the multifractal spectra. 
In summary, multifractal analysis of the combination treatment group at 14 
days helped to provide more information about the morphology of the vessels 
induced. This analysis helped to show the induced microvascular beds are 
multifractal in nature and that they possess differing complexity. Induction with 
combination PDGF and FGF at 14 days yields vessel beds which exhibit multifractal 
behavior with different doses being capable of inducing vessel morphology with 
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discrete generalized dimensions and multifractal spectra with differing heterogeneity 
and symmetry. 
3. 3 Recapitulating Native Tissue Vessel Morphology of Skin and Muscle 
3 .3 .1 Methods 
The PDGF I FGF treatment group at 14 days was selected to fine tune the 
vascular response, in order to interpolate the necessary concentrations to recapitulate 
vessel morphology observed in native tissues (Gould, Vadakkan et al. 2010). A 
fitting function was applied to each set of data at each time point for each recorded 
parameter (vessel density, fractal dimension, lacunarity). 
In order to induce target vessel morphology, the dose response of each of the 
treatment groups was plotted, and the relationship between dose and fractal dimension 
was determined. Using this information along with the known fractal dimensions of 
various tissues from chapter 2, dose concentrations were calculated which would be 
capable of induction of the target morphology, given the location on the interpolation 
curve. 
New angiogenic hydrogels were implanted in the mouse corneal micropocket 
assay, containing combination doses ofPDGF and FGF based on the calculations 
from the interpolation. These hydrogels were followed for 14 days and then the 
animals were sacrificed and the induced vessel morphology within the constructs, 
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designed to mimic host tissue vessels was analyzed for comparisons. In each 
experiment, where the induced mimetic tissues were designed to mimic host vessels, 
images of the tissues were analyzed using the algorithm described in chapter two. 
Pair wise comparisons were made for each experiment between the induced mimetic 
and host vessels, using a two tailed t test assuming unequal variance in order to 
compare vessel branching and diameter. 
3.3.2 Results: Skin and Muscle Induced Mimetic Vessels 
The best fits were seen for all measurements in the combination PDGF I FGF 
group, which had r2 values which were greater than those of the FGF only and PDGF 
only groups (which were no higher than r=0.77) at both 7 and 14 days. Importantly, 
the r values were the highest for the 14 day timepoint in the PDGF I FGF treatment 
group (r=0.94 at 14 days, compared to 0.80 at 7 days). 
The fractal dimension from each combination PDGF I FGF group at 14 days 
was plotted versus the original dose used (figure 3.10 A). Linear fits were then 
applied to the data in order to interpolate the dose of PDGF and FGF necessary to 
induce vessels with a known target fractal dimension (figure 3.10 A). Figure 3.10 
shows the original data (fractal dimension, vessel density, and lacunarity) from the 
dose escalation using the combination PDGF I FGF treatment group, plotted with the 
linear fit shown and the 95% confidence intervals plotted above and below. Native 
skin and muscle tissues from the same fluorescent mouse system were imaged prior to 
this study to identify the target fractal dimensions at 1.80 ± 0.03 and 1.70 ± 0.05, 
(Gould, Vadakk:an et al. 2010). The growth factor concentrations necessary to 
reproduce these fractal dimensions (Gould, Vadakk:an et al. 2010) were determined 
based on the linear regression in Figure 3.10, the growth factor concentrations 
corresponding to the measured fractal dimension from the intact tissues were as 
follows: 46 ng FGF-2; 184 ng PDGF-BB for skin, solid line; 22 ng FGF-2; 89 ng 
PDGF-BB for thigh muscle, dashed line. 
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Figure 3.10: Morphological Parameters Used to Calculate a Linear Fit. Fractal dimension 
(A), vessel density (B) and lacunarity parameter b (C) were plotted against dose 
released. A linear fit was applied to the data, with R2 values over 0.9 in each parameter 
based plot. Linear fit equations were used to back calculate doses necessary to 
recapitulate vessels with given morphological parameters. The doses were based on the 
linear plot for the fractal dimension. The measured values for the induced vessels using 
the interpolated skin and muscle doses are plotted and indicated by the triangle symbols. 
The 95% confidence intervals are noted as small bars above and below each value. The 
linear fit for the fractal dimension (A) had an r2 value of 0.92. For vessel density the fit 
was ~ = 0.96, for lacunarity ~ =0.92. 
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Implants containing the doses of growth factors needed to recapitulate skin and 
muscle vessel morphologies showed a similar visual appearance to native vessel 
counterparts (figure 3.11 A and B, C and D). Interestingly, even though the fractal 
dimension was used to tune the vascular response, the muscle and skin vasculature 
morphological parameters of lacunarity and vessel density also followed a linear fit. 
This is shown in figure 3.1 0, in which all the measured parameters are plotted with a 
triangle, and are highlighted with a surrounding box. These plotted values represent 
the actual measured values of the parameters from the tuned constructs, with a 95% 
confidence interval plotted. Furthermore, established vessel quantification parameters 
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Figure 3.11 : Recapitulation of Native Vessels. Induced vessels (A) meant to mimic the native 
vessels in thigh muscle (B) and similar vessels (C) induced to recapitulate skin vessels (D) were 
imaged and analyzed. Vessels induced with the hydrogel system using doses for thigh muscle and 
skin vasculature (A and C) are visually similar to native vessels in thigh muscle and skin (B and D). 
Additionally, analysis of vessel diameter and branch points indicates no significant difference 
between native vessel and induced vessel morphological characteristics (E and F) p=0.68 and 0.11 
for branch point comparisons of native and induced muscle and skin , p=0.48 and 0.55 for vessel 
diameter comparisons of native and induced muscle and skin. Scale bar = 50 micrometers. 
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of vessel diameter (p=0.55 and 0.48 for skin and muscle) and branch points (p=O.ll 
and 0.68) indicate no statistically significant difference between the induced vessels 
and the native vessels (figure 3.11 E,F). Table 3.2 provides the complete set of 
measurements from the induced vessels in the dose escalation experiments (induced 
mimetic vessels), as well as the similar measurements from the native tissues 
(measured native vessels). By using space filling morphological parameters such as 
fractal dimension to design growth factor dosing regimens we were able to tune the 
response of subsequent vessel formation in terms of characteristics such as vessel 
diameter and branch points. 
Table 3.2: Complete Set of Measurements from Dose Escalation and Mimetic Vessel 
Induction. This table provides the complete set of morphological output parameters for 
the dose escalation studies as well as the induced mimetic tuning experiments. Notice 
that the induced mimetic vessels matched the vessel morphology of the target tissues. 
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3.4 Mimicking the Vascular Morphology of the Sub Ependymal Zone 
Another vessel bed that was targeted for similar vessel recapitulation was the 
native mouse sub ependymal zone (SEZ), which is a stem cell niche in the mouse 
brain. The SEZ of the brain is a known region of stem cell growth and recently has 
been shown to have a specific structure which is likely related to the neurogenic 
properties of this niche. Recreating the vascular morphology seen in the sub 
ependymal zone of the brain was one goal of this project, and the use of this set of 
techniques to induce vessels similar to those found in the sub ependymal zone is 
described below. 
3.4.1 Methods 
This similar recapitulation was run in parallel using methods from chapter two 
and compared to the dose escalation findings to determine the necessary doses of 
growth factors to recapitulate vessel parameters from the neural stem cell niche, the 
SEZ. 
Images of the native neural stem cell niche, the subependymal zone (SEZ), 
were analyzed to identify the vessel density, fractal dimension and lacunarity. These 
measured parameters were then used as described in the previous section to calculate 
the dose needed to induce similar morphology vessels. New angiogenic hydrogels, 
with encapsulated diffusible angiogenic PDGF and FGF were then fabricated and 
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implanted in the mouse corneal micropocket assay containing concentrations of 
growth factors for induction of vessels similar to the native SEZ vessels. 
Resulting induced vessels were imaged and compared to the native 
morphology in order to determine similarities. 
3.4.2 Results 
The mean fractal dimension of the SEZ fell into a range between the low and 
medium dose groups of combined PDGF/FGF treatment (Table 3.3). 
Frac 
High Dose 0.31+0.07 1.82+0.04 1.32+0.70 
Med Dose 0.21+0.04 1.76+0.03 0.70+0.31 
Low Dose 0.10+0.06 1.59+0.12 0.35+0.23 
SEZ 0.12+0.02 1.66+0.03 0.48+0.09 
Table 3.3: Recapitulating SEZ like vasculature. Tuning as described in the previous section 
was performed, and the known values for the SEZ fractal dimension were used to determine 
the needed dose to induce SEZ like vessels. This dose was 87.07 ng PDGF and 21.77 ng 
FGF, and when used, it induced vessels which had a similar density, fractal dimension and 
lacunarity as the native SEZ. 
119 
The dose necessary for SEZ-like fractal dimension vessels was calculated 
based on interpolation from the plot in figure 3.1 0, using a linear fit between the low 
and medium dose group data sets. This value was not significantly different from the 
dose indicated by using the logarithmic equation fit to the data (87 vs. 79ng, b= 1.68 
vs. 1.66, error is 0.03). The linear fit interpolated dose from the fractal dimension 
data at 14 days was predicted to be 87.07 ng PDGF and 21.77 ng FGF. 
SEZ-like vessels were induced in the in 
vivo model using doses of PDGF and FGF 
predicted to generate similar fractal dimension. 
Figure 3.12 shows images (A-C) ofthe vessels 
which recapitulate morphology of vasculature in 
the SEZ. Vessels were grown along the surface 
of the implants and imaged in a similar manner as 
the dose escalation studies. Images A-Care 
similar setting projections of the vessels grown in 
the corneal implantation method, upon the surface 
of the gel. 
Representative images of the vessels (in 
red) in contact with the RGDS-488 labeled 
hydrogels (in green) (D-F) are shown to display in 
Figure 3.12: Projections of 
images taken of vessels grown 
to recapitulate the vasculature 
in the SEZ. A-C are 
representative projections of 
the induced vessels, while D-F 
are images of the induced 
vessels (in red) growing on the 
biomaterial PEG scaffolds 
(green). Scale bar= 50 
micrometers. 
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vivo juxtaposition with the bioactive scaffolds. 
Quantitative analysis of generated SEZ-like vessels showed that recapitulation 
of the morphological, space-filling measures (fractal dimension, vessel density and 
lacunarity) measured in the SEZ (figure 3.13) was successful. The measured 
parameters for the engineered vessels were similar to the observed parameters from 
the native tissue. 
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Figure 3.13: Classical methods do not distinguish engineered vessels from native vessels. 
This comparison with classical morphological methods helps to reinforce the concept that 
these microvascular constructs are similar in morphology to the natural microvascular 
niches. For this study n=12. 
Finally, comparison of more classical methods reported in the literature, 
including the branch points (measured from 3d stacks) and vessel diameter between 
the engineered and native vessels (Fig 3.13 A, B) showed similar values. In order to 
assure comparison of mean diameters was valid; a histogram was generated to look at 
the distribution of the vessel diameters. A normal distribution was observed, and a 
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majority of the vessels had a diameter of 6 urn, consistent with the reported mean 
vessel diameter in the SEZ. This comparison confirmed recapitulation of aspects of 
vessel morphology, as there was no significant difference between the observed 
branch point number and mean diameter in native versus engineered SEZ vessels. 
In conclusion, the optimization of the induction of vessel morphology allowed 
for a fine-tuned response, in which the scale invariant measure of the fractal 
dimension could be used to induce mimetic vessels to match target host vessel 
morphology, with respect to density, fractal dimension, lacunarity, vessel diameters 
and branching. 
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3.5 Discussion 
The main results of this study included that; (1) Vessels induced in response to 
encapsulated growth factors exhibit a tunable morphological range, and the 
combination treatment with PDGF and FGF provides the best range for fine tuning 
and optimization. (2) Induction with combination PDGF and FGF at 14 days yields 
vessel beds which exhibit multifractal behavior with different doses being capable of 
inducing vessel morphology with discrete generalized dimensions and multifractal 
spectra with differing heterogeneity and symmetry. (3) The optimization of the 
induction of vessel morphology allows for a fine-tuned response, in which the scale 
invariant measure, the fractal dimension can be used to induce mimetic vessels to 
match target host vessel morphology, with respect to density, fractal dimension, 
lacunarity, vessel diameters and branching. 
Tuning vessel morphology as described in this study could prove valuable for 
several reasons. Vessel morphology differs from tissue to tissue and under different 
physiologic conditions. The variation among morphologies found in different tissues 
likely relates to the different functions of tissues, and may be a product of 
development and remodeling, whereby early vessel bed morphology is tuned to a 
certain shape to match needs of the eventual tissue. One goal of this study was to 
provide a better understanding of the tunability of the host vascular response in tissue 
engineering with a potential for broader applications in vessel remodeling in repair. 
These broader applications include regrowth of vessels similar to those found in 
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native tissues as a potential therapeutic for ischemic diseases (Li, Liu et al.; Carmeliet 
and Jain 2000; Ferrara and Kerbel 2005). For this reason, the findings of a tunable 
range in the induction of host vessels in this engineered system could prove useful in 
future studies. 
Another reason tuning induced vessel morphology could prove useful is to 
address the hurdle in tissue engineering of the production of vascularized thick tissues 
(Carmeliet and Jain 2000; Griffith and Naughton 2002; Laschke, Harder et al. 2006) 
which exists because diffusion-based transport of most metabolic substrates is limited 
to 100-150 microns in human tissues (Vacanti; Vacanti, Vacanti et al. 2007). The 
fundamental understanding of how to shape and control vessel morphology given in 
this chapter could provide insight for tissue engineering, and also for the study of 
normal and aberrant vessel growth (Muthukkaruppan VR 1982; Less, Skalak et al. 
1991; Carmeliet and Jain 2000; Sharma, Sharma et al. 2005; Goh, Sanghera et al. 
2009; Adhemar Longatto Filho 2010). 
In order to tune the vascular response in vivo, biomaterials have been tailored 
in this thesis to provide a robust system for vessel induction and stabilization. The 
rational design ofbioactive scaffolds has helped to provide factors for the rapid 
induction of vascularization, as well as for the long term stabilization of vessels in 
constructs (Zhu). These scaffolds could provide a biocompatible, mechanically 
tunable, bioactive substrate for the delivery of cells and other factors in order to allow 
for induction of host vessels and perfusion (Cheung, Lau et al. 2007). One such 
scaffold which was described in chapter 1 and was used in this study is poly (ethylene 
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glycol) (PEG), a hydrophilic and biocompatible polymer, which acts as a "blank 
slate" by resisting protein adsorption and cell adhesion. The material was tailored in 
this study to incorporate desired characteristics, including cell adhesion through the 
addition of covalently immobilized RGD peptide (a sequence commonly found in 
fibronectin) which allows for integrin binding (Gunn, Turner et al. 2005). These 
hydrogels were also rendered degradable by incorporating matrix metalloproteinase 
(MMP) sensitive cleavable cross links (GGGPQGIWGQGK) into the polymer 
backbone (West and Hubbell1999; Moon 2008). The degradable crosslinker within 
these hydrogels had been shown to allow for invading vessels which secrete MMPs, 
(specifically MMPs 2 and 9) to degrade this peptide sequence and therefore the 
hydrogel (Moon, Saik et al. 2010). The polymer was photocrosslinked by adding a 
photosensitive chemical initiator into the polymer solution under relatively gentle 
conditions, therefore, this scaffold could be used to incorporate cells in future studies 
(Leslie-Barbick, Moon et al. 2009). Also PEGylated growth factors could be made 
and incorporated in future studies to stabilize host vessel invasion. In this manner, 
short-term diffusible factors and covalently bound factors may have the opportunity 
to work in concert to help provide rapid and stable vascularization of implanted 
constructs. 
Growth factors proved critical to the optimization of the induction and tuning 
of the angiogenic response. Growth factors incorporated into scaffolds in this study 
were carefully chosen to provide a robust vessel response. The two angiogenic 
growth factors which were used in this study included basic fibroblast growth factor 
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(FGF-2) and platelet derived growth factor-BB (PDGF-BB). These factors provided 
for a robust vascular host response which was optimized and proved tunable in this 
chapter. These growth factors had been chosen for several reasons. FGF-2 is 
released by macrophages in response to hypoxia and initiates vessel formation via 
stimulation of endothelial cell proliferation and migration (Beenken and Mohammadi 
2009). FGF-2 also stabilizes vessels by inducing migration and proliferation of 
smooth muscle cells (Jackson and Reidy 1993) and by regulating production of 
angiogenic molecules, including collagenases, ~ 1 integrins, and urokinase type 
plasminogen activator (Bikfalvi, Klein et al. 1997; Davis 2005; Davis 2008). When 
added to FGF-2, PDGF-BB helps to stabilize vessel formation (Cao 2003). The 
combination ofPDGF-BB and FGF-2 had already been established as a synergistic 
combination to induce blood vessel growth and stability in the mouse cornea when 
used in a 4:1 ratio (Cao 2003) as compared to the use of each growth factor alone. 
There were other reasons that FGF-2 and PDGF-BB were desirable in vascularization 
of constructs in this study, including that vessels induced using Vascular Endothelial 
Growth Factor (VEGF) (another angiogenic factor) appear strikingly similar to tumor 
or diseased vasculature (Jain 2005), because they are more leaky and hemorrhagic 
(Jain, Au et al. 2005). In contrast, PDGF-BB and FGF-2 have been shown to create 
more natural appearing vessels (Cao 2003; Cao 2004). In this study, in combination, 
these factors proved to be best optimized and tunable to mimic normal tissue vessel 
beds. 
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The implantation method in this study was developed in vivo using the mouse 
cornea, which had previously been demonstrated as an excellent location for the study 
ofthese types of constructs (Moon, Saik et al. 2010; Poche, Saik et al. 2010). 
Constructs were implanted in the cornea for three reasons, which are similar to those 
listed by Tong et al. in their study of pathological tumor vessels (Tong and Yuan 
2008). First, the assay could imitate general conditions similar to tissue scaffold 
implantation and vascularization. Second, induced vessels could be quantitatively 
examined microscopically (Gaudric, N'Guyen et al. 1992; Auerbach, Lewis et al. 
2003). Third, the external nature of the cornea allowed for rapid surgical 
implantation and analysis. 
In this group of experiments, mimetic vessels were induced to match host 
vessel morphology. The attempt was made to induce vessels similar in structure to 
target tissue vessels because different tissues possess different microvascular 
morphology, likely related to their functions in the delivery of nutrients and 
metabolites (Humphrey, Buschow et al. 2001). Normal tissues require a precise and 
unique vessel pattern to maintain an equilibrium between growth and cellular 
demands (Jain 2003; Jain, Au et al. 2005). Tissues possess different vessel 
morphology related to their initial development, metabolic need, physiological 
function and their ultrastructural shape and dynamics (Caplan 1985). For example, 
the lung provides a highly branched vascular system, which optimizes oxygen 
exchange and blood flow (Stenmark and Mecham 1997). Kidneys provide highly 
structured loops for osmotic exchange ofwaste products (Smith 1951). Skeletal 
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muscle possesses vessels that are ideal for delivery of nutrients while uniquely shaped 
to allow for the linear application of forces (Carlson 1973; Tong, Boucher et al. 
2004). Skin possesses less vascular density, likely related to the decreased metabolic 
need (Jain 2003), but the microvessels are uniquely distributed to allow for the 
dynamic motion ofthe tissue (Hibbs, Burch et al. 1958). All ofthese tissues Have 
been shown to possess a network of vessels to allow for the spatial organization of the 
organs and the adequate delivery of nutrients to cells of an organ (Jain 2003). The 
importance of the microvascular vessel morphology was highlighted in the problem 
of the replacement and repair of skeletal muscle (Jain, Au et al. 2005). In fact, Jain 
postulated that the reason there was such difficulty in the development of tissue 
engineering strategies to repair skeletal muscle was because this tissue is densely 
perfused and has an extremely high metabolic rate and thus the constructs require a 
"rich supply of blood vessels throughout ... to meet the demand for oxygen and 
nutrients" (Jain, Au et al. 2005). Ultimately, in this study, induced vessels were 
tailored to match normal tissue microvessels, and this became possible through the 
application of the new microvascular quantification scheme provided in chapter 2. 
Novel microvascular quantification techniques were employed, along with 
classical measures in this study to recapitulate normal tissue microvessels. The 
method to quantify the microvasculature used here combined fractal dimension 
(Mandelbrot 1982; Sandau and Kurz 1997) and lacunarity (Landini, Murray et al. 
1995; Plotnick, Gardner et al. 1996; Tolle, McJunkin et al. 2008) along with 
traditional diameter measurements and branching analysis (Masters 1989; J.B. 
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Bassingthwaighte 1994; Herman, Kocsis et al. 2001; Avakian, Kalina et al. 2002; Jain 
2003; Jain, Au et al. 2005; Doubal, MacGillivray et al. 2010; Gould 2010; Grauslund, 
Green et al. 2010; Sng, Sabanayagam et al. 2010). This was discussed in chapters 1 
and 2. The space filling methods used to quantify vascular morphology contained 
scale-invariant measures of vessel distribution, which could be valuable to the 
engineering community, because this ensures scalability in design (Baish, Gazit et al. 
1996; Bianchi, Rosi et al. 2007; Bui, Sutalo et al. 2009; Liu, Wood et al. 2009). 
The findings in this chapter that the morphology of induced vessels can be 
tuned, using space-filling parameters may prove valuable in future design of tissue 
engineered constructs (Bianchi, Rosi et al. 2007), therapies for ischemic disease (Cao 
2003) and the induction ofknown vascular patterns in vivo (Gould 2010). The 
approach described here combined tailored angiogenic scaffolds with customized 
delivery of growth factors to induce host vascularization, and used the fractal 
dimension of induced vessels to fine tune the response. The information from the 
dose response allowed for the selection of the appropriate doses to recapitulate the 
fractal dimension and other measures of microvascular morphology of normal tissues. 
In this study, one powerful observation from the vessel morphology mimicry 
experiments was that through simply tuning the fractal dimension of vessels formed, 
it was possible to induce a vascular structure with a desired fractal dimension, and to 
recreate the desired diameters and branch points, as well as density and lacunarity of 
target vessel networks. It was possible to tune the delivery of angiogenic factors to 
generate specific vascular structures; this was proven by the linear response of these 
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vessel parameters to loaded protein (figure 3.10). This study has gone beyond 
proving the tunability of the angiogenic response, and has also provided information 
on the range of doses of factors that may be used for angiogenesis in the corneal 
micropocket system. Control over microvascular morphology induced in engineered 
bioactive scaffolds may aid therapeutic strategies for re-vascularization. However, 
complex anatomical relationships seen for instance in the 3-5 tufts of capillaries 
surrounded by Bowman's capsule or in the juxtaglomerular apparatus in the kidney 
may require more complex methods to recapitulate vessel architecture. The methods 
described here may not be applicable to their design, because of their complex 
structures and extracellular matrix components as well as the importance of several 
specialized cell types required for physiological function. This thesis has helped to 
inform a formulation parameter necessary to synthesize bioactive scaffolds for a 
particular angiogenic application. In the future this methodology could be used to 
optimize other factors within bioactive scaffolds, and to study other angiogenic 
compounds in vivo in applications within tissue engineering, therapeutic 
angiogenesis, and other applications in regenerative medicine. 
In conclusion, optimization of the modified mouse corneal micropocket 
angiogenesis assay in this thesis has lead to the finding that the tunability of the 
angiogenic response can be used to induce vessels which mimic normal tissue 
microvasculature. In the future this system could provide a robust tunable platform 
for further studies involving vessel morphology in diseased, remodeling or engineered 
tissues. 
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Chapter 4. Additional Methods for Tuning Vessel Morphology: Tethered 
Growth Factors and Cell Signaling Peptides 
4.1 Introduction 
Following the use of the growth factor customization to tune vessel 
morphology, several projects designed to test the effects of tethered growth and 
signaling factors on vessel morphology were carried out. These projects involved the 
use of several in vitro assays and several in vivo assays, similar to those described in 
the previous chapter. The methods for quantification of a response developed in 
chapter 2, including the scale invariant parameters were used to measure the 
responses to the various differing factors. 
Tethered growth factors used for this purpose included PEGylated PDGF -BB 
and PEGylated QK which is a peptide derivative of the active signaling sequence 
from VEGF (Leslie-Barbick, Saik et al.). QK is an abbreviation for the sequence ac-
KLTWQELYQLKYKGI-amide, which is very similar to the native VEGF-receptor 
binding region ofVEGF15, ac- KVKFMDVYQRSYCHP-amide. This sequence has 
been shown to activate VEGFR-1 and 2 in vitro and is much more physiologically 
stable than complete VEGF protein. These factors were well known to be angiogenic 
on their own and to induce tubule formation in vitro (D'Andrea, Iaccarino et al. 2005; 
Biondi, Ungaro et al. 2008), however they had never been studied in a tethered form 
bound to synthetic tissue engineering scaffolds. The key benefit of tethering the 
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factors is that they may serve to stimulate continuous angiogenesis, as they remain 
bound to the angiogenic scaffold while vessels grow into and degrade the 
biodegradable synthetic material. Over time, the degradation of the scaffold releases 
the tethered factors so that as the scaffold is degraded the factors serve to 
continuously stimulate angiogenesis for much longer than diffusible factors 
crosslinked into the gels. This acts as a slow, continuous release which is much 
different than the quick burst kinetics exhibited by the diffusible growth factors after 
implantation. 
Tethered cell signals were studied in vivo to attempt to use native signaling 
and adhesion pathways to stimulate angiogenesis and to determine their effects on 
induced vessel morphology. A sequence from the cell signaling protein Ephrin Al 
was utilized, which contained the extracellular domain ofEphrin Alplus the Fe 
segment. This protein had been previously shown to be critical in endothelial 
signaling and adhesion, and this study provided a platform to study its effects on 
vessel morphology in vivo. 
This chapter presents compiled work from multiple collaborative endeavors. 
Within each project, my specific contribution involved the collaborative experimental 
design of all projects, as well as in vivo experimentation and analysis of the response 
to the biomaterials. For complete in vivo studies, biomaterials were synthesized and 
prepared in the laboratory of Jennifer West, and then the materials were cross-linked 
into implantable hydrogels by my collaborator, Jennifer Saik. I performed surgical 
implantation of these materials, as well as processing of the animal tissues, imaging 
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of the resulting angiogenic scaffolds, pre-processing of images for analysis, analysis 
of resulting images for morphological quantification of the vessel response, statistical 
comparison of these groups, and generation of all figures and graphs associated with 
these functions. I also contributed to the written manuscripts which were produced as 
a product of these studies, including background, methods, results and discussion of 
the in vivo findings in each manuscript, as well as editorial support and criticism of 
the projects. The methods that follow provide descriptions of the synthesis of these 
PEGylated products as well as the steps for implantation of the materials for in vivo 
studies. 
4.2 Materials and Methods 
4.2.1 Polymer synthesis 
Poly( ethylene glycol) (PEG) diacrylate was synthesized by reacting dry PEG 
(MW = 6000 Da; Fluka) with acryloyl chloride (Sigma, St. Louis, MO) and triethyl 
amine (TEA; Sigma) in anhydrous dichloromethane (DCM; Sigma). The reaction was 
performed using 1 :4 PEG:acryloyl chloride and 1 :2 PEG:TEA molar ratios under 
argon gas overnight. 2 M K2C03 was used to wash the solution before allowing it to 
separate into aqueous and organic phases. The organic phase containing PEGDA was 
dried using anhydrous MgS04 and filtered. PEGDA powder was obtained by 
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precipitating in diethyl ether, filtering, and drying overnight under vacuum and stored 
at -20°C under argon gas. 
The cell-adhesive peptide, Arg-Gly-Asp-Ser, (RGDS, American Peptide, 
Sunnyvale, CA) was conjugated to a hetero-bifunctional PEG to form PEG-RGDS. 
RGDS peptide was dissolved into anhydrous dimethyl sulfoxide with one drop of 
diisopropylethylamine. The solution ofRGDS was dripped onto dry acryloyl-PEG-
succinimidyl carboxymethyl (PEG-SCM, Laysan, Arab, AL) using a molar ratio of 
1.1:1 PEG-SCM: RGDS. The reaction was placed on a rocker overnight, followed by 
dialysis against water in a regenerated cellulose membrane. The final product was 
sterilized via filtration and lyophilized. Successful conjugation was confirmed with a 
gel permeation chromatography (GPC) system equipped with a PLgel column (5~m, 
500A, Polymer Laboratories, Amherst, MA) and an evaporative light scattering 
detector (Polymer Laboratories). 
Degradable hydrogels were synthesized by incorporating a matrix 
metalloproteinase-sensitive peptide, GGGPQGIWGQGK (abbreviated PQ), into the 
backbone of the base polymer. Fmoc chemistry was used to synthesize the PQ 
peptide on an APEX 396 solid phase peptide synthesizer (Aapptec, Louisville, KY). 
Matrix-assisted laser desorption/ionisation-time of flight mass spectrometry (MALDI-
ToF MS Autoflex; Broker Daltonics, Billerica, MA, solvent: methanol) 
characterization confirmed successful peptide synthesis. Using a 2.1: 1 molar ratio of 
PEG-SCM to peptide, the synthesized PQ peptide was conjugated to PEG by 
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following a procedure similar to that for PEG-RGDS. PEG-PQ-PEG conjugation was 
also confirmed using GPC. 
4.2.2 Growth Factor or Cell Signaling Molecule Conjugation (PEG-ephrinAJ, 
QK, PDGF-BB, and Laminin-Based Peptides) 
Acryloyl-PEG-succinimidyl carbonate (PEG-SMC) was synthesized in house 
to formulate a product capable of reacting in aqueous conditions, and thus useful for 
protein conjugations. Synthesis followed procedures previously described by the 
West Laboratory (Figure 4.1). (Leslie-Barbick, Moon et al. 2009) Briefly, PEG 
(Fluka/Sigma, MW = 3400 Da) was reacted with Ag20 (Sigma), acryloyl chloride 
(Sigma), and KI (Sigma) in anhydrous dichloromethane (DCM; Sigma) at 4 °C 
overnight, at molar excess ratios of 1.5, 1.1, and 0.3 respectively. The solution was 
filtered using Celite 521 (Spectrum Chemical Mfg Corp, Gardena, CA) and dried 
prior to dissolution in di H20. The solution was adjusted to pH 3 and heated to 35 °C 
for 1 h. Activated charcoal (Fisher Pittsburg, PA) was used to remove iodine, and 
NaCl and DCM were added. Unwanted components were removed via DCM 
extraction and phase separation with 2 M K2C03. Monoacrylated PEG was dried and 
concentrated followed by ethyl ether precipitation and vacuum filtration. 
Monoacrylated PEG in anhydrous acetonitrile (Sigma) and pyridine (Sigma) was 
reacted with a four molar excess of disuccinimidyl carbonate (Sigma) under argon 
overnight. The product was dried and dissolved in anhydrous DCM. After filtration, 
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PEG-SMC was purified in acetate buffer (0.1 M, pH 4.5, 15% NaCl) via phase 
separation. The purified PEG-SMC was dried with anhydrous MgS04 and 
precipitated into ethyl ether. After filtration and drying, PEG-SMC was characterized 
by proton nuclear magnetic resonance spectroscopy ( 1 H-NMR, A vance 400 Hz; 
Bruker) and stored at -80 °C under argon. 
In figure 4.1 the reaction is described for EphrinA1-Fc, but this same method 
may be used to modify other peptides which possess a free amine in their structure, 
including the aminated N terminus. For each of the peptides used in these studies, the 
same SCM modification for PEGylation of the peptides was used. EphrinA1-Fc was 
obtained from R&D Systems (Minneapolis, MN) as a recombinant fusion protein 
containing the extracellular binding portion of ephrinA 1 and the F c fragment of 
human IgG. This protein was reacted with acryloyl-PEG-SMC to form PEG-
ephrinA1. 200 mM sodium bicarbonate buffer (pH 8.5) was used to dissolve 
synthesized acryloyl-PEG-SMC. The solution was sterilized via filtration (0.2 J.lm) 
and combined with ephrinA 1 at a 1: 100 molar ratio of ephrinA 1 :PEG-SMC. In the 
0 
A. HOj ~OlnH _ II ("-" ' 1, + ~CI 
poly( ethylene glycol) acryloyl chloride 
B. ~o~o,N)_ 
o J.M )-_) 
0 
acrylol-PEG- succinimidyl carbonate 
0 
__ l_.A_g_P_.K_I--1._ ~0 0~"0 O..._N~ 
2. pyridine, DSC - II l J. ~ )-_) 
0 
acrylol-PEG- succinimidyl carbonate 
H 
-. ~O~N'ephrinA1 
0 0 
acrylol-PEG-ephrinA I 
Figure 4.1: PEG-SMC for the PEGylation of growth factors and cell signaling and adhesive 
molecules. 
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synthesis ofPEG-PDGF-BB, PDGF-BB was obtained from Prospec bio (Prospec bio, 
Israel) and was reacted in a 1:400 molar ratio, PDGF-BB:PEG-SMC in 200 mM 
sodium bicarbonate buffer (pH 8.5). In the case of the QK peptide, this 15 residue 
peptide was designed to react with PEG-SMC at the first lysine residue only by the 
protection of all other lysine residues with acetyl groups (Ac ), so the peptide sequence 
is (Ac-KLTWQELYQL(K(Ac))Y(K(Ac))GI-amide. This peptide was purchased 
commercially from Aappatec (Aappatec, Louisville, KY). QK was reacted with PEG-
SMC at a 10:1 molar ratio in the presence ofDMSO via slow mixing. 
In each conjugation, the reaction was placed on a rocker for four days at 4 °C 
before lyophilization under sterile conditions. The PEG-peptide or protein 
(EphrinA1, QK, PDGF-BB) powder was reconstituted and stored in HEPES Buffered 
Saline (100 mM NaCl, 10 mM HEPES in deionized water; HBS; pH 7.4) for up to 
three months at 4°C. A western blot was used to confirm successful conjugation. 
4.2.3 Angiogenesis Assay: Hydrogel Implantation into the Mouse Cornea 
To visualize vessel invasion into the materials, hydrogels were implanted into 
Flkl-myr::mCherry transgenic mice, which express an endothelial cell specific 
florescent protein. (Poche, Larina et al. 2009) Hydrogel preparation and implantation 
followed the protocol outlined in Poche et al., (Poche, Larina et al. 2009) and all 
animal experiments were conducted in accordance with Baylor College of Medicine 
Institutional Animal Care and Use Committee protocols. Briefly, hydrogels were 
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prepared at 10% polymer weight of degradable PEG-PQ-PEG, 3.5 J.llllOl!ml PEG-
RGDS, 10 J..Ll/ml acetophenone stock solution, and the described concentration of 
PEG-peptide or protein for each set of experiments. In the case of the Ephrin AI 
studies, this was 160 ng soluble platelet derived growth factor BB (PDGF-BB) per gel 
with or without 1.6 ng PEG-ephrinA1 (n=5 and 6, respectively). A mold of precise 
thickness was made by separating two glass slides with a 0.005 in 
polytetrafluoroethylene (PTFE) spacer and securing the glass slides with binder clips. 
0.12 J..Ll ofthe polymer solution was then injected between glass slides. Hydrogels 
were exposed to UV light (B-200SP UV lamp, 365 nm, 10mW/cm2) for 2 min and 
immediately implanted into a micropocket formed in the cornea. (Poche, Saik et al. 
2010) Briefly, a partial thickness incision was made in the cornea of anesthetized 
mice. A Von Graefe knife was used to separate the layers of the cornea stroma, 
creating a micropocket for hydrogel implantation. Fourteen days after implantation, 
mice were euthanized, and corneas were collected and fixed in 4% paraformaldehyde. 
The tissue was flatmounted and imaged on a Zeiss LSM 510 MET A confocal 
microscope using a Zeiss 40x/1.2NA C-Apochromat water immersion objective lens. 
The mCherry fluorophore was excited with a 543 nm laser for visualization of 
endothelial cells that invaded the cornea and hydrogel in response to growth factor 
release. Images of vessels on the hydrogel were compiled from projections of z-
stacks exactly 22 J..Lm in thickness, spaced 1.1 Jlm apart. 
Confocal z-stacks were used to quantify vessel parameters. Vessel branch 
points and diameters were quantified using the image browser in the LSM software. 
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Fractal dimension, lacunarity, and vessel density were quantified as previously 
described. (Gould, Vadakkan et al. 2011) The fractal dimension was quantified to 
describe the complexity of the vessel network and lacunarity to examine 
nonuniformity of cell distribution in a scale-invariant manner (Gould, Vadakkan et al. 
2011). 
4.3 Tethered Growth Factors for Long-Term Stable Release 
The work described below is adapted from two papers, currently in press: 
"Covalently immobilized platelet-derived growth factor-BB promotes angiogenesis in 
biomimetic poly( ethylene glycol) hydrogels". Saik JE, Gould DJ, Watkins EM, 
Dickinson ME, West JL. Acta Biomaterilia. 2010 Aug 27, and "An Immobilized 
VEGF-mimetic Peptide Promotes Microvasculature Formation in Poly( ethylene 
glycol) Diacrylate Hydrogels" Julia E. Leslie-Barbick, Ph.D.; Jennifer E. Saik, B.S.; 
Daniel J. Gould, B.S.; Mary E. Dickinson, Ph.D; Jennifer L. West, Ph.D. 
Biomaterials. 2011 April20. 
4.3.1 PEGylated growth factor PDGF-BB 
PDGF-BB was previously shown to effect angiogenesis as described in the 
introduction and background sections ofthis thesis. Furthermore, the FDA has 
approved the use ofPDGF-BB for use in the treatment of periodontal bone defects 
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and diabetic foot ulcers, making it a viable tool for tissue engineering. The goal of 
this project was to conjugate PDGF-BB to the PEG molecule in order to improve its 
delivery over time and this goal was based on previous work that has shown 
PEGylated PDGF-BB has improved solubility, decreased immunogenicity, and 
increased stability without loss of bioactivity (Veronese 200 1; Roberts, Bentley et al. 
2002; Fishburn 2008). 
4.3.1.1 Methods 
For concise methods on the in vitro aspects of these studies, please see 
appendix section 2. In this Methods Section, I focus on the in vivo experiments, as 
they were the primary contribution I provided to the work. 
Synthesis and Purification of PEG-RGDS and Degradable PEG-PQ-PEG 
PEG-RGDS was synthesized by dissolving the cell-adhesive peptide, Arg-Gly-
Asp-Ser, (RGDS, American Peptide, Sunnyvale, CA) into anhydrous dimethyl 
sulfoxide and adding diisopropylethylamine. Dissolved RGDS was added to dry 
acryloyl-PEG-succinimidyl carboxymethyl (PEG-SCM, Laysan, Arab, AL) at a 1.1:1 
PEG-SCM: RGDS molar ratio. This mixture was placed on a rocker overnight, 
dialyzed against water in a regenerated cellulose membrane to remove unwanted 
products, and lyophilized. 
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Hydrogels were rendered degradable by the incorporation of a collagenase-
sensitive peptide, GGGPQGIWGQGK (abbreviated PQ), into the backbone of the 
PEGDA base polymer. The PQ peptide was first synthesized using Fmoc chemistry 
on an APEX 396 solid phase peptide synthesizer (Aapptec) and characterized using 
MALDI-TOF. The synthesized peptide was conjugated to PEG by following a 
similar procedure as above with a 2.1 molar excess of PEG-SCM. Conjugation of 
PEG-RGDS and PEG-PQ-PEG were confirmed using a gel permeation 
chromatography (GPC) system equipped with a PLgel column (5J..Lm, 500A, Polymer 
Laboratories, Amherst, MA) and an evaporative light scattering (ELS) detector 
(Polymer Laboratories). The PEG-RGDS was dissolved in 0.1% ammonium acetate 
in dimethylformamide (DMF) solvent and tested against a PEG-SCM standard. 
Synthesis and Purification of acryloyl-PEG-succinimidyl carbonate (PEG-
SMC) 
The organic solvents needed to accommodate the short half-life of the 
succinimidyl carboxymethyl reactive group on the PEG-SCM, which was purchased 
and used for conjugation of peptides, were not compatible with proteins used in this 
study. It was therefore necessary to synthesize a heterobifunctional acryloyl-PEG-
succinimidyl carbonate (PEG-SMC) in-house. PEG-SMC is functionally similar to 
the commercially available PEG-SCM, but has a longer reaction half-life and can thus 
be used under aqueous conditions. 
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PEG (Fluka!Sigma, MW = 3400 Da ) was reacted with Ag20 (Sigma, St. 
Louis, MO), acryloyl chloride (Sigma, St. Louis, MO), and K1 (Sigma, St. Louis, 
MO) in anhydrous dichloromethane (DCM; Sigma, St. Louis, MO) at 4 °C overnight, 
at molar excess ratios of 1.5, 1.1, and 0.3 respectively. Silver was removed by 
filtering the solution through Celite 521 (Spectrum Chemical Mfg Corp, Gardena, 
CA). A Rotovap was used to dry the solution prior to dissolution in di H20. The pH 
was adjusted to 3 with HCl, and the solution was heated to 35 °C for 1 h. Iodine was 
removed by adding activated charcoal (Fisher, Pittsburg, PA), and the solution was 
filtered through Celite 521. NaCl and DCM were added, followed by DCM 
extraction. Phase separation with 2 M K2C03 was used to remove acid and chloride 
ions. Monoacrylated PEG was dried with sodium sulfate (Fisher, Pittsburg, PA), and 
a Rotovap was used to concentrate the solution followed byethyl ether precipitation 
and vacuum filtration. A four molar excess of disuccinimidyl carbonate (Sigma) was 
reacted with the monoacrylated PEG in anhydrous acetonitrile (Sigma) and pyridine 
(Sigma) under argon overnight. The product was dried using a Rotovap prior to 
dissolving in anhydrous DCM. The solution was filtered, and PEG-SMC was purified 
in acetate buffer (0.1 M, pH 4.5, 15% NaCl) via phase separation. The purified PEG-
SMC was dried with anhydrous MgS04• PEG-SMC was precipitated into ethyl ether, 
filtered, and dried overnight under vacuum. PEG-SMC was characterized by proton 
nuclear magnetic resonance spectroscopy (1H-NMR, A vance 400Hz; Bruker, 
Billerica, MA, USA) and matrix-assisted laser desorption/ionisation-time of flight 
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mass spectrometry (MALDI-TOF; Bruker Daltonics, Dillerica, MA, USA). The final 
PEG-SMC product was stored at -80 °C under argon. 
Synthesis of PEG-PDGF-BB and PEG-FGF-2 
In-house synthesized acryloyl-PEG-SMC was dissolved in 50 mM sodium 
bicarbonate buffer (pH 8.5) and sterilized via filtration (0.2 J.tm). PDGF -BB (ProSpec 
Bio, Israel) was conjugated to PEG-SMC using a 400:1 PEG-SMC: PDGF-BB molar 
ratio in 200 mM sodium bicarbonate buffer (pH 8.5) at 4 °C for 4 d (Figure 1 ). The 
resulting PEG-PDGF-BB solution was lyophilized under sterile conditions. PEG-
PDGF-BB powder was reconstituted and stored in HEPES Buffered Saline (100 mM 
NaCl, 10 mM HEPES in deionized water; HBS; pH 7.4) with 0.1% BSA at 4 °C for 
up to three months. A similar procedure was followed for PEG-FGF -2 (ProSpec Bio) 
at a 100:1 PEG-SMC: FGF-2 molar ratio. All growth factor conjugations were 
confirmed via Western Blot analysis on a 15% Tris-HCL precast polyacrylamide gel 
(Biorad, Hercules, CA). Primary antibodies included rabbit polyclonal anti-PDGF-B 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and rabbit polyclonal anti-
FGF -basic antibody (Millipore, Billerica, MA). Secondary antibody HRP-conjugated 
goat anti-rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA) and an ECL ™ 
chemiluminescent western blotting analysis system (GE Healthcare, 
Buckinghamshire, UK) were used. The western blot membrane was exposed to film 
(Kodak, Rochester, NY) for 15 sand developed using a Micromax Developer (Hope, 
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Seattle, WA) with T2 developer and T2 fixer (White Mountain Imaging, Salisbury, 
NY). The presence ofPEG was confirmed using a PEG stain adapted from (Zhang, 
Wang et al. 2006), which allows barium iodine to react with PEG to form a yellow 
color. 
Unconjugated PDGF-BB was quantified using a PDGF-BB ELISA (R&D 
systems, Minneapolis, MN). PEG chains mask antibody binding to PEG-PDGF, so 
the amount ofunconjugated PDGF-BB was quantified after running a sample of the 
reacted solution on an ELISA. With the amount of soluble PDGF-BB quantified, 
appropriate concentrations ofPEG-PDGF-BB were calculated. 
Formation and Surface Modification of PEGDA Hydrogels 
Six kDa PEGDA was dissolved in HBS to a 10% polymer weight percentage 
solution. A stock solution of the photoinitiator 2-dimethoxy-2-phenylacetophenone 
(acetophenone, Sigma) was prepared by dissolving 300 mg acetophenone in 1 ml N-
vinylpyrrolidone (NVP) and then added to the polymer solution at a concentration of 
10 J.Ll/ml. The solution was vortexed and sterile filtered. Hydrogels were 
polymerized between two glass slides separated by a 0.75 mm thick poly( tetra 
fluoroethylene) (PTFE) spacer. The glass slides and spacer were secured using clips. 
Polymer solution was exposed to UV light (B-200SP UV lamp, UVP, 365 nm, 10 
mW/cm2) for 30 sand stored in PBS with 0.1% sodium azide. 
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For all studies, unconjugated PDGF-BB and PEG-SMC were removed via 
diffusion before the hydrogels were used. Alternatively, soluble PDGF-BB could 
also be left in place to act as a diffusible growth factor to encourage cell migration in 
the surrounding tissue for other applications. 
To quantify the surface concentration of immobilized PEG-PDGF-BB, 
hydrogels were synthesized as described above and then degraded in 0.1 N sodium 
hydroxide for three days. After complete hydrogel degradation, the protein 
concentration was read on a Nanodrop 2000 (Thermo Scientific, Wilmington, DE). 
Hydrogel Implantation into the Mouse Cornea 
Hydrogels were prepared following the protocol outlined in Poche et al. 
(Poche, Larina et al. 2009). Briefly, the prepolymer solution was prepared to a 10% 
polymer weight percentage (100 mg/ml) ofPEG-PQ-PEG, 3.5 ~mol/ml PEG-RGDS, 
10 ~1/ml acetophenone stock solution, and 160 ng soluble PDGF-BB per gel with or 
without 1.6 ng PEG-PDGF-BB per gel (n=8). Hydrogels were prepared by injecting 
0.12 ~1 polymer solution in between the glass slides spaced by a 0.005 in thick PTFE 
spacer secured with binder clips and exposed to UV light for two min. 
Bioactive hydrogels were implanted into the cornea following a 
modified mouse cornea micropocket angiogenesis assay (Poche, Saik et al.). All 
animals were used under an approved protocol of the Institutional Animal Care and 
Use Committee at Baylor College of Medicine. Briefly, mice were anesthetized and a 
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partial thickness incision of approximately 50 llm in depth was made. The layers of 
the cornea stroma were separated using a Von Graff knife for immediate implantation 
after hydrogel crosslinking. Flkl-myr: :mCherry transgenic mice were utilized, which 
enable visualization ofvessel invasion via endothelial cell specific florescence [24]. 
Mice were euthanized and corneas were collected and fixed in 4% paraformaldehyde 
fourteen days after implantation. Flatmounts of tissue were made and imaged on a 
Zeiss 510 META confocal microscope using a 40x water immersion objective lens. 
A 543 nm laser was used to excite the mCherry fluorophore. Images of vessels on the 
hydrogel were compiled from projections of z-stacks exactly 22 !lm in thickness, 
spaced 1.1 !lm apart. 
Statistics 
One-way ANOVA and subsequent Tukey's Least Significant Difference 
(LSD) tests were used to statistically analyze the bioactivity ofPEG-PDGF-BB and 
HUVEC tubulogenesis on surface-modified hydrogels and the movement of cells 
inside the hydrogels. In the tubulogenesis study, a generalized linear model in 
Mini tab was used to analyze statistical differences in tubule formation of the co-
culture ofHUVEC and lOTl/2 cells. For each analysis, p<0.05 was considered 
significant. 
146 
4.3.1.2 Results 
PEGylated PDGF-BB bioactivity in vitro 
In vitro studies confirmed that the PEGylated PDGF-BB was bioactive by 
seeding hydrogels containing the PEG-PDGF-BB with lOt 1;2 cells and comparing 
them to hydrogels without PEG-PDGF-BB (figure 4.2 from (Saik, Gould et al. 
2011)). The Hydrogels containing the PEGylated factor PDGF-BB exhibited robust 
spreading and proliferation, and the spatial distribution of this effect was confined to 
regions patterned with the PEGylated factor. Bioactivity of the conjugated PDGF-BB 
was confirmed by quantifying lOTI/2 proliferation on surfaces modified with PEG-
RODS and PEG-PDGF-BB as compared to surfaces modified with PEG-RGDS alone. 
Soluble PDGF-BB was added to the media of some gels modified with PEG-RGDS to 
serve as a positive control. As shown in Figure 4.2 A, IOTl/2 proliferation significantly 
increased in the presence of either soluble or bound PDGF-BB at 48 h (ANOVA, 
p<0.05). There was no significant difference in proliferation in the presence of soluble 
PDGF-BB compared to PEG-PDGF-BB, suggesting that conjugated PEG-PDGF-BB 
retained its bioactivity at levels similar to that of the soluble growth factor. The capability 
to spatially control immobilized PDGF-BB was demonstrated with hydrogels patterned 
with immobilized PDGF-BB (Figure 4.2 B-C). IOTl/2 cells were evenly seeded onto 
surfaces with and without PEG-PDGF-BB at 4 hours (Figure 4.2 B). By 48 hours, 
IOTl/2 cells seeded onto these patterned hydrogels appear to have proliferated more on 
areas with immobilized PDGF-BB (Figure 4.2 C). 
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Figure 4.2: Bioactivity ofPEG-PDGF was confirmed by seeding 10Tl/2 cells onto modified surfaces . (A) 
By 48 hr, 10Tl/2 proliferation had significantly increased in the presence ofPDGF-BB (ANOVA, # 
p<0.05). No significant difference between soluble and bound forms ofPDGF-BB indicated that 
covalently-immobilized PEG-PDGF-BB retained its bioactivity. (B-C) Hydrogels with patterned regions 
ofPEG-PDGF-BB demonstrated the utility of spatial control of PDGF-BB. 10Tl /2 cells seeded onto these 
patterned gels were evenly dispersed at 4 hours (B) but exhibited increased proliferation on regions 
patterned with PDGF-BB after 48 hours (C). (adapted from Saik, Gould eta! 2011) 
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Further in vitro studies from this project confirmed that the PEG-PDGF-BB enhanced 
endothelial tubule formation when compared to PEG-FGF-2 and a combination of these 
growth factors (figure 4.3). 
Thirty days after seeding HUVECs on surfaces modified with PEG-RGDS and 
PEG-PDGF-BB, endothelial cell tubules and branching networks were visible (Fig 4.3 
A). HUVECs on surfaces modified with PEG-RGDS alone exhibited the normal 
cobblestone morphology of the cell type (Fig 4.3 B). Early tubulogenesis was apparent 
after 18 d, with robust tubulogenesis at day 30. The presence oftubulogenesis after 30 d 
suggests that the bioactivity of covalently immobilized PEG-PDGF-BB was maintained. 
Statistical analyses indicated significantly higher tubule formation on surfaces modified 
with PEG-RGDS and PEG-PDGF-BB as well as surfaces modified with the combination 
ofPEG-RGDS, PEG-PDGF-BB, and PEG-FGF-2 when compared to surfaces modified 
with PEG-RGDS alone (ANOVA with Tukey's LSD, p<0.05, Fig 4.3 C). 
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Figure 4.3: Modified surfaces significantly enhanced endothelial cell tubule formation. (A) HUVECs 
seeded onto modified surfaces exhibit extensive tubule formation (arrows) as early as 18 days 
compared to the cobblestone appearance ofHUVECs seeded on surfaces with only PEG-RGDS (B) . 
(C) A significant increase in tubule formation on surfaces with covalently immobilized PDGF -BB (* 
p<O.Ol) and surfaces with both covalently immobilized PDGF-BB and FGF-2 (# p<0.05) is seen as 
compared to surfaces modified with PEG-RGDS alone. (adapted from Saik, Gould et al2011) 
Tethered growth factor PEG-PDGF-BB appears to enhance the in vivo 
vascular response. 
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Bioactive hydrogels were implanted into the mouse cornea to assess the role of 
PEG-PDGF-BB in inducing angiogenesis in vivo. Hydrogels contained soluble PDGF-
BB to initiate the angiogenic response by stimulating vessels from the surrounding 
limbus to invade into the cornea. Once vessels reached the bioactive hydrogel, the 
immobilized PEG-PDGF-BB (Figure 4.4) induced a more robust vascular response than 
hydrogels with soluble PDGF-BB alone (Figure 4.4). These in vivo experiments were 
performed with hydrogels containing 1.6 ng PEG-PDGF-BB, 160 ng diffusible 
PDGF-BB compared to diffusible PDGF-BB alone (Figure 4.4). There were 
significant differences when comparing the releasable factor to the tethered factor in 
concert with the releasable factor, using a t test assuming unequal variance, with a p 
value< 0.05. Figure 4.4 highlights the visible differences between the treatment 
group and the group lacking the PEGylated factor PDGF-BB in the images for 
comparison. The differences between vessel diameter, vessel density and fractal 
dimension were found to be significant, however the lacunarity comparison was not 
found to be significantly different (although there was a similar trend). Interestingly, 
the PEGylated PDGF stimulated vessel growth with a higher average vessel diameter, 
still within the range of physiological function, compared to the implants with only 
diffusible factors. Similar trends were seen where the PEGylated PDGF-BB seemed 
to stimulate a more robust response with greater branching and larger vascular tubules 
using the doses examined. 
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Figure 4.4: Effects of PEGylated PDGF-BB. Top panels represent vessels grown 
on implants with diffusible factors alone. Bottom panels are implants with 1.6ng 
PEGylated PDGF-BB, in addition to the 160ng diffusible PDGF-BB in both . The 
bar graphs show significantly different values for vessel density, fractal dimension, 
and vessel diameter. P<0.05, n=9. (adapted from Saik, Gould et al 201 1) 
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Controlled delivery ofPDGF-BB is particularly useful for in vivo applications. 
Soluble PDGF-BB was necessary to stimulate the initial angiogenic response of the 
surrounding limbic vessels into the cornea. Since soluble PDGF-BB degrades very 
rapidly in vivo, the presence ofPEG-PDGF-BB enables prolonged angiogenic signaling 
on the hydrogel, leading to an increase in vessel density and diameter. This study presents 
the first work with a PEGylated growth factor in vivo. Furthermore, the in vivo data 
corroborated the in vitro studies ofthe PEGylated PDGF-BB and these findings 
provide another method for fine-tuning of the microvascular morphological 
parameters in angiogenic scaffolds. In the future, PEGylated PDGF-BB could be 
used in concert with biological scaffolds to help induce microvascular structures with 
high vessel density (30%, roughly double the density when using diffusible PDGF-
BB alone), wide diameter (close to 11 microns), high fractal dimension approximately 
1.8 (indicating complex structures) and high lacunarity parameter b, approximately 
1.00 (which corresponds to a low amount of distributed empty space within the 
constructs). This may be useful in the design ofmicrovascularized constructs to 
recapitulate skin which showed a fractal dimension of 1.8, and lacunarity parameter b 
of 1.03 with vessel density of0.24 and diameters in the range of6-10 microns (shown 
in chapter 2 and 3). The use of this material is not limited to the design of one 
microvascular type, and the value ofPEG-PDGF-BB, in terms of its stability and its 
ability to induce a robust response should be considered in its future use. 
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4.3.1.3 Conclusion 
Biomimetic hydrogels can be designed to incorporate cell adhesive 
sequences and covalently immobilized growth factors to stimulate a desired cellular 
response in tissue engineered constructs. This work demonstrated that PEG-PDGF-BB 
maintains its bioactivity and can be successfully incorporated into PEG-based hydrogels. 
HUVECs seeded onto hydrogel surfaces modified with covalently immobilized growth 
factors formed extensive and branching networks of tubules. Additionally, a co-culture of 
HUVEC and mouse pericyte precursor 1 OTl/2 cells seeded onto modified surfaces 
induced tubule formation independent of growth factor modification as early as two days 
after cell seeding. Finally, bioactive hydrogels containing both soluble PDGF-BB and 
immobilized PEG-PDGF-BB lead to a significant increase in vessel density and 
complexity when implanted into the mouse cornea angiogenesis assay as compared to 
hydrogels with soluble PDGF-BB alone. Further work is necessary to determine optimal 
combinations of cell types as well as both bound and soluble growth factors to form 
stable and functional vascular networks. 
4.3.2 PEGylated QK (a bioactive peptide derivedfrom VEGF) was found to 
effect angiogenic induction and morphology. 
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Another growth factor that has been previously described and is implicated in 
angiogenesis is VEGF. A 15 amino acid peptide sequence called QK, derived from 
the VEGF receptor 1 domain 2 - VEGF binding interface has been shown to bind 
various VEGF receptors in vitro (D'Andrea, Iaccarino et al. 2005). This peptide was 
studied in vitro in the West laboratory and was shown to possess similar activity to 
lower concentrations of VEGF. It has been shown to activate downstream pathways 
of the VEGF receptor and to stimulate tubulogenesis in vitro (D'Andrea, Iaccarino et 
al. 2005). Beyond this, the peptide has appeal in bioengineering applications because 
it is relatively more stable and resistant to denaturation than native VEGF and it is 
much cheaper to synthesize than complete protein VEGF, or to produce concentrated, 
purified VEGF for commercial use. It can be PEGylated and covalently bound to 
synthetic biomaterials. This section describes a collaborative effort where I again 
contributed by providing the in vivo portion of the experiments as well as analysis 
and results for the manuscript. 
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4.3.2.1 Methods 
In these experiments, QK was PEGylated for use in in vitro studies by a past 
student in the West lab, Julie Barbick. Her findings in vitro along with these in vivo 
results can be found in the manuscript listed above (Leslie-Barbick, Saik et al.). 
Complete methods for all in vitro experiments can be found in appendix section 3. 
Preparation and Purification of PEG-QK: 
The angiogenic peptide Ac-KLTWQELYQL[K(Ac)]Y[K(Ac)]GI-amide was 
designed to react with PEG-SCM at the first lysine (K) residue only, by protecting all 
other free amines with acetyl groups (represented by Ac). QK (MW=2036 Da, Aapptec, 
Louisville, KY) was dissolved in DMSO at a concentration of7.4 mM. N,n-
diisopropylethylamine (DIPEA, Sigma, 2 mol per mol PEG) was added to the solution to 
act as a base catalyst. Acryloyl-PEG-succinimidyl ester (PEG-SCM, Laysan, MW=3400 
Da) was similarly dissolved at a concentration of 1.5 mM. PEG-SCM was added 
dropwise to QK in a 10: 1 molar ratio with slow mixing and allowed to react for 4 d at 
25°C. The product was precipitated in cold isopropanol and dried overnight. PEG-QK 
was then lyophilized and stored in HEPES buffered saline (HBS) with 0.1% bovine 
serum albumin (BSA) at 4°C until use. Conjugation was characterized by MALDI-TOF 
(MS Autoflex, solvent: methanol). 
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Synthesis ofPEG-VEGF 
In brief, VEGF 165 (Sigma) was reacted with acryloyl-PEG-SMC in a 1:200 molar 
ratio in sterile 50 mM sodium bicarbonate buffer (pH 8.5, 0°C) for 4 d. PEG-VEGF was 
then lyophilized under sterile conditions and stored in HEPES buffered saline (HBS) with 
0.1% bovine serum albumin (BSA) at 4 °C until use. Conjugation was confirmed via 
Western blot by visualizing an increase in molecular weight. 
In Vivo Mouse Cornea Micropocket Angiogenesis Assay: 
Hydrogels were implanted into the mouse cornea micropocket angiogenesis assay 
following the protocol outlined in Poche et al. Hydrogels were prepared by making a 
10% polymer weight percentage (0.1 g/ml) prepolymer solution ofPEG-PQ-PEG, 
3.5 J.lmol/ml PEG-RGDS, 10 f.ll/ml acetophenone stock solution, and 640 ng soluble 
VEGF per gel with or without 1.6 ng PEG-VEGF or 32 ng PEG-QK per gel. Hydro gels 
did not contain encapsulated cells. The difference in concentration of QK and VEGF 
comes from the observation previously noted by D'Andrea et al. that 385 mol QK had 
equal bioactivity to 1 mol VEGF in a proliferation assay [2]. As a positive control, 
hydro gels were crosslinked with incorporation of PEG-VEGF ( 400 pmol/mL) instead 
ofPEG-QK, and as a negative control, hydrogels were prepared with PEG-RGDS 
only. Prepolymer solution (0.12 f.ll) was injected in between the glass slides spaced by a 
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0.005 in thick PTFE spacer secured with binder clips and crosslinked via exposure to UV 
light for 2 min. 
Bioactive hydrogels were implanted into a modified mouse cornea micropocket 
angiogenesis assay. All animals were used under an approved protocol of the 
Institutional Animal Care and Use Committee (and AALAS) at Baylor College of 
Medicine. Flkl-myr::mCherry transgenic mice were utilized, which enable visualization 
of vessel coverage via endothelial cell specific florescence. Briefly, a partial thickness 
incision of approximately 30 ~-tm in depth was made in the cornea of anesthetized mice. 
A Von Graefe knife was used to separate the layers of the cornea, creating a micropocket 
approximately 700 microns in length where the implants could be placed approximately 
3-400 microns away from the limbic vessels with great reproducibility. 
Mice were euthanized 14 d after implantation, and corneas were collected and 
fixed in 4% paraformaldehyde. Tissue flatmounts were prepared and imaged on a Zeiss 
LSM 510 META confocal microscope using a 40x/1.2NA C-Apochromat water 
immersion objective lens corrected for UV vis IR working distance 0.28 mm with a 543 
nm laser for excitation of the mCherry fluorophore. Images of vessels on the hydrogel 
were compiled from projections of z-stacks exactly 22 ~-tm in thickness, spaced 1.1 ~-tm 
apart. These images where then compiled into z-stacks, and the three dimensional data 
set was used to count branching and vessel diameters, using the image browser in the 
LSM software. 
Next, the stacks were processed into projections usmg a maximum intensity 
projection setting in the LSM Image examiner software. Projections were then processed 
into grayscale images and thresholded to preserve the vessel elements without dilating or 
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eroding them and the images were then opened in MA TLAB and analyzed for vessel 
density and several scale-invariant space filling parameters including fractal dimension 
and lacunarity using a program available free online through the MA TLAB central 
exchange (Moisy 2006; Vadakkan 2009; Vadakkan 2009; Gould, Vadakkan et al. 2010). 
Briefly, the fractal dimension quantifies the amount of space filled by an object and 
lacunarity quantifies how it fills space, and both do this in a scale-invariant manner 
(Mandelbrot 1982; Lopes and Betrouni 2009; Gould, Vadakkan et al. 2010). Finally all 
groups were compared using anova analysis with post hoc tukeys test to identify 
statistically significant differences. 
4.3.2.2 Results: 
Briefly, the peptide was shown to stimulate tubule formation on the surface of 
hydrogels and in three dimensional cultures in degradable hydrogels in vitro. Our 
findings in vivo were similar, in that there was greater coverage ofhydrogels 
containing the QK peptide in comparison to PEGylated whole VEGF and diffusible 
VEGF alone. 
Immobilized VEGF and QK induce more complete vessel coverage of the 
hydrogel in vivo 
To investigate the role ofthe immobilized VEGF mimicking peptide in vivo, 
bioactive hydrogels were implanted in a mouse cornea micropocket, an established, 
reproducible, and quantifiable assay. Hydrogels contained non-bound, diffusible 
VEGF to stimulate an angiogenic response from the surrounding limbus into the 
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normally avascular cornea. Vessel coverage of the hydrogels is illustrated with three 
representative images of each treatment group (Figure 4.5, A). 
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Figure 4.5 A: QK peptide with VEGF enhances angiogenesis in vivo when compared to VEGF alone 
or PEG-VEGF and VEGF. Images of the different experimental groups are shown here for visual 
comparison. Figure 4.4 continues below. Scale bar= 50 micrometers. 
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Figure 4.5 8: Morphological Parameters from OK in vivo experiments. These parameters 
were measured from the images of the microvessels similar to what is shown in 4.4 A. 
Bioactive hydrogels incorporating releasable VEGF alone and in combination with PEG-
VEGF or PEG-OK were implanted into the mouse cornea micropocket and imaged 
fourteen days after implantation. The presence of PEG-OK significantly increased the 
number of branch points (B) and vessel density (C) as compared to VEGF alone and 
VEGF with PEG-VEGF (p < 0.05). Additional space filling parameters were quantified , 
which also showed that the presence of PEG-OK significantly increased fractal dimension 
(D), and the value of the lacunarity parameter (E) as compared to VEGF alone and VEGF 
with PEG-VEGF. No significant difference between vessel diameters existed (F). The 
advantage of immobilized growth factors can be seen in the percentage of hydrogels with 
complete vessel coverage (G), where only 12% of hydrogels with VEGF alone displayed 
complete vessel coverage of the hydrogel as compared to 33% in the presence of PEG-
VEGF and 53% with PEG-OK. 
Furthermore, PEG-QK was shown to enhance vessel branch points (B) and 
vessel density (C) as well as space filling properties of fractal dimension (D) and 
lacunarity (E). These space filling parameters provide scale invariant methods to 
160 
161 
parse out differences in vessel morphology. Fractal dimension quantifies the 
complexity of the vessel network via a measurement ofhow much space in each 
image is filled with vessels (Sandau and Kurz 1997). Lacunarity quantifies the 
uniformity of vessels to describe how the vessels fill the image5• Vessel diameter (F) 
remained similar between all treatment groups. Although the morphological 
parameters do not show a significant difference between VEGF alone and VEGF with 
PEG-VEGF, PEG-VEGF did increase the percent ofhydrogels with vessels covering 
the hydrogel (G). Importantly, in our study, the concentration of the QK peptide was 
32ng in contrast to the concentration of tethered VEGF which was 1.6 ng. This 
difference in concentration coupled with the difference in PEGylation of the native 
VEGF could account for the more robust response seen in the QK containing group. 
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4.3.2.3 Discussion 
D'Andrea et al. 's contribution of the QK peptide which binds to and activates 
VEGF receptors responsible for the induction of angiogenesis is a useful material for 
angiogenic engineering scaffolds. Although they examined the peptide in depth, they 
did not examine the effects of QK bound in a matrix. PEG hydro gels have been 
shown to support angiogenic activity when modified with bioactive peptides and 
proteins and this is why they were used as a matrix material to examine the 
angiogenic effects of covalently linked QK. In vitro results suggest that the covalent 
incorporation of the angiogenic peptide QK could be used to promote angiogenesis in 
tissue engineered matrices. The in vivo work using hydrogels without encapsulated 
cells in the mouse cornea micropocket angiogenesis assay shows that PEG-QK 
supports a high level of vessel coverage, outperforming that of unbound VEGF and 
PEG-VEGF hydrogels. 
The PEG-QK containing group stimulated a more robust response than the 
VEGF diffusing group or the PEG-VEGF containing group. This was reflected by 
greater vessel branching, fractal dimension and lacunarity parameter b in the QK 
containing group (p<0.05). Interestingly the average vessel diameters were not 
significantly different from each other. Furthermore, the PEG-QK containing group 
seemed to generate excellent coverage vessels more frequently than the VEGF 
diffusing or the PEG-VEGF containing hydro gels, with a much higher percent of 
coverage in the groups containing PEGylated growth factor, in particular in the group 
163 
containing PEG-QK. The advantage of immobilized growth factors was seen in the 
percentage ofhydrogels with complete vessel coverage (G), where only 12% of 
hydro gels with VEGF alone displayed complete vessel coverage of the hydrogel as 
compared to 33% in the presence ofPEG-VEGF and 53% with PEG-QK. 
In comparison to PEGylated PDGF-BB, this material produced vessels with 
greater density (40% compared to 30%), and higher fractal dimension (1.87 vs 1.80), 
yet with lower vessel diameters (8 vs 10 microns), more similar to the PDGF-BB 
alone and VEGF-A alone treatments. This material may prove useful in the design of 
microvasculature for the kidney, since the kidney was shown to have a fractal 
dimension of 1.89, lacunarity of 1.92 (vs 1.7 in QK) and a density of36% (chapter 2). 
This study shows the success of incorporating a covalently-linked 15-amino 
acid biomimetic peptide into a tissue engineering matrix to promote angiogenesis. 
There is no known current published research in which bioactive peptides are 
incorporated into tissue engineering matrices to promote angiogenesis in vivo. 
There may be advantages to incorporating small peptides instead of large 
proteins for angiogenesis treatment strategies. Synthesized peptides allow more 
flexibility of design for bioactivity without a requirement for modifying genetic 
translation in bacterial production. QK was synthesized to allow only one PEG chain 
to be conjugated per peptide. Native VEGF protein dimers can be modified with up 
to 50 PEG chains, this can lead to a distribution of reaction products, where excess 
PEG chains may cause steric hindrance during ligand-receptor binding. Additionally, 
smaller peptides may be easier to incorporate into bioactive scaffolds, as diffusion 
into a scaffold may be faster and more complete. 
4.3.2.4 Conclusion 
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PEG-QK has been shown to promote angiogenesis in PEG hydro gels, without the 
use of sequestered growth factor proteins. Just as researchers have come to agree that it 
is more advantageous to include cell-adhesive peptides rather than full-sized ECM 
proteins in engineered matrices, this novel work introduces the use of a covalently linked 
angiogenic peptide, PEG-QK, as a comparable and possibly more favorable angiogenic 
factor than PEG-VEGF for covalent incorporation in scaffolds to promote angiogenesis. 
4.4 Tethered Ephrin Al, a cell-cell signaling protein was studied for its 
effect on vessel morphology in vivo. 
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The work described below is adapted from the manuscript, currently available 
online titled: "Biomimetic Hydrogels with Immobilized EphrinA1 for Therapeutic 
Angiogenesis", Jennifer E. Saik1, Daniel J. Gould1, Aakash K. Keswani 1, Mary E. 
Dickinson2, Jennifer L. West1' t Biomacromolecules. 2011 June 6. 
4. 4.1 Introduction 
Ephrin A1 is a signaling molecule that signals through the EphA receptor to 
stimulate cell-cell adhesion, and it plays a critical role in cell guidance in 
development and in adult tissues (Mellitzer, Xu et al. 2000). The signaling Ephrin 
and the Eph receptor are both membrane bound, and signaling through the receptor is 
thought to effect cell adhesion and morphology through Nck and SHEP1 which 
directly affect cell adhesion and the cytoskeleton (Mellitzer, Xu et al. 2000). In 
endothelial cells, this receptor ligand pair has been shown to enhance cell-cell 
adhesion and signaling (Davis, Gale et al. 1994). The involvement ofthe ephrin-eph 
signaling cascade in physiology and in disease states has been recently elaborated in 
recent works (Pasquale 2008) and has been shown to be bidirectional. In the past, 
others have incorporated ephrin-A1 into synthetic hydrogels to study endothelial cell 
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adhesion, and have suggested that it is dependent on alpha(v)beta3 integrins (Moon, 
Lee et al. 2006). These studies demonstrated the angiogenic potential of synthetic 
materials functionalized with this protein (Moon, Lee et al. 2006). For this reason a 
recombinant fusion protein containing the extracellular binding portion ofEprinA1 
and the Fe fragment of human IgG (R&D Systems, Minneapolis, MN) was PEGylated 
for studies in vitro by Jennifer Saik, a student in the West lab, and many of the in 
vitro findings can be found in the publication related to this topic (Saik and Gould et 
al. 2011 ). Briefly, in vitro, the protein was found to have stimulatory effects on cell 
tubule formation and the deposition of extracellular matrix. The studies below 
represent the in vivo findings of the effect of the PEGylated protein on the induced 
vessel morphology in the modified corneal micropocket assay described previously in 
this chapter. 
4.4.2 Methods 
Conjugation ofthe protein and the in vitro methods are described briefly above 
and in the manuscript associated with this work (Saik, Gould et al.). In vivo, the 
micropocket surgery was performed as described above and the analysis of vessel 
morphology was performed as described above and in chapter 2. 
In order to measure the cellular association and morphology for in vitro 
studies, three dimensional images of the cultures at several timepoints were collected, 
and then analyzed using Farsight software. Farshight is available free online 
(http://farsight.freedesktop.org/releases/farsight2) and aids in the quantification of 
cellular interactions, such as the percent shared borders, which reflects cellular 
interconnectivity. 
4.4.3 Results 
PEG-Ephrin AI in vitro 
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First, several comparisons were made of the PEG-Ephrin AI in vitro to 
determine the ability of human umbilical derived endothelial cells (HUVECS) seeded 
on the surface of gels containing PEGylated Eprin AI to form tubules. A dose-
dependent effect was seen, where higher doses of the bound Ephrin A I stimulated 
more tubule formation and this effect was shown to be long lasting in contrast to 
controls containing no PEGylated Ephrin A I. This effect was shown to be reversible 
in the presence of soluble EphA2 which is a natural binding partner for the tethered 
Ephrin AI, thus demonstrating the importance of the PEGylated Ephrin-AI 
interaction. Next, three dimensional cultures were established using cocultures of 
Human Umbilical Vein Endothelial Cells (HUVECs) and Human Brain Derived 
Pericytes, in order to test the effects of increasing PEG-Ephrin A I in vitro on cell 
association at different timepoints over one week. All three dimensional co-cultures 
containing the tethered Ephrin AI were shown to possess more cell association in 
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comparison to controls (figure 4.6). Figure ( 4.6) demonstrates the quantification of 
the cellular interactions from the images of the cellular three dimensional cultures. 
Measuring cell shared borders helped to demonstrate an effect of Ephrin A 1 in 
both its concentration and over time. This type of quantification may prove useful in 
future in vitro studies of endothelial cell three dimensional cultures. 
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Figure 4.6: In Vitro quantification of Ephrin Effects. In order to quantify the resulting tubule 
formation , the parameter percent shared borders was calculated to examine the percentage of 
each cell 's edges that were interacting with other cells to form tubule networks. Robust tubule 
formation was seen at early time points using low PEG-ephrinA 1 concentrations and at late 
timepoints using higher PEG-ephrinA 1 concentrations . A two-way AN OVA shows a significant 
effect of PEG-ephrinA 1 concentration and time. 
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PEG-Ephrin AI in vivo 
Next, an evaluation of the effects of the PEGylated Ephrin A1 on vessels in 
vivo was undertaken. Small hydrogel disks were fabricated and implanted as 
previously described (Moon, Saik et al. 2010; Poche, Saik et al. 2010) in the 
flk1::myr-mCherry mouse cornea. One group contained releasable PDGF-BB alone 
as an angiogenic factor and the other contained releasable PDGF-BB along with 
tethered PEG-Ephrin A1 to stimulate angiogenesis. Implanted gels were then allowed 
two weeks for vessel invasion and growth, and were then harvested and resultant 
vessels were imaged and analyzed. Figure (4.7) describes the findings from these in 
vivo studies. 
Overall, PEG-Ephrin A 1 was shown to stimulate cellular interactions and 
tubulogenesis in vitro and 
was shown to induce 
vessels with more branch 
points, greater density and 
smaller diameters in vivo. 
Complete microvascular 
quantification from these 
studies was described in 
aforementioned 
manuscript and is shown 
PDGF 
PDG F and 
PEG-ephrinAl 
Figure 4.7: In Vivo effects of Ephrin A1 . Bioactive hydrogels 
incorporating releasable PDGF-88 and PEG-ephrinA 1 (B) 
showed a more robust vascular response than hydrogels 
with releasable PDGF-88 alone (A) when implanted into the 
mouse cornea. 
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in table 4-1 below. 
In conclusion, PEG-Ephrin Al was shown to effect the formation of 
endothelial tubules in co-culture systems in vitro. PEGylated Ephrin Al was shown 
to affect blood vessel morphology. PEG-EphrinAl in this system provided another 
unique pathway to control microvessel morphology, where it increased density and 
complexity of the network, but also stimulated formation of smaller diameter vessels. 
This signaling molecule may provide a unique tool in the future for patterning 
biomimetic hydro gels for use in the formation of micro vascularized constructs with a 
need for high density, small-diameter microvessels. 
A table was constructed to compare the resulting vessel morphologies from 
studies in this chapter (PEG-PDGF-BB, PEG-QK, and PEG-Ephrin Al) and the target 
vessel morphologies from chapter two and is shown below. 
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Treatment I Measured Vessel Fractal Lacunarity Average 
Morphology Density Dimension Vessel 
Diameter (um) 
PDGF-BB 160ng 0.18 1.67 0.7 6.9 
VEGF-A 0.2 1.75 0.5 8.5 
VEGF-A and PEGVEGF-A 0.22 1.77 0.69 7 
Skin 0.24 1.8 1.03 7.27 
Cortex 0.24 1.75 0.97 8.45 
PDGF-BB and PEGPDGF-BB 0.3 1.79 1 10.5 
Kidney 0.36 1.89 1.92 8.55 
VEGF-A and PEGQK 0.45 1.87 1.7 8 
PDGF-BB and PEG Ephrin A 1 0.5 1.9 2.5 7 
Table 4.1 Comparison of covalent factors and target vessel morphologies. In this 
table, all the measured morphological parameters from the experiments conducted in 
chapter four are shown as are several of the measured parameters from kidney, skin 
and cortex. As described, PEG-PDGF-BB could prove valuable in the design of 
microvascular scaffolds for skin, while PEGQK could prove useful in design of kidney 
vascular scaffolds, while PEG-EphrinA 1 could be used to induce extremely 
vascularized scaffolds with high complexity and average vessel diameters. 
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4.5 Conclusions 
In conclusion, several different growth factors and cell signaling molecules 
were studied to determine their effects on cell growth in vitro and on host vasculature 
in vivo in the mouse corneal micropocket assay. The provision of a sensitive 
quantitative tool to examine the morphological properties of induced vessels allowed 
for sensitive statistical quantification of treatment groups, and has contributed 
dramatically to studies of new biomaterials and novel scaffolds. These systems can 
now be adapted for further use in the development of biomaterials for tissue 
engineering applications. The results presented here demonstrate the potential of 
biocompatible, PEG-based hydrogels containing immobilized growth factors as a 
promising methodology to engineer a microvascular system within tissue engineered 
constructs for regenerative medicine applications. 
In this chapter, I was able to probe the effects of many different covalently 
bound growth factors and cell signaling ligands using the modified mouse corneal 
micropocket assay in conjunction with my novel microvessel quantification tool. 
This chapter highlights the functionality of this robust system, in exploring the host 
angiogenic response to biomaterials. This work should provide a platform for future 
studies of angiogenic biomaterials as well as for investigation of microvascular 
morphology. In terms of tissue engineering applications, this work has helped to 
provide new strategies for microvascular induction and host integration, and in the 
following chapter, I explore pre-vascularization strategies in vitro for rapid 
anastomosis and integration in vivo. 
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Chapter 5: Cell-based Studies: Towards Anastomosis between the Host 
Vessels and Implanted Encapsulated Endothelial Cells 
174 
This final chapter is designed to reflect more recent studies involving the use 
of endothelial cells pre-encapsulated within hydrogel constructs for host implantation 
and integration. The findings of these studies are reported in the article titled 
"Building Vascular Bridges: Advances in Tissue Engineering" authored by 
Jennifer E. Saik1and Daniel J. Gould1, Mary E. Dickinson2 and Jennifer L. West1• tin 
preparation for submission. 
5.1 Introduction 
The formation of stable and functional vessels remains a tremendous challenge 
for replacement of damaged or diseased tissues. Strategies developed to address this 
issue include those described earlier in this thesis, whereby the host vasculature is 
induced to grow into tissue engineered constructs to provide a rapid supply of 
nutrients and metabolites. Also previous studies have demonstrated the long term 
nature ofvessels induced in response to the growth factors utilized in this project. 
One alternative approach involves the encapsulation of cells within constructs capable 
of forming vessel networks. The provision ofthese encapsulated cells would allow 
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for the rapid formation of a microvasculature in vitro and then the anastomosis of this 
pre-formed microvasculature with the host induced vessels. 
This was the specific goal of the set of experiments described in this chapter: 
to develop a pre-vascularized construct for rapid perfusion after implantation. A 
deeper understanding of functional vessel anastomosis may contribute to the fields of 
tissue engineering, vessel biology, and cancer. Vascularized tissue constructs have a 
wide variety of applications in the replacement of damaged or diseased tissues 
including peripheral limb ischemia and chronic diabetic wounds. While many 
approaches utilize potent growth factors to induce angiogenesis, an alternative 
employs cells themselves to recruit vessels via naturally secreted chemokines. Cell-
based approaches eliminate the time-delay inherent in releasing growth factors and 
reduce the necessary concentration of potent growth factors. In the current study, cell-
laden hydrogels were evaluated using a mouse cornea micropocket angiogenesis 
assay (Moon, Saik et al. 2010; Poche, Saik et al. 2010), a reproducible and 
quantifiable assay in a normally avascular tissue (Kenyon 1996). Flkl-myr::mCherry 
transgenic mice were utilized, which display endothelial specific fluorescence to aid 
in capillary visualization (Larina 2009). 
5.2 Methods 
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5.2.1 Cell Culture and Encapsulation 
Two cell types were chosen for the in vitro formation of tubules for 
anastomosis. These included b.End3 cells (brain derived endothelial cells) and 1 Ot Yz 
cells (pericytes). Previously, b.End3 cells have been demonstrated to mimic 
properties of the blood brain barrier in their diffusive and transport characteristics 
(Omidi, Campbell et al. 2003). B.End3 cells and 10tl/2 cells ( Cambrex/Lonza, 
Walkersville, MD) were used between passages 2 and 6 and cultured. Cells were 
maintained in endothelial cell growth medium (EGM-2 media, Cambrex/Lonza). 
Before 3D encapsulation, cells were labeled with Celltracker Red CMTPX 
(Molecular Probes). 50 J.lg Celltracker Red was dissolved in 4 J.ll DMSO and diluted 
in cell media for a final concentration of 5 J.lglml. b.End3 cells were incubated in the 
prepared media for 45 min at 3 7°C. Labeling was visually confirmed via fluorescence 
microscopy, and labeling media was replaced with normal EGM-2 medium (without 
VEGF). Cells were washed with phosphate buffered saline (PBS) before enzymatic 
lifting using trypsin/EDT A and subsequent encapsulation as described below. 
The synthetic scaffold chosen to encapsulate the cells in this study was a poly 
(ethylene glycol) (PEG) based hydrogel comprised of a biocompatible polymer with 
tunable mechanical properties (Hahn 2006). It was used to encapsulate a co-culture 
ofbEnd.3 endothelial cells and 1 OTl/2 pericyte precursors under mild 
photocrosslinking conditions in order to retain cell viability. These PEG-based 
hydrogels act as a "blank slate" through their resistance to protein adsorption and 
177 
subsequent cellular adhesion. Inclusion of immobilized cell-adhesive factors such as 
the fibronectin-derived peptide RGDS allow for precise mediation of cell-material 
interactions. The hydrogels were rendered biodegradable by incorporating a matrix 
metalloproteinase-sensitive peptide into the polymer backbone (West and Hubbell 
1999). Collagenase-degradable hydro gels with encapsulated cells (3 x 10 7 cells/mL, 
labeled with Celltracker Red) were prepared. Briefly, PEG-PQ-PEG (0.1 g/mL) and 
acryloyl-PEG-RGDS (3.5 J..tmol/mL) were mixed with a cell suspension and 
photocrosslinked by exposing to long wavelength UV (365 nm, 10 mW/cm2) for 
7 min, using eosin y as the photoinitiator (0.3% w/v). 
5.2.2 Two Step Implantation 
In order to provide vessels at the site of implantation for rapid anastomosis, 
prior to implanting the tubule containing constructs, a unique implantation scheme 
was developed. Mouse corneas were prevascularized by implanting hydrogels 
containing 320 ng of soluble platelet-derived growth factor-BB and 80 ng fibroblast 
growth factor-2 (see figure 5.3). In these studies, n=10, where the experiment was 
performed with n=5 on two separate days. Experiemental quantification for the in 
vivo tubules comes from images of these implants. For the in vitro tubule 
quantification, n=8. 
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Figure 5.1: Schematic for the novel implantation scheme. First, angiogenic hydrogels are 
implanted in the cornea, 14 days time is allowed to pass so that induced vessels may 
create a vascularized pocket. Next, hydrogels with encapsulated endothelial cells are 
incubated in culture for 48 hours to induce formation of preformed tubu les. Finally the 
initial hydrogels are excised and replaced with the hydrogels containing cells. The tissue is 
harvested at several time points and examined for tubules and anastomosis. 
The new multi-step process was required for successful implantation and 
anastamosis because the cornea is normally an avascular site. The goal was to prime 
the recipient vessel bed in order to allow for a rapid anastomotic event. 
5.3 Results 
5.3.1 Cell Encapsulation and Tubule Formation 
Figure 5.2: Encapsulated cells display high viability and robust tubule formation in 
vitro. A co-culture of bEnd.3 and 10T1/2 cells at a 4:1 ratio in matrix 
metalloproteinase-sensitive PEG-based hydrogels demonstrate 82% ~ 1.5% 
viability (A, green= live; red = dead) after culturing for 48 hours. Cells also form 
robust tubules as visualized via actin (red) and nuclei (blue) staining . The white 
arrow highlights an example of a tubule with interconnecting cells. Scale bar= 50 
um. 
b.End3 cells were noted to form tubules in PEG-based hydrogels when 
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combined with 10tl/2 smooth muscle precursor cells in vitro (figure 5.1). The ability 
to form these tubules in vitro is of critical importance to the success of implantation 
and integration. These cells proved ideal because they are observed to form tubular 
networks within 48 hours of in vitro cell culture. Encapsulated cells were allowed to 
culture for 48 hours before implantation, at which point staining confirmed high 
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viability of 82% ± 1.5%. Extensive tubule formation with branching, cell-cell 
interconnections, and network formation was visualized via actin staining (figure 5.1). 
In addition, cell types were encapsulated alone, and examined for tubule 
formation and viability. When encapsulated in the hydrogel constructs and cultured 
in vitro the 10 t Yz cells remained distributed throughout the scaffolds, in a balled 
formation, lacking any tubulogenic structures. Likewise, the bend.3 cells alone when 
encapsulated did not form extensive tubular networks in comparison to the co-culture. 
These findings are demonstrated in figure 5.2. 
l OTl/2 
bEnd.3 
Figure 5.3: Encapsulated individual cell types do not form tubular networks in 
vitro. These cell types do demonstrate good viability, as represented by the 
high proportion of green cells (live stain) versus red cells dead stain) in the left 
live/dead staining . Frames on the right show the dapi (blue)/ phalloidin (red) 
images of the individual cell cultures, where there is not noticeable robust tubule 
formation . Given neither cell type forms reliable or robust tubules when alone 
in culture, the use of the co-culture system is validated for in vitro tubule 
formation. 
5.3.2 Two Step Implantation and Anastomosis 
Implants containing encapsulated growth factors induced an angiogenic 
response in the areas of the hydro gels. Two weeks after the implantation of the 
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growth factor containing hydrogels, the implants were surgically excised, leaving 
only a vascularized pocket, an ideal site for the transplantation of the cell containing 
implants. Cell-laden implants were soaked in media containing 12 nmol/ml PDGF for 
2 hours before being inserted, in order to ensure their survival and to continue to 
sustain their tubulogenic potential. Three days after implantation, corneas were 
examined for anastomosis and perfusion using confocal microscopy. This new and 
unique implantation scheme represents a novel approach to creating a pre-
vascularized bed for implantation, and is a valuable contribution for future cornea 
based implantation studies. 
Cherry-labeled capillaries sprouting from red blood cell-filled arterioles were 
seen connecting to cell-formed tubules (Fig 5.4 A-C). The presence of the originally 
seeded bEnd.3 cells in the tubules was confirmed using immunohistochemistry to 
stain for the middle t antigen, which was used to immortalize the bEnd.3 cells 
(Rothermel2005) (Fig 5.4 D-F). Image stacks of the immunohistochemistry were 
processed with both Imaris to provide a three dimensional image (D) and with Imera 
to recreate a three dimensional volume rendering (E and F) that clearly shows a 
region of anastomosis and red blood cells inside the encapsulated micro-tubular 
network. Notably, 72% of the cell-formed tubules contained red blood cells, 
confirming their functionality. These functional tubules had an average diameter of 8 
f..tm while nonfunctional tubules had an average diameter of 4 f..tm (Fig 5.4 G). 
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Figure 5.4: Anastomosis between cell-formed tubules and host vasculature. Transgenic mice with 
fluorescently-tagged endothelial cells (red) enable visualization of smaller vessels (A, red arrow) 
branching from red blood cell filled arterioles 12 1-1m into the hydrogel. B) cherry-labeled capillaries (red 
arrow) connect to unlabeled cell-formed tubules containing red blood cells (yellow arrow) 32 1-1m into 
the hydrogel. C) Cells are seen spreading (yellow arrow) and forming tubules as deep as 58 1-1m into 
the hydrogel. D-F) To confirm the connection between implanted cells and host vasculature, bEnd.3 
cells were stained for expression of the middle t antigen (green). D) Cherry labeled vessels 
anastamose to middle t antigen-positive bEnd.3 cells in a 3D rendering . E) A three dimensional 
rendering of red labeled host vasculature connecting to green labeled bEnd.3 cells confirms the 
presence of red blood cells (dark blue) in the cell-formed tubule. F) Upon closer examination , the 
precise location of anastomosis (red arrow) and presence of red blood cells (yellow arrow) is visible. 
G) The tubule diameter confirms that larger diameter tubules (8 1-1m) are similar in size to host 
vasculature and contain red blood cells while smaller diameter tubules (4 1-Jm) remain nonfunctional. 
H) 72% of cell-formed tubules contain red blood cells. 
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5.4 Discussion 
The ultimate product of this study was the formation of a prevascularized 
tissue engineered construct, which was then successfully anastamosed to the host 
microvascular system and perfused with host red blood cells. This work presents the 
first precise visualization and confirmation of anastomosis between tubules formed by 
self-assembling cells in vitro and the host vasculature only 72 hours after implantation 
in a synthetic material. Additionally, the time of in vitro incubation was shortened to 
only 48 hours, and networks formed by encapsulated bEnd.3 and IOTI/2 cells were 
maintained once implanted in vivo. 72% of cell-formed tubules were perfused with 
red blood cells after only 3 days in the mouse cornea. 
PDGF has previously been shown to induce an angiogenic response in the 
mouse cornea model (Saik, Gould et al. 2011) and was used to enhance vessel growth 
into the cornea similar to vascular endothelial growth factor significantly increasing 
vessel density. Previous studies had demonstrated the importance of in vitro 
incubation before implantation (Peters 2002) but required at least five to seven days 
incubation time prior to anastomosis (Chen, Aledia et al. 2008). For ultimate 
translation into clinical applications with cells derived from human patients, this work 
reduces the time of incubation before implantation and shortens the time to 
anastomosis to 72 hours. Furthermore, while long term stable vessels were formed in 
natural matrices (Koike, Fukumura et al. 2004), a synthetic PEG-based polymer can 
be used as a more advanced platform for testing and identifying key processes in 
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vessel development and anastomosis. This system is widely applicable to vessel 
development and disease, including ischemia and organ transplant, and will likely 
shed insight on mechanisms and therapies. Future studies of this in vivo assay will 
pinpoint the exact moment of anastomosis and the required factors. Furthermore, this 
technological feat will allow for greater development in complexity and scale, 
including expansion of incorporated cell types and implant locations. 
Some limitations of this study include the two step process itself, during 
which, the surgical removal of the previously implanted growth factor containing 
hydrogel is technically very challenging, and should only be attempted after 
successful mastery of the primary hydrogel implantation. The site within the cornea 
is very different from other potential implantation sites due to it angiogenic and 
immune privilege. The goal of primary vessel induction is to pre-vascularize, 
effectively reducing the angiogenic privilege. It would be interesting to find out if the 
immune privilege is maintained in this setting. Furthermore, other sites will not 
contain the anti-angiogenic factors and stroma like the cornea possesses. This may 
make other sites more amenable to anastamosis and host integration, and could reduce 
the process to a one step implantation. 
Future studies involving this system will likely focus on the anastomotic 
requirements, as well as long term studies of integration of these cells. Ideally, long 
term tracers of the cells can be incorporated to monitor the cell remodeling over time. 
The major leap this project demonstrates is the dramatic decrease in incubation time 
in vitro and the time required for anastomosis in vivo, ofwhich both factors will be 
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critical to the development of clinical strategies for tissues engineering in the future. 
Furthermore, this technique could allow for determination if the angiogenic privilege 
of the cornea is coupled to the immunogenic privilege. Studies to determine this 
might include two step induction then implantation with hydrogels containing 
immunogenic stimuli, versus primary implantation without induction of vessels. 
In conclusion, this study has provided insight into rapid anastamosis and 
integration of pre-tubularized tissue scaffolds and the host microvasculature. 
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Chapter 6: Conclusions and Future Directions 
In this thesis, I have described a coordinated effort to optimize tissue 
engineering scaffolds through several approaches. These approaches included the 
development of a new classification system for the scale-invariant measure of vessel 
networks, which will provide useful scalable design parameters for microvascularized 
constructs. Also I have fine tuned the angiogenic response, using a combination of 
the new vessel morphological measurements along with classical vessel morphology 
measures to induce vessels with similar morphology to those found in native skin, 
muscle and brain. I have adapted new biomaterials and tested their feasibility and 
utility in vivo with our unique corneal micropocket assay. Finally, I have combined 
cells in scaffolds in order to pre-vascularize corneal implants for rapid host 
anastomosis and perfusion. All of these efforts were designed to help address one of 
the major hurdles of tissue engineering, which is microvascularization of tissue 
engineered constructs. 
The first chapter described the incredible need for vascularized scaffolds, in 
order to help reduce the dramatic costs, both financially and with respect to the 
patients' immune suppression. It also detailed some of the most recent approaches to 
this problem requiring the development of a tissue engineered construct. Finally, 
advances in vessel biology and the use of angiogenic factors were described, in order 
to set up the use of these materials in this thesis. 
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The second chapter helped then to set up the yard stick for the measurement or 
quantification of the vascular response, using statistical methods to probe scale-
invariant measures of vascular morphology. These methods were critical to the 
studies, as they helped to augment the typical measurements of vessel branching and 
diameter as well as density. Furthermore, these measurements became crucial to the 
fine tuning of the angiogenic response in the third chapter. 
These studies provided information about normal early microvascular 
structures, but recently, other investigators have started to use the simple fractal 
analysis to look at vascular morphology in diseased vessels as well (Sabo, Boltenko et 
al. 2001; Jain 2005). Although most of the recent studies focus on tumor vessels and 
tumor vessel morphology, there may be other applications of the fractal analysis in 
non tumor vessel pathology, including stroke (Doubal, MacGillivray et al. 2010), 
ischemic disease, kidney disease (Sng, Sabanayagam et al. 20 10) and diabetic 
vasculopathy (Grauslund, Green et al. 2010). The future holds promise for the 
application of new, scale-invariant morphological analysis ofthe microvasculature, 
not just for engineering applications, but also for therapeutic and diagnostic purposes. 
In the future I would propose several studies using the expanded platform I 
have provided in chapter two to characterize diseased and remodeling vessels. In 
these studies, I would suggest examining histological samples from human tumors 
which are solid and are known to have a vascular component which is known to effect 
treatment. For instance, colon cancer is currently treated with AVASTIN, a 
therapeutic VEGF inhibitor, which improves survival and outcomes of effected 
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individuals (Labianca, Beretta et al.). It would be interesting to examine a cohort of 
patients who received A V ASTIN therapy prior to tumor resection, and to compare 
them to patients who had not received neo-adjuvant therapy in order to determine the 
effect on vessel fractal dimension and multifractal spectra ofneo adjuvant therapy. 
Sabo and colleagues were able to show clinical relevance of fractal dimension in the 
predicted morbidity and mortality of renal cell carcinoma, vascularized kidney tumor 
(Sabo, Boltenko et al. 2001). I would like to similarly probe colon cancer and to 
determine if tumor vessel fractal dimension after resection, predicts morbidity or 
mortality. Likewise, I would like to examine mesothelioma (Yano), and breast 
adenocarcinoma (Bachelot 2007), other known vascular tumors. Ultimately if the 
fractal dimension ofr the multifractal spectra proved useful, it could be a clinical test 
worth administering to provide patients with predictive information about their 
disease progression. Also, if the test shows some role for its use in neoadjuvant 
therapy, it could provide a new outcome to measure the effectiveness of future 
angiostatic or angiotoxic therapy. 
This method could also be used to examine remodeling in new, surgically 
implanted tissues. Currently, skin and soft tissue grafting is a common procedure 
performed in the united states, to repair tissue defects. Yet, little is known about the 
microvascular morphology following skin grafting. Wu and colleagues showed in 
2008 using a slice by slice tomography reconstruction (Brey, King et al. 2002) that 
the vessels in split thickness tissue grafts remodel over time (Wu, Kathuria et al. 
2008). They were only able to estimate vessel density. I think that this new 
190 
classification system could provide valuable morphological information in a similar 
study. I would like to examine flap vessel morphology and remodeling in the 
autografting and allografting of tissues for reconstructive therapy. 
Ultimately the use of this system could continue to provide more utility in 
future angiogenic tissue engineering strategies, as described in this thesis in the third 
chapter. In the third chapter, I used many different doses of growth factors in several 
different combinations in extensive experiments involving tremendous numbers of 
live implantations, in order to fully characterize the vascular response in the presence 
of our novel biomaterial scaffolds to diffusible growth factors. This allowed for the 
induction of a wide array of vascular responses, which were then characterized and 
plotted out to try and determine the relationship between the dose concentration of a 
combination of factors and the morphology of vessels generated. Later, this 
relationship was exploited, in order to induce vessels with similar morphology to 
those seen in the skin, muscle and sub ependymal zone of the brain. 
Importantly, in this chapter, the fine-tuning of vessel morphology allowed for 
the optimization of one set of inductive angiogenic factors to mimic normal host 
tissue morphology. This set of experiments provided a large data set for the 
optimization of PDGF, FGF and combinations of those factors. It could be used in 
future experiments where only one of the factors may be used to generate an 
angiogenic bed. Also the tuning has established a method for future studies, which 
could involve new factors or encapsulated cells to systematically implant constructs 
and slowly tune the desired morphological response. The utility of this tuning could 
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be in the mimicry of native microvessel beds, but it could also be in the identification 
of the minimum required dose for vessel induction and cell perfusion and survival. 
Future experiments should focus on the utility of inducing microvessel 
morphology. This method could be combined with live imaging and fluorescent 
markers of metabolism to identify if set morphologies allow for better perfusion and 
survival of encapsulated cells and scaffolds. Also these studies could isolate other 
morphological effects by encapsulating materials known to affect endothelial cells or 
supportive pericytes to determine their role in microvascular development, perfusion 
and remodeling. Importantly, the study described in chapter three has helped to 
benchmark key morphological parameters for measurement in future studies. It has 
also developed an in vivo platform for future use in the development of angiogenic 
and cell containing tissue engineering scaffolds. 
In the fourth chapter I described three recently published studies, where we 
examined the use of covalently bound factors, which mimic the activity of several 
growth and cell signaling peptides. In this section I described in depth the in vivo 
work, which represented my contribution to the projects. These studies were exciting 
applications for my method and they have helped to contribute to our knowledge of 
the use of these factors and peptides in vivo. These PEGylated factors will likely be 
used in future applications for the microvascularization of tissue engineering 
constructs. 
Again, this fourth chapter demonstrates the utility of the system developed in 
the third chapter in the design of angiogenic materials. It did so by using the new 
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platform involving both the micropocket assay and the quantitative techniques to 
probe the angiogenic nature of several new tethered angiogenic peptides. PEG-
PDGF-BB was one of the first demonstrations of a PEGylated angiogenic growth 
factor for tissue engineering design. PEG-QK provided one of the first examples of a 
PEGylated small peptide for angiogenic purposes for tissue engineering design. PEG-
Ephrin-Al studies demonstrated the value ofthe in vivo angiogenic platform in 
probing angiogenesis and helped to show that Eprin-Al may have future utility in 
tissue engineering strategies. Although loose comparisons were made in the table in 
this chapter between the vessels seen in these studies, future projects could 
incorporate these covalent factors and optimize their induced vessel morphology, over 
time in vivo. Ideally, each of these factors could be optimized for vessel induction 
and then used in projects to induce microvascularization of tissue scaffolds in vivo for 
use in therapeutic human applications. 
In the final portion ofthis project, in the fifth chapter, I describe an experiment 
which has delivered dramatic results. The goal was to induce in vivo anastomosis 
between host and encapsulated cells, to form a prevascularized construct for tissue 
engineering applications. This was possible through the use of a new commercially 
available cell type, the bend cell, which in vitro replicates some of the functions ofthe 
normal blood-brain barrier. 
Critical to this aim was the development of a novel implantation scheme, 
which allowed for induction of a vascular bed prior to implantation of the cell-
containing scaffolds in the corneal micropocket. I first implanted the cornea with an 
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angiogenic implant for induction of the vascular response, and then with pre-
tubulogenic encapsulated brain endothelial cells. This novel two-stage implantation 
scheme will set the stage for future examination of the critical factors regulating host 
microvessel anastomosis. This two step process was critical to the success of 
anastamosis early in these implants, because the initial implantation of growth factor 
laden hydrogels helped to prime the recipient site location for implantation. The 
priming of the vascular response provides in intermediate step, which could be 
utilized in conjunction with what I developed in the third chapter, to fine tune the 
induced recipient bed for anastamosis. This could be valuable to induce vessels with 
morphology similar to normal vessels in the tissue which encapsulated cells are 
normally found in. In effect this allows for the priming step to induce vessels similar 
to the target tissues. Also, this step could be used to induce the minimum necessary 
vasculature to support a cell containing scaffold. This step provides one more 
advantage, which is the dissociation of the administration of inductive growth factors 
from the implantation of encapsulated cells. This could be critical in applications 
involving cell types which may be sensitive to growth factors, like stem cells which 
are desired to stay in a less differentiated success for tissue engineering applications. 
Future studies should involve the use of other cell types encapsulated in the 
hydrogels for implantation in the second step, either alone or in conjunction with 
endothelial cells, to allow for rapid host integration. These studies could help to 
develop the platform for the integration of tissue engineered scaffolds containing cells 
for regenerative applications. Also other sites, like the omental cavity and the dorsal 
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skin fold should similarly be implanted and examined for host integration, following 
success in the cornea, to see if these more accessible sites, which are not normally 
angiogenically privileged like the cornea, could be useful for future engineering 
strategies. 
The in vivo corneal micropocket assay should continue to be used to identify 
new angiogenic materials, and to optimize angiogenesis and cell integration. These 
methods should be adapted further for more cell based scaffolds, in order to test the 
feasibility of cell laden scaffolds for return of function or partial function of different 
organs, like liver, pancreas, and kidney. Cells derived from these organs or stem cells 
capable of differentiating to the adult cells found in these organs which are 
responsible for synthesis of secreted hormones and cytokines should be tested in the 
corneal model first, then scaled to other larger models. Also, the morphological 
quantification system should be used to look at diseased vessels, like those found in 
human tumors and in microangiopathic diseases, including diabetes and coronary 
artery disease. Insights into the microvascular morphology of these disease states 
could provide more data for models of disease pathology and could help us to better 
understand aberrant vessel morphology. Finally, biomaterials that were identified as 
valuable for tuning the angiogenic response in this thesis should be tested in other 
angiogenic assays and for use in tissue applications to move them towards use in 
humans. 
Some of the future implications of this work will be in helping to design tissue 
engineered constructs for use in humans, for optimization of angiogenic scaffolds, 
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optimization of cell-laden hydrogels, and for fine tuning microvascular morphology 
in vitro and in vivo. 
In closing, this thesis has been an excellent and rewarding opportunity to help 
to advance the field of tissue engineering by designing new strategies to overcome the 
hurdle of engineering microvascularized tissue constructs. In the future, these 
methods will be utilized in similar projects to create constructs for further study of 
tissue engineering constructs and as potential therapeutics for the use in treatment of 
human diseases. 
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Appendix 
Section 1: Anova tables from dose escalation studies 
PDGF/ PDGF/ PDGF/ PDGF/ PDGFI PDGFI PPDGFI PDGFI PDGF/ PDGFI PDGF PDGF PDGF PDGF PDGF PDGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF 7days 7days 7days 14days 4days 14days 7days 7days 7days 14days 4days 14days ?days ?days ?days 14days 14days 14days 14days 14days 14days 14days 640nc 160na 40na 640n 160n 40nc 640na 160na 40no 640na 160na 40na 640/160na 1 60/40n 40110na 6401160na 160/40na 40110na 87121nc 189/47n 320/80n 88122na 
PDGF 7davs640na ns o.o· ns 0.01 0.01 ns 0.01 0 01 ns ns 1101 ns 0.05 0.01 ns 0 01 n n1 0.01 0.05 ns 001 
POGF 7rl•v< 1 Rnnn 0 01 ns ns nm ns 0.05 0.01 005 ns 0 01 ns ns 
_0.01 ns 0.05 0 01 0 01 n< ns ~01 
PDGF 7davs40na 0.01 ns ns 0.01 ns ns 0.01 001 ns O.o1 0.01 ns 001 ns ns ns 0.05 0.01 ns 
PDG F · 4rlavs R40nn ns 0.01 ns n< nm n< ns 0.01 ns ns ns ns ns n n· n n~ ns ns ns 
PDGF 14davs 1BOno 0.05 ns ns 0.01 ns ns 0.05 0.01 ns ns ns ns ns ns ns O.o1 ns 
PDGF 14 davs 40nc 0.01 ns ns 001 on· ns nm Qll1 ns 001 ns ns ns 001 001 ns 
FGF 7davs 640nc 0.05 0.01 ns ns 0.01 ns ns 001 ns n n~ n n1 ruJ1 ns ns 0.01 
FGF 7davs 160na 0.05 ns ns ns O.o1 ns ns 0.05 ns ns ns ns 0.01 ns 
FGF 7davs 40na 0.01 O.n1 ns O.Ut 001 ns 0.01 ns ns ns 0.01 0.01 ns 
FGF 14davs 64Dna ns 0.01 ns ns 0.05 ns 005 0.01 n n1 ns ns_ 0.05 
FGF 14davs 160na 0.01 ns ns ns ns ns 0.01 0.05 ns ns ns 
FGF 14davs40na nnt OJl1 _ns 0.01 ns ns ns 0.01 0.01 ns 
I PnGFIFGF 7rl""sR40/1Rnnn 0.05 0.01 ns 0.01 0 01 0 01 ns ns 0.01 
PDGFIFGF 7days 160/40na ns ns ns 0.05 0.05 ns ns ns 
PDGFIFGF 7davs40/10na 0.01 ns ns ns ns 0.01 ns 
PDGFIFGF 14davs6401160n no· 0 01 001 ns ns 001 
PDGFIFGF 14davs 160/40na ns ns ns 0.01 ns 
PQGFIFGF 14dalls40/10na ns 0.05 001 ns 
PPDGFIFGF 14da s87121n 0.05 0.01 ns 
, PDGFIFGF 14davs 189/47na ns ns 
PDGFIFGF 14davs320/80na 001 
PDGFIFGF 14da s8R/22nn 
TableA1: Comparison of Vessel Density From Experimental Groups Using Analysis of Variance 
and Post- Hoc Tukey Test. ANOVA testing was performed on the mean values from the vessel 
density measurements, and then a post hoc tukey's test was applied to identify differences between 
the experimental groups. This table represents the output differences from the Tukey test, in the 
comparison of the means of each group. Differences between means that were above the score 
needed to signify a difference with a p value of at least 0.05 are represented by the number 0.05; 
those with a difference between means with a p value of at least 0.01 are represented with 0.01 in 
the table. Those comparisons which did not have significant differences between means are 
represented with ns in the table. 
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PDGF/ PDGFI PDGFI PDGFI PDGFI PDGFI PPDGFI PDGFI PDGFI PDGFI 
PDGF PDGF PDGF PDGF PDGF PDGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF 
?days ?days ?days 14days 14days 14days ?days ?days ?days 14days 14days 14days ?days ?days ?days 14days 14days 14days 14days 14days 14days 14days 
640ng 160na 40na 640na 160na 40na 640n 160n 40na 640na 160na 40na 6401160n 160140n 40110n 640!160n 160/40na 40110na 87/21na 189/47n 320180n 88122na 
PDGF 7davs640na ns 001 ns 0.05 0.01 ns 005 001 ns ns 0.01 ns ns 0.01 ns 0.05 001 001 ns ns 0 05 
PDGF ?da s 160na 0 01 ns ns 001 ns ns 0.01 ns ns 001 ns ns 005 ns ns 0.01 . 0 01 ns ns 0.05 
PDGF 7dav<40no 0.01 0.05 ns 0.01 0.01 ns O.Dl 0.01 ns 0.01 0.01 ns 001 0.01 ns ns 001 0.05 ns 
PDGF 14rl"'"R4nna ns 001 ns ns 001 ns ns 001 ns ns ns ns ns 0.01 0.01 ns ns 0 05 
PDGF 14davs 160na 001 ns ns 0.01 ns ns n n1 001 ns ns 0.05 ns ns ns ns 0 05 ns 
PDGF 14 davs 40na 0 01 001 ns 0 01 _Q,01 ns 0.01 001 001 001 0.01 ns ns 0.01 005 0.05 
FGF 7davs640na ns 001 ns ns 001 ns ns ns ns ns 0.01 0 01 ns ns 0.05 
FGF ?davs 160na 0 01 ns ns 0.01 0 01 ns ns ns ns ns ns ns 0 05 ns 
FGF ?davs 40na 
. 001 _llU1 ns_ 0.01 O.Dl 001 0.01 0.01 0.05 0.05 O.Dl 0.05 0.05 
FGF 14rl"'" R4Dnn ns 001 ns ns ns ns ns 0.01 001 001 ns 0.05 
FGF 14davs 160na 0 01 ns ns ns ns ns 0.01 0 01 ns ns ns 
FGF 14da s40na 0 01 001 0 01 0.01 O.Dl ns ns 001 0 05 0.05 
PDGFIFGF ?davs 640/160na ns 001 ns 0.05 001 001 ns ns 0.05 
PDGFIFGF?da s160140na ns ns ns 0.01 0.01 ns ns ns 
PDGF/FGF 7davs40!10na 001 ns ns ns ns 0.05 ns 
PDGFIFGF 14da s 6401160n ns 0.01 0.01 ns ns 0 05 
PDGF/FGF 14davs 160/40na ns ns ns 0 05 ns 
PDGFIFGF 14da s40/1 Dna ns 0 01 0 05 ns 
PPDGFIFGF 14davs87121n 001 0.05 ns 
PDGFIFGF 14davs 189147na ns ns 
PDGFIFGF 14da s 320/BOnn 005 
PDGFIFGF 14davsBB/22na 
Table A2: Comparison of Fractal Dimension From Experimental Groups Using Analysis of 
Variance and Post- Hoc Tukey Test. ANOVA testing was performed on the mean values from 
the fractal dimension measurements, and then a post hoc tukey's test was applied to identify 
differences between the experimental groups. This table represents the output differences from 
the Tukey test, in the comparison of the means of each group. Differences between means that 
were above the score needed to signify a difference with a p value of at least 0.05 are 
represented by the number 0.05; those with a difference between means with a p value of at 
least 0.01 are represented with 0.01 in the table. Those comparisons which did not have 
significant differences between means are represented with ns in the table. 
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PDGFI PDGFI PDGFI PDGFI PDGFI PDGFI PPDGFI PDGFI PDGF/ PDGFI 
PDGF PDGF PDGF PDGF PDGF PDGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF 
?days ?days 71dn~ys IR;days 1~dn~ns ~:~~~s ?days ?days ?days 14days 14days 14days ?days ?days ?days 14days 14days 14days 14days 14days 14days 14days R4n~n 1Rn~ 4 nn 4"~" s4on 1Rnnn Onn 64nn 1Rnnn 4nnn 6401160nn 160140n 40110nn 640/160nn 160/40nn 40/IOna 87121na 189147n 320/BOn 88122na 
PDGF 7davs640nn ns 0 01 ns 001 0 01 ns 001 001 ns 0.05 001 ns ns 0.01 n< 0 01 0 01 0.01 0.05 ns 0 01 
PDGF 7davs 160na 001 ns ns 0 05 ns ns_ JJ.Ot ns ns 0.01 001 ns 0.05 ns ns 0.05 . OJ]5_ _ns_ ns ns 
PDGF 7davs40na ns ns ns 001 ns ns ns ns ns 001 ns n< 0 01 n< ns ns ns 0.01 ns 
PDGF 14davs640na ns ns ns ns ns ns ns ns 001 ns ns ns ns ns ns ns 0.05 ns 
PDGF 14davs 150na ns ns ns ns ns ns ns 0.01 ns ns n "1 n< n< ns n< n n1 n< 
PDGF 14 davs 40na 0.05 ns ns ns ns ns 0.01 ns ns 001 ns ns ns ns 001 ns 
FGF 7da s 640na 0.05 001 ns ns 001 ns ns 0.05 ns ns n 05 001 ns ns 0.05 
FGF 7rl"t< I RDnn ns ns n< n< n n1 n< n< n n1 n< n< ns ns 0 01 ns 
FGF 7davs 4Dna 0.05 ns ns 001 0.05 ns 0.01 ns ns ns ns 001 ns 
FGF ns ns 0.01 ns n< n< n< n< ns ns o no n< 
FGF 14rlavs 1RDnn ns 0 01 n< n< ns n< ns ns ns 0.01 ns 
FGF 14davs40nn 0.01 ns ns 001 ns ns ns ns 001 ns 
PnGFIFGF 7davsR40/160n 0.01 0.01 ns 0.01 n 01 001 001 ns 001 
PDGFIFGF 7davs 160/40nn ns ns ns ns n< ns o no n< 
PDGF/FGF 7davs4011 Onn 001 ns ns ns ns 001 ns 
PnGF/FGF 14d>~·s64D/1ROn 0.01 0 01 0.01 n< n< nm 
PDGFIFGF 14davs 160/40n ns ns ns 0.01 ns 
PDGFIFGF 14da s4011 Dna ns ns 001 ns 
PPDGFIFGF 14da s87121n ns 0.01 ns 
PDGFIFGF 14devs 189147n 001 ns 
PDGF/FGF 14davs 320/BOn 001 
PDGFIFGF 14davs88122nn 
Table A3: Comparison of Lacunarity Parameter (b) From Experimental Groups Using Analysis 
of Variance and Post- Hoc Tukey Test. ANOVA testing was performed on the mean values 
from the Lacunarity Parameter (b) measurements, and then a post hoc tukey's test was applied 
to identify differences between the experimental groups. This table represents the output 
differences from the Tukey test, in the comparison of the means of each group. Differences 
between means that were above the score needed to signify a difference with a p value of at 
least 0.05 are represented by the number 0.05; those with a difference between means with a p 
value of at least 0.01 are represented with 0.01 in the table. Those comparisons which did not 
have significant differences between means are represented with ns in the table. 
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PDGF/ PDGF/ PDGF/ PDGF/ PDGF/ PDGF/ 
PDGF PDGF PDGF PDGF PDGF PDGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF 
?days ?days ?days 14days 14days 14days ?days ?days ?days 14days 14days 14days ?days ?days ?days 14days 14days 14days 
640na 160na 40na 640na 160na 40na 640na 160na 40na 640na 160na 40na 640/160nq 160/40na 40/10na 640/160nq 160/40na 40/1 Dna 
PDGF 7davs 640na ns 0 01 ns 001 0.01 001 0 01 001 ns ns 001 001 001 0.01 001 ns 001 
PDGF 7davs 160na ns 001 ns 0.01 001 ns 0.01 0.01 ns 0.01 0.01 001 ns 001 ns 0.01 
PDGF 7davs40na 0.01 ns ns 0.01 ns ns 001 ns ns . 0.01 O.Dl ns JlOJ om ns 
PDGF 14davs 640na ns 0.01 ns 0.01 001 ns 0.01 0.01 001 0.01 001 0.01 ns 0.01 
PDGF 14davs 160na ns 0.01 ns ns 001 ns ns 0.01 001 ns 001 ns ns 
PDGF 14 davs 40na 0.01 ns ns 001 001 ns 001 0.01 ns 0.01 0.01 ns 
F.GEidavs 6'\0na 0.01 0.01 ns 00.1 _0.01 0..01 _r:tS. n n1 om 001 001 
FGF 7davs 160na ns 001 ns ns 001 0.01 ns 0.01 ns ns 
FGF 7da s 40na 0.01 0.01 ns 001 0.01 ns 0.01 001 ns 
FGF 14da s 640na 0.01 0.01 001 ns 001 001 0.01 001 
FGF14da s160na 001 0.01 0.01 ns 0.01 ns 0.01 
FGF 14da s40na 001 0.01 ns 0.01 001 ns 
PDGF/FGF 7davs 640/160na 001 0.01 ns 001 001 
PDGF/FGF 7davs 160140na 001 0.01 001 0.01 
PDGF/FGF 7dav.s40/1 Dna 001 ns ns 
PDGF/FGF 14da s 6401160n 001 001 
PDGFIFGF 14davs 160/40na 001 
PDGF/FGF 14davs40/10na 
Table A4: Comparison of Branch Points From Experimental Groups Using Analysis of 
Variance and Post- Hoc Tukey Test. ANOVA testing was performed on the mean values from 
the Branch Point measurements, and then a post hoc tukey's test was applied to identify 
differences between the experimental groups. This table represents the output differences from 
the Tukey test, in the comparison of the means of each group. Differences between means that 
were above the score needed to signify a difference with a p value of at least 0.05 are 
represented by the number 0.05; those with a difference between means with a p value of at 
least 0.01 are represented with 0.01 in the table. Those comparisons which did not have 
significant differences between means are represented with ns in the table. 
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PDGFI PDGF/ PDGFI PDGFI PDGF/ PDGFI 
PDGF PDGF PDGF PDGF PDGF POGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF FGF 
7days ?days ?days 14days 14days 14days ?days ?days ?days 14days 4days 14days 7days ?days ?days 14days 14days 14days 
640na 160na 40na 640nn 160na 40na 640na 160na 40nn 640nn 1160nn 40na 6401160na 160/40nc 40/10na 640/160na 160/40na 4011 On a 
PDGF 7davs 640na ns 0.01 ns 0.01 0.01 ns 0.01 001 0.01 0.01 0.01 0 01 ns 001 0.01 001 0 01 
PDGF 7davs 160na 0.01 n.o1 0.01 0.01 ns 0.01 001 0.01 0.01 0.01 001 ns 001 001 001 001 
_PDGF Jdavs40na n 01 n< n n1 nn1 ns ns ns n n1 n n1 n n1 nn1 n< ns O.OJ ns 
PDG F 14davs 640no 0.01 001 0.01 0 01 o.n1 0.01 n.n1 n n1 n n1 n< n n1 
. 0.01 0.01 001 
PDG F 14davs 160na 0 01 0.01 ns 0.01 ns 001 0.01 0.01 0.01 ns ns 0.01 ns 
PDGF 14 davs 40no 0.01 0.01 ns 0.01 ns ns 0.01 0.01 0.01 ns ns ns 
FGF 7davs 640nn 0.01 0.01 0.01 0.01 0.01 0.01 ns 0.01 0.01 0.01 001 
FGF 7davs 160no n n1 ns n n1 nn1 nn1 n n1 ns 0.01 0.01 ns 
FGF 7davs 40no 0.01 n< n< 001 0 01 ns ns ns ns 
FGF 14davs640nn n n1 nn1 n n1 nn1 ns ns ...D..OJ _ns 
FGF 14davs 160na ns 0.01 001 001 ns ns ns 
FGF 14davs40na 001 001 001 ns ns ns 
PDGFIFGF 7davs 6401160na 001 001 0.01 0.01 0.01 
PDGFIFGF 7davs 160140no 001 0.01 0.01 0.01 
PDGFIFGF 7da s4011 Ona ns 0.01 ns 
POGFIFGF 14davs 640!160n ns ns 
PDGFIFGF 14da s 160/40na ns 
PDGFIFGF 14da s40/10no 
Table AS: Comparison of Vessel Diameter From Experimental Groups Using Analysis of 
Variance and Post- Hoc Tukey Test. ANOVA testing was performed on the mean values from 
the vessel diameter measurements, and then a post hoc tukey's test was applied to identify 
differences between the experimental groups. This table represents the output differences from 
the Tukey test, in the comparison of the means of each group. Differences between means that 
were above the score needed to signify a difference with a p value of at least 0.05 are 
represented by the number 0.05; those with a difference between means with a p value of at 
least 0.01 are represented with 0.01 in the table. Those comparisons which did not have 
significant differences between means are represented with ns in the table. 
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Appendix Section 2: PEG PDGF Studies In Vitro Methods 
In this appendix section, the entire methods are described for the experiments 
pertaining to the studies on PEG PDGF. 
MATERIALS AND METHODS 
Cell Maintenance 
HUVECs (Lonza, Walkersville, MD) were cultured in endothelial growth 
medium EGM-2 (Lonza), supplemented with ascorbic acid, epidermal growth factor, 
fibroblast growth factor (hFGF-2), heparin, hydrocortisone, insulin-like growth factor, 
GA-1000 (gentamicin, amphotericin-B), 2% fetal bovine serum (Bulletkit, Lonza), 2 mM 
L-glutamine, 1 U/ml penicillin, and 1 J.lg/ml streptomycin (GPS, Sigma, St. Louis, MO, 
USA). IOTl/2 cells (American Type Culture Collection, Manassas, VA) were cultured in 
Dulbecco's modified Eagle's Medium with high glucose (DMEM, Gibco, North 
Andover, MA) supplemented with 10% fetal bovine serum and 2 mM L-glutamine, 1 
U/ml penicillin and 1 J.lg/ml streptomycin (GPS, Sigma). HUVECs were used from 
passages 4 to 6, and lOTl/2 cells were used from passages 15 to 19. Cells were 
maintained in an incubator at 37 °C and 5% C02 with media replenished every two days 
and subculturing as necessary. 
Synthesis and Purification of Poly( ethylene glycol) Diacrylate (PEGDA) 
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Poly( ethylene glycol) (PEG) (MW = 6000 Da; Fluka, Milwaukee, WI) was 
acrylated by reacting dry PEG with acryloyl chloride (Sigma, St. Louis, MO) and triethyl 
amine (TEA; Sigma) in anhydrous dichloromethane (DCM; Sigma) under argon gas 
overnight at 1 :4 PEG:acryloyl chloride and 1 :2 PEG:TEA molar ratios. The resulting 
solution was washed with 2 M K2C03 and allowed to separate into aqueous and organic 
phases overnight. PEGDA, in the organic phase, was dried using anhydrous MgS04 
followed by filtration. The polymer was precipitated in diethyl ether, filtered, and dried 
overnight under vacuum. PEGDA powder was stored at -20°C under argon gas. 
Synthesis and Purification of PEG-RGDS and Degradable PEG-PQ-PEG 
PEG-RGDS was synthesized by dissolving the cell-adhesive peptide, Arg-Gly-
Asp-Ser, (RGDS, American Peptide, Sunnyvale, CA) into anhydrous dimethyl sulfoxide 
and adding diisopropylethylamine. Dissolved RGDS was added to dry acryloyl-PEG-
succinimidyl carboxymethyl (PEG-SCM, Laysan, Arab, AL) at a 1.1: 1 PEG-SCM: 
RGDS molar ratio. This mixture was placed on a rocker overnight, dialyzed against 
water in a regenerated cellulose membrane to remove unwanted products, and 
lyophilized. 
Hydro gels were rendered degradable by the incorporation of a collagenase-
sensitive peptide, GGGPQGIWGQGK (abbreviated PQ), into the backbone of the 
PEGDA base polymer. The PQ peptide was first synthesized using Fmoc chemistry on 
an APEX 396 solid phase peptide synthesizer (Aapptec) and characterized using 
MALDI-TOF. The synthesized peptide was conjugated to PEG by following a similar 
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procedure as above with a 2.1 molar excess of PEG-SCM. Conjugation ofPEG-RGDS 
and PEG-PQ-PEG were confirmed using a gel permeation chromatography (GPC) system 
equipped with a PLgel column (5).lm, 500A, Polymer Laboratories, Amherst, MA) and an 
evaporative light scattering (ELS) detector (Polymer Laboratories). The PEG-RGDS was 
dissolved in 0.1% ammonium acetate in dimethylformamide (DMF) solvent and tested 
against a PEG-SCM standard. 
Synthesis and Purification of acryloyl-PEG-succinimidyl carbonate (PEG-
SMC) 
The organic solvents needed to accommodate the short half-life of the 
succinimidyl carboxymethyl reactive group on the PEG-SCM, which was purchased and 
used for conjugation ofpeptides, were not compatible with proteins used in this study. It 
was therefore necessary to synthesize a heterobifunctional acryloyl-PEG-succinimidyl 
carbonate (PEG-SMC) in-house. PEG-SMC is functionally similar to the commercially 
available PEG-SCM, but has a longer reaction half-life and can thus be used under 
aqueous conditions. 
PEG (Fluka/Sigma, MW = 3400 Da) was reacted with Ag20 (Sigma, St. Louis, 
MO), acryloyl chloride (Sigma, St. Louis, MO), and KI (Sigma, St. Louis, MO) in 
anhydrous dichloromethane (DCM; Sigma, St. Louis, MO) at 4 °C overnight, at molar 
excess ratios of 1.5, 1.1, and 0.3 respectively. Silver was removed by filtering the 
solution through Celite 521 (Spectrum Chemical Mfg Corp, Gardena, CA). A Rotovap 
was used to dry the solution prior to dissolution in di H20. The pH was adjusted to 3 with 
204 
HCl, and the solution was heated to 35 °C for 1 h. Iodine was removed by adding 
activated charcoal (Fisher, Pittsburg, PA), and the solution was filtered through Celite 
521. NaCl and DCM were added, followed by DCM extraction. Phase separation with 2 
M K2C03 was used to remove acid and chloride ions. Monoacrylated PEG was dried 
with sodium sulfate (Fisher, Pittsburg, PA), and a Rotovap was used to concentrate the 
solution followed byethyl ether precipitation and vacuum filtration. A four molar excess 
of disuccinimidyl carbonate (Sigma) was reacted with the monoacrylated PEG in 
anhydrous acetonitrile (Sigma) and pyridine (Sigma) under argon overnight. The product 
was dried using a Rotovap prior to dissolving in anhydrous DCM. The solution was 
filtered, and PEG-SMC was purified in acetate buffer (0.1 M, pH 4.5, 15% NaCl) via 
phase separation. The purified PEG-SMC was dried with anhydrous MgS04. PEG-SMC 
was precipitated into ethyl ether, filtered, and dried overnight under vacuum. PEG-SMC 
was characterized by proton nuclear magnetic resonance spectroscopy (1H-NMR, A vance 
400Hz; Broker, Billerica, MA, USA) and matrix-assisted laser desorption/ionisation-
time of flight mass spectrometry (MALDI-TOF; Broker Daltonics, Dillerica, MA, USA). 
The final PEG-SMC product was stored at -80 °C under argon. 
Synthesis ofPEG-PDGF-BB and PEG-FGF-2 
In-house synthesized acryloyl-PEG-SMC was dissolved in 50 mM sodium 
bicarbonate buffer (pH 8.5) and sterilized via filtration (0.2 )lm). PDGF-BB (ProSpec 
Bio, Israel) was conjugated to PEG-SMC using a 400:1 PEG-SMC: PDGF-BB molar 
ratio in 200 mM sodium bicarbonate buffer (pH 8.5) at 4 °C for 4 d (Figure 1 ). The 
-------------·-------------
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resulting PEG-PDGF-BB solution was lyophilized under sterile conditions. PEG-PDGF-
BB powder was reconstituted and stored in HEPES Buffered Saline (100 mM NaCl, 10 
mM HEPES in deionized water; HBS; pH 7.4) with 0.1% BSA at 4 °C for up to three 
months. A similar procedure was followed for PEG-FGF-2 (ProSpec Bio) at a 100:1 
PEG-SMC: FGF-2 molar ratio. All growth factor conjugations were confirmed via 
Western Blot analysis on a 15% Tris-HCL precast polyacrylamide gel (Biorad, Hercules, 
CA). Primary antibodies included rabbit polyclonal anti-PDGF-B antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA) and rabbit polyclonal anti-FGF-basic antibody 
(Millipore, Billerica, MA). Secondary antibody HRP-conjugated goat anti-rabbit IgG 
(Santa Cruz Biotechnology, Santa Cruz, CA) and an ECL ™ chemiluminescent western 
blotting analysis system (GE Healthcare, Buckinghamshire, UK) were used. The western 
blot membrane was exposed to film (Kodak, Rochester, NY) for 15 sand developed 
using a Micromax Developer (Hope, Seattle, W A) with T 2 developer and T 2 fixer (White 
Mountain Imaging, Salisbury, NY). The presence of PEG was confirmed using a PEG 
stain adapted from (Zhang, Wang et al. 2006), which allows barium iodine to react with 
PEG to form a yellow color. 
Unconjugated PDGF-BB was quantified using a PDGF-BB ELISA (R&D 
systems, Minneapolis, MN). PEG chains mask antibody binding to PEG-PDGF, so the 
amount ofunconjugated PDGF-BB was quantified after running a sample of the reacted 
solution on an ELISA. With the amount of soluble PDGF-BB quantified, appropriate 
concentrations ofPEG-PDGF-BB were calculated. 
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Formation and Surface Modification of PEGDA Hydrogels 
Six kDa PEGDA was dissolved in HBS to a 10% polymer weight percentage 
solution. A stock solution of the photoinitiator 2-dimethoxy-2-phenylacetophenone 
(acetophenone, Sigma) was prepared by dissolving 300 mg acetophenone in 1 ml N-
vinylpyrrolidone (NVP) and then added to the polymer solution at a concentration of 10 
J.tl/ml. The solution was vortexed and sterile filtered. Hydrogels were polymerized 
between two glass slides separated by a 0.75 mm thick poly(tetra fluoroethylene) (PTFE) 
spacer. The glass slides and spacer were secured using clips. Polymer solution was 
exposed to UV light (B-200SP UV lamp, UVP, 365 nm, 10 mW/cm2) for 30 sand stored 
in PBS with 0.1% sodium azide. 
The effects ofPEGylated proteins in 2D were studied by modifying the surface of 
bulk PEGDA hydrogels as previously described (Moon, Lee et al. 2007). Briefly, 5 mm 
diameter circles were punched from the hydrogel slabs prepared above. A solution 
containing 10 J.Ll/ml acetophenone along with PEG-RGDS and PEGylated growth factors 
was then added in sufficient volume to completely cover the surface of the hydrogel. The 
exact combination and concentrations of each factor are given in the individual 
experiments below. Hydrogels were then exposed to UV light for 2 min followed by 
soaking in sterile PBS to allow for swelling and removal of the photoinitiator solution. 
Patterned hydrogel surfaces were also made to emphasize the utility of spatial 
control ofPEG-PDGF-BB. Hydrogels were patterned by pipetting a solution containing 
10 J.Lllml acetophenone along with PEGylated growth factors onto the surface of a 5 mm 
diameter of a bulk hydrogel with a black transparency to block UV light from part of the 
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gel. Hydrogels were exposed to 2 min ofUV light followed by extensive rinsing. PEG-
RGDS was then immobilized to the entire surface by adding a solution containing 10 
)lllml acetophenone with PEG-RGDS to completely cover the surface of the hydrogel 
followed by 2 min UV light exposure. 
For all studies, unconjugated PDGF-BB and PEG-SMC were removed via 
diffusion before the hydrogels were used. Alternatively, soluble PDGF-BB could also be 
left in place to act as a diffusible growth factor to encourage cell migration in the 
surrounding tissue for other applications. 
To quantify the surface concentration of immobilized PEG-PDGF-BB, hydrogels 
were synthesized as described above and then degraded in 0.1 N sodium hydroxide for 
three days. After complete hydrogel degradation, the protein concentration was read on a 
Nanodrop 2000 (Thermo Scientific, Wilmington, DE). 
Bioactivity of Conjugated PDGF-BB via lOTl/2 Proliferation 
In order to evaluate the bioactivity of covalently attached PEG-PDGF-BB, lOTl/2 
cells (8.5 x 104 cells/cm2) were seeded onto gels modified with 5 mg/ml PEG-RGDS 
alone or in combination with 0.70 nmol/ml PEG-PDGF-BB. As a positive control, 0.70 
nmol/ml soluble PDGF-BB was added to the media of gels modified with PEG-RGDS 
alone. Cells were imaged using an Axiovert 135 (Zeiss) inverted fluorescent microscope 
after 48 h of culture. Cell nuclei were visualized via incubation with Hoechst 33342 dye 
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(Bis- 119 Benzimide, Sigma) at a concentration of 5 j..lg/ml in DMEM without serum for 
one hat 37 °C. Four fluorescent images were taken per gel at excitation= 350 nm and 
emission = 460 nm. Cell nuclei were quantified using ImageJ. Cell counts in the 
presence ofPDGF-BB were normalized to counts on surfaces modified with PEG-RGDS 
alone. Data from three separate experiments using gels with PEG-RGDS (n=31), PEG-
PDGF-BB and PEG-RGDS (n=28), and PEG-RGDS and soluble PDGF-BB (n=18) was 
pooled for statistical analysis as described below. 
Quantification of Tubule Formation 
To investigate the impact of covalently incorporated growth factors on vascular 
tubulogenesis, surface-modified PEGDA hydrogels were used. Bulk hydrogels were 
prepared from 10% 6kDa PEGDA and surfaces were modified as described above. Four 
modified surfaces were investigated: (1) 50 mg/ml PEG-RGDS, (2) PEG-RGDS and 0.27 
nmol/ml PEG-FGF-2, (3) PEG-RGDS and 0.70 nmol/ml PEG-PDGF-BB and (4) PEG-
RGDS, PEG-PDGF-BB, and PEG-FGF-2. HUVECs (8.5 x 105 cells/cm2) or a co-culture 
ofHUVECs and 10T1/2 cells at a ratio of 4:1 were seeded onto the modified gels and 
cultured in EGM-2 media either with or without FGF-2 and imaged using an Axiovert 
135 (Zeiss) inverted fluorescent microscope. Hydrogels were observed over a 30-day 
period and images of the entire surface of the gels were merged in Adobe Photo shop 
Elements. Tubules and modified surface areas were traced in Adobe Illustrator and 
quantified using ImageJ. For gels seeded with HUVECs alone, data from three separate 
experiments using gels with PEG-RGDS (n=10), PEG-FGF-2 and PEG-RGDS (n=3), 
PEG-PDGF-BB and PEG-RGDS (n=10), and PEG-FGF-2, PEG-PDGF-BB (n=4) was 
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pooled. For the co-culture ofHUVEC and lOTl/2 hydrogels, data from three separate 
experiments using gels in media with FGF-2 with PEG-RGDS (n=lO), PEG-FGF-2 and 
PEG-RGDS (n=3), PEG-PDGF-BB and PEG-RGDS (n=l2), and PEG-FGF-2, PEG-
PDGF-BB, and PEG-RGDS (n=l2) was pooled. Similarly, data from three separate 
experiments using gels in media without FGF-2 with PEG-RGDS (n=7), PEG-FGF-2 and 
PEG-RGDS (n=6), PEG-PDGF-BB and PEG-RGDS (n=8), and PEG-FGF-2, PEG-
PDGF-BB, and PEG-RGDS (n=7) was pooled. 
Immunohistochemistry 
To examine tubule morphology, immunohistochemistry was performed to identify 
endothelial pericyte cell markers. After 30 din culture, gels were fixed in 4% 
paraformaldehyde for 30 min and washed with phosphate buffered saline (PBS). Cells 
were permeabilized with 0.5% Triton-X for 10 min followed by a second PBS wash. 3% 
normal donkey serum (Sigma) was used as a blocking agent prior to application of the 
primary antibodies. Gels were incubated overnight at 4 °C in a 1 :200 dilution of mouse 
anti-alpha smooth muscle actin (R&D systems, Minneapolis, MN) and a 1: 100 dilution of 
goat anti-PECAM-1 (Santa Cruz Biotechnology) in 3% bovine serum albumin solution in 
PBS. Following incubation, gels were rinsed five times in PBS for 1 h each time. A 
1:400 dilution of Alexafluor 488 donkey anti-goat IgG (Invitrogen) and Alexafluor 555 
donkey anti-mouse IgG (Invitrogen, Carlsbad, California) was applied overnight at 4 °C 
in order to visualize the primary antibodies. After washing, gels were incubated in a 
DAPI solution (2 J.lM, Invitrogen) for 45 min. Images were taken using a confocal 
microscope (Zeiss Live5, Plan-Apochromat 20x objective with 0.8 numerical aperture 
and Plan-Apochromat oil-immersion 63x with 1.4 numerical aperture, for Alexafluor 
488: excitation= 489 nm, emission BP filter= 500-525 nm; for Alexafluor 555: 
excitation= 532nm, emission BP filter= 560-675 nm, for DAPI: excitation= 405 nm, 
emission BP filter= 415-480 nm). 
Cellular Encapsulation into Hydrogels 
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To further understand the effects of covalently immobilized growth factors 
on cells in 3D, HUVECs were encapsulated into MMP-sensitive hydrogels containing 
covalently immobilized growth factors. HUVECs were fluorescently labeled the day 
before encapsulation by incubation with 10 Jlg green CMFDA Cell Tracker® (Invitrogen, 
Eugene, Oregon) in the culture media for 1 h. Following incubation, cells were rinsed 
with PBS and fresh media was added. 
Polymer solution was prepared in HBS (10 mM, pH 7.4) with a final formulation 
of 10% PEG-PQ-PEG, 3.5 J.tmol/ml PEG-RGDS, and 0.3% w/v Irgacure 2959 (Ciba 
Corporations, Based, Switzerland). Four treatment groups were observed, including 
hydrogels containing: (1) PEG-RGDS alone, (2) PEG-RGDS and PEG-FGF, (3) PEG-
RODS and PEG-PDGF-BB, and (4) PEG-RGDS, PEG-FGF-2, and PEG-PDGF-BB. 0.03 
nmol/L PEG-FGF and 0.08 nmol/L PEG-PDGF-BB were used for both the individual 
factor groups and the combination of factors. Fluorescently-labeled HUVECs were 
harvested using trypsin-EDT A and counted using a Coulter counter to resuspended cells 
at a known concentration. 30,000 cells/Jll cells were pelleted by centrifuging at 2700 
RPM for 4 min. 5 Jll droplets of cell-laden polymer were formed and exposed to UV 
light for 7 min and the resulting cell-laden hydrogels were immediately immersed in 
EGM-2 media for in vitro analysis. 
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Activity of the cells in the hydro gels was monitored for 60 h using a Zeiss LSM 
5Live confocal microscope. Images were captured every hour and analyzed using 
Logger Pro Software to track cell movement. Data from three separate experiments was 
pooled using hydrogels with PEG-FGF-2 and PEG-RGDS, PEG-PDGF-BB and PEG-
RODS, and PEG-FGF-2, PEG-PDGF-BB, and PEG-RGDS (n=30) for collapse data 
analysis. 
Zymography 
To determine MMP activity, media was collected from gels with encapsulated 
HUVECs 60 h after encapsulation. Standard zymography was performed on a 10% 
precast polyacrylamide gel with gelatin (Biorad, Hercules, CA) following a Millipore 
protocol. Briefly, after running electrophoresis, gels were immersed in a 25% triton-X-
I 00 solution in water with gentle mixing for 30 min. After decanting the solution, a 
developing buffer (50 mM Tris base, 50mM Tris-HCl, 0.2 M NaCl, 5 mM CaCb, 5 mM 
Brij 35) was applied overnight at 37 °C. Gels were then stained with Coomassie Blue 
and destained with Methanol:acetic acid:water (50:10:40). Gel images were obtained 
using a Fujifilm LAS 4000 and analyzed for the presence ofMMP bands. 
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Appendix section 3 : PEG-QK Methods 
Cell Culture 
Human umbilical vein endothelial cells (HUVEC, Cambrex/Lonza, Walkersville, 
MD) were used between passages 2 and 6 and cultured as previously described [10]. 
Cells were maintained in VEGF-free endothelial cell growth medium (EGM-2 media, 
Cambrex/Lonza). Before 3D encapsulation, HUVECS were labeled with Celltracker Red 
CMTPX (Molecular Probes). 50 IJ.g Cell tracker Red was dissolved in 4 !J.l DMSO and 
diluted in cell media for a final concentration of 5 IJ.g/ml. HUVECs were incubated in the 
prepared media for 45 min at 37°C. Labeling was visually confirmed via fluorescence 
microscopy, and labeling media was replaced with normal EGM-2 medium (without 
VEGF). Cells were washed with phosphate buffered saline (PBS) before enzymatic 
lifting using trypsin/EDT A and subsequent encapsulation as described below. 
Preparation and Purification of Poly( ethylene glycol) Derivatives 
Preparation and Purification of Poly( ethylene glycol) Diacrylate 
(PEGDA):Poly(ethylene glycol) (PEG; Fluka/Sigma, MW = 6000 Da) was reacted at a 
1:4 molar ratio with acryloyl chloride (Sigma) in anhydrous dichloromethane (DCM; 
Sigma) with triethylamine (TEA; Sigma; 1:2 (PEG:TEA) molar ratio) overnight under 
argon at 25°C. PEGDA was purified by phase separation using 2 M K2C03. The 
PEGDA-containing organic phase was dried using anhydrous MgS04 and filtered. 
PEGDA was precipitated in diethyl ether, filtered, and dried overnight and under 
vacuum. The final product was characterized by 1H-NMR and stored at -20°C under 
argon until use. 
Preparation and Purification of PEG-succinimidyl carbonate (PEG-SMC): 
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Monoacrylated PEG was prepared by through a reaction of PEG (Fluka/Sigma, MW = 
3400 Da) with 1.5 molar excess Ag20 (Sigma), 1.1 molar excess acryloyl chloride 
(Sigma), and 0.3 molar ratio K1 (Sigma) in anhydrous dichloromethane (DCM; Sigma) at 
0-4°C overnight. The product was filtered in solution using Celite 521 (Spectrum 
Chemical Manufacturing Corp, Gardena, CA) to remove silver. The filtered product was 
dried via Rotovap, and then dissolved in DI H20, followed by altering the pH to pH=3 
using HCI. The solution was then heated to 35°C for 1 h, and activated charcoal (Fisher) 
was added to remove iodine. The solution was again filtered using Celite 521. NaCl was 
added with DCM, followed by extraction ofDCM. Phase separation using 2M K2C03 
removed chloride ions and acid. Resulting monoacrylated PEG was dried using sodium 
sulfate (Fisher), concentrated via Rotovap, precipitated in ethyl ether, and vacuum 
filtered. PEG monoacrylate was then reacted with 4 molar excess disuccinimidyl 
carbonate (Sigma) in anhydrous acetonitrile (Sigma) and pyridine (Sigma) overnight 
under argon. The resulting solution was dried via Rotovap, then dissolved in anhydrous 
DCM and filtered. PEG-SMC was isolated via phase separation in acetate buffer (0.1 M, 
pH 4.5, 15% NaCl), dried using anhydrous MgS04, filtered, precipitated in ethyl ether, 
filtered, and dried overnight and under vacuum. PEG-SMC was characterized by 1H 
NMR and MALDI-TOF and stored at -80°C under argon until use. 
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Preparation and Purification of PEG-QK: The angiogenic peptide 
Ac-KLTWQELYQL[K(Ac)]Y[K(Ac)]GI-amide was designed to react with PEG-SCM at 
the first lysine (K) residue only, by protecting all other free amines with acetyl groups 
(represented by Ac). QK (MW=2036 Da, Aapptec, Louisville, KY) was dissolved in 
DMSO at a concentration of7.4 mM. N,n-diisopropylethylamine (DIPEA, Sigma, 2 mol 
per mol PEG) was added to the solution to act as a base catalyst. Acryloyl-PEG-
succinimidyl ester (PEG-SCM, Laysan, MW=3400 Da) was similarly dissolved at a 
concentration of 1.5 mM. PEG-SCM was added dropwise to QK in a 10:1 molar ratio 
with slow mixing and allowed to react for 4 d at 25°C. The product was precipitated in 
cold isopropanol and dried overnight. PEG-QK was then lyophilized and stored in 
HEPES buffered saline (HBS) with 0.1% bovine serum albumin (BSA) at 4°C until use. 
Conjugation was characterized by MALDI-TOF (MS Autoflex, solvent: methanol). 
Preparation and Purification of PEG-RGDS: The cell-adhesive peptide RGDS 
(American Peptide, Sunnyvale, CA) was dissolved in DMSO at a concentration of 30 
mM. DIPEA was added to the solution to act as a base catalyst. Acryloyl-PEG-N-
hydroxysuccinimide (PEG-SCM, Laysan, MW=3400 Da) was similarly dissolved at a 
concentration of 30 mM. PEG-SCM was added dropwise to RGDS in a 1:1 molar ratio 
with slow mixing and allowed to react for 4 d at 25°C. The product was dialyzed against 
DI H20 for 8 h using a membrane with a 3500 Da molecular weight cutoff (Spectrum 
Laboratories, Rancho Dominguez, CA). PEG-RGDS was then lyophilized and stored at 
-80°C under argon until use. Conjugation was characterized by gel permeation 
chromatography (GPC) using a PLgel column (5 ~-tm, 500 A, Polymer Laboratories, 
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Amherst, MA), 0.1% ammonium acetate in DMF solvent, and evaporative light scattering 
(ELS) detector (Polymer Laboratories), run against unreacted PEG-SCM for comparison. 
Synthesis of Collagenase-Degradable PEG-PQ-PEG: A collagenase-sensitive 
peptide (PQ), GGGPQGIWGQGK, was prepared on a peptide synthesizer (Aapptec, 
Louisville, KY) using standard Fmoc chemistry. The peptide was cleaved from the resin 
using 95% trifluoroacetic acid (TF A), 2.5% triisopropylsilane (TIPS) in water and 
precipitated in ether. The peptide was reacted with PEG-SCM (Laysan, MW=3400 Da) 
in a 2:1 ratio (PEG-SCM:PQ) in DMSO and DIPEA (2 mol per mol PEG) for 4 d at 25°C 
to generate a PEG-diacrylate derivative with PQ in the polymer backbone. PEG-PQ-PEG 
was dialyzed against DI H20 for 8 h using a membrane with a 3500 Da molecular weight 
cutoff(Spectrum Laboratories), and conjugation was confirmed via GPC with ELS 
detection as described previously. 
Synthesis of PEG- VEGF: PEG-VEGF was synthesized as previously described in 
detail [ 1 0]. In brief, VEGF 165 (Sigma) was reacted with acryloyl-PEG-SMC in a 1:200 
molar ratio in sterile 50 mM sodium bicarbonate buffer (pH 8.5, 0°C) for 4 d. PEG-
VEGF was then lyophilized under sterile conditions and stored in HEPES buffered saline 
(HBS) with 0.1% bovine serum albumin (BSA) at 4 °C until use. Conjugation was 
confirmed via Western blot by visualizing an increase in molecular weight as previously 
described in detail [10]. 
Bioactivity Assay 
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Bioactivity ofPEG-QK was determined by measuring its pro-mitotic effect on 
endothelial cells. HUVECs were seeded at 1.05 x 103 cells/cm2 in EGM-2 medium 
without VEGF on Day 1. On Day4, medium was replaced with EGM-2 medium without 
VEGF and FGF, with an addition of either 0.13 pmoVml VEGF (positive control), 50 
pmoVml QK, 50 pmol/ml PEG-QK, or no VEGF (negative control). The levels of QK 
were chosen to correspond with the bioactivity levels reported in D'Andrea's original 
paper on the peptide, which showed that the bioactivity of 1 mol VEGF was equal to that 
of385 mol QK [D'Andrea 2005]. This medium was replaced after 4 h with EGM-2 
without VEGF and FGF. On Day 6, cells were treated with a Hoechst 33342 dye (Bis-
Benzimide, Sigma), which labels cell nuclei. Hoechst dye was added at a concentration 
of 5 f..lg/ml in EGM-2 without VEGF and FGF, and cells were incubated with this media 
for 1 h. Fluorescent images were taken immediately of each well, with 4-6 images per 
well, using a fluorescent microscope with excitation= 350 nm, emission= 460 nm. Cell 
nuclei were quantified using ImageJ. Statistical differences between groups were 
analyzed using ANOVA, followed by Tukey's Least Significant Difference post hoc 
analysis, with p<0.05 considered statistically significant. 
Formation of Modified PEGDA Hydrogels 
Formation ofPEGDA Hydrogels: Hydrogels were formed as previously described 
in detail [10]. In brief, 6 kDa PEGDA was dissolved in HEPES buffered saline (HBS) in 
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a 10% w/v solution and sterile filtered. Photoinitiator, 10 ).lLimL of 300 mg/mL 2,2-
dimethoxy-2-phenylacetophenone in N-vinylpyrrolidone (NVP), was added to the 
solution. The polymer solution was pipetted into molds and crosslinked through 
exposure to long wavelength ultraviolet light (B-200SP UV lamp, UVP, 365 nm, 10 
mW/cm2) for 30 s. After crosslinking, the mold was removed, and the PEGDA hydrogel 
slab was placed in sterile PBS with 0.1% sodium azide until further use. 
Surface Modification of PEGDA Hydrogels: Hydrogel slabs were soaked for 1 h 
in sterile PBS to remove sodium azide. 5 mm diameter circles were punched from 
PEGDA hydrogel slabs. A polymer solution consisting of 173 nmol/mL PEG-QK, 
30 ).lmol/mL PEG-RGDS, 1 ).lmol/mL eosin Y, and 3.95 ).lLimL NVP was prepared. 
From this solution, 1 0 ).lL was pi petted onto the top surface of the gel, completely 
covering the surface. The gel and polymer solution were exposed to a 532 nm laser at 
30 mW/cm2 for 30 s. Positive control hydrogels were made with 420 pmol/mL PEG-
VEGF instead ofPEG-QK, and negative control hydrogels contained PEG-RGDS only. 
Each surface-modified gel was then soaked in sterile PBS for 1 d to allow non-reacted 
polymer, excess photoinitiator, and residual sodium azide to diffuse from the gel. 
Formation of Three-dimensional Proteolytically Degradable PEG Hydrogels: 
Collagenase-degradable hydrogels with encapsulated HUVEC cells (3 x 107 cells/mL, 
labeled with Celltracker Red) were prepared. Briefly, PEG-PQ-PEG (0.1 g/mL), 
acryloyl-PEG-RGDS (3.5 ).lmol/mL), and acryloyl-PEG-QK (152 nmol/mL or 760 
nmol/mL) were mixed with a cell suspension and photocrosslinked by exposing to long 
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wavelength UV (365 run, 10 mW/cm2) for 7 min, using Irgacure 2959 as the 
photoinitiator (0.3% w/v). Two concentrations ofPEG-QK were investigated; the lower 
corresponds to the bioactivity levels of comparative positive control PEG-VEGF 
hydrogels; the second is five times higher. As previously noted, D'Andrea et al. found 
that 385 mol QK had equal bioactivity to 1 mol VEGF in a proliferation assay [2]. As a 
positive control, hydro gels were crosslinked with incorporation of PEG-VEGF ( 400 
pmollmL) instead ofPEG-QK, and as a negative control, hydrogels were prepared with 
PEG-RODS only. 
------- ------------------
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Characterization of Hydro gels 
Quantification of Surface-Immobilized QK, VEGF, and RGDS: Hydrogel disks 
were modified with either PEG-QK, PEG-VEGF, or PEG-RGDS, and then soaked to 
allow unbound peg-modified factor to diffuse from the hydrogel. The amount of PEG-
QK bound to the hydrogel was determined by measuring the absorbance of PEG-QK in 
the soak solution after hydrogel modification. The absorbance ofPEG-QK, which 
includes a tryptophan amino acid residue, was measured at 280 nm 
spectrophotometrically (Vivian) and compared to prepolymer solution standards. 
Similarly, an ELISA assay was used to determine the amount ofVEGF that was 
covalently immobilized on positive control hydrogel surfaces as previously described by 
measuring the amount ofPEG-VEGF removed by soaking [10]. A ninhydrin assay was 
used to quantify the amount of covalently-linked PEG-RGDS on the surface of the gels, 
as previously described [ 1 0]. 
Biological Activity on Hydrogels 
Endothelial Tubule Formation on Surface ofHydrogels: HUVECs were seeded 
(8.5 x 104 cells/cm2) onto gels with either PEG-RGDS and PEG-QK, PEG-RGDS and 
PEG-VEGF, or only PEG-RGDS covalently attached to the surface. HUVEC 
tubulogenic response on the gels was monitored and EGM-2 medium changed every 
other day. Three experimental groups were observed: QK- and RGDS-modified 
hydrogels cultured in EGM-2 medium (without soluble VEGF), VEGF- and RODS-
modified hydrogels cultured in EGM-2 medium (without soluble VEGF), and RODS-
modified hydrogels cultured in EGM-2 medium (without soluble VEGF). Images were 
taken of each entire gel and merged using Photoshop Elements software. Tubules were 
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traced using Adobe Illustrator software, and length of each tubule was calculated in 
ImageJ software (NIH, Bethesda, Maryland). The total sum of tubule length per area was 
calculated for each sample. Data from separate experiments was pooled, and ANOV A 
followed by Tukey's Least Significant Difference post hoc analysis was performed to 
determine significant differences between groups, with p<0.05 considered statistically 
significant. All data are presented as mean ± standard deviation. 
In some samples, cells were permeabilized with 0.1% Tween-20 for 30 min, 
blocked with BSA for 30 min, then treated with Alexafluor 488-conjugated phalloidin 
(10 U/mL, Molecular Probes) and DAPI (2 jlM, Invitrogen, Carlsbad, California) for 
45 min to label cell actin filaments and nuclei, and visualized using confocal microscopy 
(Zeiss Live5, Plan-Apochromat 20x objective with 0.8 numerical aperture and digital 
zoom of 1 or 2, for Alexafluor 488 phalloidin: excitation = 489 nm, emission BP filter = 
500-525 nm; for DAPI: excitation= 405 nm, emission BP filter= 415-480 nm, pinhole= 
7 !liD). Tubules stained with phalloidin/DAPI were captured via z-stack images. 
Time Lapse Study of Endothelial Tubulogenesis in Three-dimensional Degradable 
PEG Hydrogels: Three-dimensional collagenase-degradable constructs were transferred 
to a confocal microscope (Zeiss Live5, Thornwood, NY) with a stage chamber providing 
a regulated environment (37°C and 5% C02). No additional proteolytic enzymes or 
protease inhibitors were added to the culture. Z-stack images were collected every hour 
for 60 h using the Multi Time Series macro (Zeiss), Plan-Apochromat 20x objective with 
0.8 numerical aperture, and excitation wavelength= 532 nm, emission bandpass (BP) 
filter= 560-675 nm, and pinhole= 7 jlill. Time lapse movies were analyzed for tubule 
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formation, cell migration, and cell-cell contact formation. For tubule formation, tubules 
were traced at 22 h and 32 h time points and quantified. Total tubule length per viewing 
field was analyzed. For cell migration quantification, the movement of three randomly 
selected cells per viewing field was tracked using Logger Pro software, which allows the 
tracing and quantification of cell paths through timeframe progression. For cell-cell 
contact formation quantification, the number of all cell-cell contacts formed within the 
viewing field was counted by timeframe progression using Zeiss LSM5 Image Browser. 
The number of cell-cell contacts formed was normalized by the number of cells present in 
the first frame analyzed. Data from separate experiments was pooled, and ANOV A, 
followed by Tukey's Least Significant Difference, was performed to determine 
significant differences between groups, with p<0.05 considered statistically significant. 
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